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                 A3 adenosine receptor (A3AR) subtype is implicated in several 
pathological conditions such as cardiac and cerebral ischemia, 
neurodegenerative diseases as well as chronic inflammatory diseases including 
rheumatoid arthritis, asthma and cancer. It has been suggested that the 
selective inhibition of A3ARs by antagonists could be useful as therapy for the 
various diseases conditions (CHAPTER 1). In the past few years, there has 
been an intensive effort to develop different heterocyclic scaffolds as hA3AR 
antagonists. Among them, the pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidine 
(PTP) tricyclic scaffold has demonstrated good affinity towards the hA3 
receptor  and broad selectivity  range over  other receptor subtypes. Recently, 
our group has reported new potent and selective pyrazolo-triazolo-pyrimidine 
(PTPs) derivatives with phenyl ring at C
2 





 positions. However, these PTP derivatives and also most of the 
tricyclic compounds, have a number of limitations such as poor aqueous 
solubility due to high molecular weight and a complex nature of the structure, 
which makes the synthetic preparation difficult and time consuming. 
Moreover, these problems may affect the drug like properties of the analogues. 
Taking into account these drawbacks, in this thesis the tricyclic PTP scaffold 
is simplified into the bicyclic pyrazolopyrimidine scaffold in an attempt to 
identify a lead compound with better physico chemical properties and similar 
pharmacological profile as PTP counterpart (CHAPTER 2). 
In this project, a new series of pyrazolopyrimidines bearing a chloro group at 
C
4




 positions were designed and 
synthesized as a result of  a molecular simplification of  parent  PTP ligands 







 positions of the PPs on the hA3 adenosine receptor 
affinity and selectivity over hA1, hA2A, hA2B receptor subtypes.  
Binding evaluation of new 4-chloro-2-(ar)alkyl-2H-pyrazolo[3,4-d]pyrimidin-
6-amine derivatives with C
6
-free amino, benzamides and phenylacetamide 
(81-84, 101-120 & 121-124) showed moderate affinity at hA3AR and 
xi 
 
selectivity at other receptor subtypes (CHAPTER 4). Especially, analogue 
116, with a phenyl ethyl substitution at N
2
 position and a para-
methylbenzamide at C
6
 position, displayed the best hA3 affinity profile (Ki 
hA3 = 1.5 µM) and about 7 fold selectivity at the hA1 and hA2A ARs. Further, 
analogues 115 & 120 of the same series emerged for their high selectivity 
(115, hA1/A3 = 21 and 120, hA1/A3=35) against the hA1 adenosine receptors, 
while showed almost equal (115, Ki hA3 = 2.8 µM & 120, Ki hA3 = 2.9 µM) 
affinity at the hA3AR. Similarly, some of the N
2
-neopentyl derivatives also 
displayed good affinity and moderate selectivity; for example compound 112, 
with N
2
 neopentyl, and C
6
 p-toluamide substitutents showed a moderate 
affinity at the hA3AR (Ki hA3 = 5.0 µM) and its para-CF3 analogue 111 
displayed the best combined affinity and selectivity profile with Ki hA3 = 6.6 
µM; hA1/A3 >15, hA2A/A3 >15 in the whole series. 
To rationalize the experimental hA3 affinity and selectivity profiles of the 
initial 4-chloro-PP series, molecular modeling investigations were also 
performed on the newly synthesized PP derivatives. Among them, 3D-QSAR 
(quantitative structure activity relationship) methodology such as  Topomer 
CoMFA (Comparative molecular field analysis) studies were conducted to 





of the bicyclic nucleus for recognition at the hA3AR (CHAPTER 5). The final 





= 0.325) and the model demonstrated that both steric effects & 
electrostatic effects were predominant for the ideal interaction of the 
antagonists with the hA3 receptor. 
Additionally, molecular docking studies were performed on 4-chloro PP 
derivatives (CHAPTER 6) using newly constructed hA2A based hA3 
homology model and hA2AAR crystal structure to depict the hypothetical 
binding mode and interactions of these derivatives.  Binding interactions of 4-





phenyl of the benzamide chain, π-π stacking interaction with pyrazolo-
pyrimidine ring and hydrogen bonding with C
6
amide are essential for hA3 
affinity. However,derivatives of 4-chloro-PP’s lost one of the stabilizing H-
xii 
 
bonding interaction with Asn250 (TM6), which was deemed essential for 
hA3AR affinity. 
Considering the low affinity and poor selectivity profile of the 4chloro-PP 
analogues, further ligand modification was carried out to design a better series, 
in which the lipophilic chloro group at C
4
 was replaced by hydrogen bond 
acceptor ester substitutent (CHAPTER 7). 
In this new study, 6-amino-2-(alkyl or aralkyl)-2H-pyrazolo[3,4-d]pyrimidines 
bearing ester substituents at C
4





 positions were designed and synthesized (CHAPTER 8). The 
objective of this work was to investigate the significance of the ester 
substituents and additional electron withdrawing and or electron donating para 
substituents of the C
6 
benzamide on the hA3AR affinity and selectivity. Based 
on the binding experiments (CHAPTER 9), the newly synthesized 
pyrazolopyrimidine-4-carboxylate derivatives displayed a better affinity 
profile (2-3 fold increment) at hA3AR but also ameliorated (about 15-17 fold) 
the selectivity against other adenosine receptor subtypes. In addition, these 
new derivatives showed better physico chemical properties than PTP 
derivatives, hence enhanced the drug like properties of the lead compounds. 
 Indeed, in the pyrazolopyrimidine-4-carboxylates series, most of the 
compounds showed very low micro molar range affinity at hA3AR and over 
100 fold improvement in the selectivity against adenosine receptor subtypes as 
compared to 4-chloro-pyrazolopyrimidines. In particular, compound 133, 
bearing N
2
 methyl and C
6
 free amino groups, showed  the best affinity in the 
whole series with  Ki hA3 = 0.7 µM, which is >142 fold more potent than its 4-
chloro-PP counterpart  (81, Ki hA3 = >100 µM). Similarly, compound 147, 
bearing N
2
 neopentyl and C
6
 para-toluamide groups, showed the best 
combined affinity and selectivity profile with Ki hA3 = 0.9 µM; hA1/A3 = 
>111, hA2A/A3 = >111. In addition, another compound (146) from the same N
2
 
neopentyl series displayed almost equal affinity (Ki hA3 = 1.3 µM) and 
selectivity profile (hA1/A3 = >77, hA2A/A3 = >77) as compound 147. 
Subsequently, steric para substituted benzamide compounds 153 and 155 
displayed comparable affinity and selectivity as compound 147. 
xiii 
 
Consequently, molecular docking investigations were carried out on this new 
series of PP-4-carboxylate derivatives (CHAPTER 9) using newly 
constructed hA2A based hA3 homology model and hA2AAR crystal structure to 
depict the hypothetical binding mode and interactions. Docking analysis 
showed that these analogues retained all of the essential interactions displayed 
by the 4-chloro PP derivatives. Similarly, they also showed additional 
stabilizing hydrogen bonding interactions with ‘N’ of the pyrimidine, pyrazole 
and also with carbonyl of the ester substituent. In addition, para substituents 
of the benzamide chains showed additional hydrophobic interactions with 
Val169, Val259 and Ile253, which are crucial for hA3 affinity and selectivity 
over other receptor subtypes. 
Eventually, new PP derivatives were also tested for their ADA inhibitory 
activity (CHAPTER 10). Some of the compounds showed promising 
inhibitory potency, which could be further improved by the additional 
substitution at the N
2
 position of the pyrazole ring. 
            In summary, the molecular simplification of PTP ligands and further 
ligand modification of 4-chloro-pyrazolopyrimidines to pyrazolo[3,4-
d]pyrimidine-4-carboxylates have given rise to a new class of  potent and 
selective hA3AR antagonists. Molecular modeling evaluation employed in our 
study has provided new perspectives on the structural features and binding 
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Figure 44. Binding orientation of 125 (PTP) (magenta) and analogue 147 




Figure 45. Crystal structure of Adenosine deaminase.  
Figure 46. A. Binding mode of reference ligand (+)-EHNA into the ADA 




Figure 47. A. Binding mode of compound 151 inside the ADA binding 
cavity, B. 2D view of the compound 151 inside the ADA binding cavity. 
 
 
Figure 48. Superimposition of ligand 151 (blue) & 162 (magenta) inside 
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Chapter 1 General Introduction 
The information pertained to this chapter has been compiled from our below 
review 
article: 
 Cheong, S. L.; Federico, S.; Venkatesan, G.; Moro, S.; Spalluto, G.; 
Pastorin, G. Human A3 adenosine receptor as multifaceted therapeutic 
target: pharmacology,medicinal chemistry and in silico approach. 
Med. Res. Rev. 33 (2), 235-335, 2013. doi:10.1002/med.20254. 
          
1.1 Introduction 
           Adenosine is a nucleoside made up of of adenine attached to a ribose 
moiety through a β-N9-glycosidic linkage (Figure 1). In our body, adenosine 
acts as an endogenous modulator that regulates many physiological processes 
through activation of specific human adenosine receptors (hARs). These 
receptors, which consist of seven transmembrane domains, are members of G 
protein-coupled receptor (GPCR) family and are  activated by different stimuli 
such as photons, neurotransmitters, neuromodulators, biogenic amines (e.g. 
catecholamines and histamine), peptides (e.g. gonadotropin- releasing 
hormones (GnRH), thyrotropin- releasing hormone (TRH)) and glycoproteins 









    
 
Figure 1. Structure of adenosine        Figure 2.Scematic view of  A1AR with    
                                                          TM domains as representative example of    
                                                       adenosine receptors
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            These receptors posseses common central domain consisting of seven 
transmembrane (TM 1–7) helices (approximately 20-25 aminoacids for each 
helix).These helices are connected via three intracellular (IL1, IL2 and IL3) 
and three extracellular loops (EL1, EL2 and EL3). The extracellular region of 
the protein is composed of the amino terminus and several loops, comprising 
the ligand-binding cavity. The carboxyl end is located at the cytoplasmic side 
of the membrane. Moreover, the helix contains two cysteine residues, 
observed in TM3/EL1 interface and EL2, which form a vital disulfide linkage 
(Figure 2). This linkage is considered to be important for the packing and 
stabilization of the conformations of these seven TM domains. Consequently, 
the specific properties of these receptors are conferred by these domains.
3
 
Moreover, TM domains of GPCRs contain the primary sequence homology 
and the most conserved residues are situated within the TM domains and 
constitute the important structural determinants of receptor function.  
 
1.2 Characterization and physiological significance of adenosine receptors 
subtypes 
            Adenosine receptors are categorized into four subtypes, such as A1, 
A2A, A2B and A3 adenosine receptors (Figure  3).
4
 All of these ARs possess 












Figure 3. Different subtypes  of  endogenous adenosine receptors and their 
second messenger interactions with G protein subunit Gi or Gs. 
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A1 Adenosine receptors (A1ARs). The A1ARs are the most conserved 
adenosine receptor subtype across different species
5
 and they are found at the 
highest density in the brain (cortex, cerebellum, and hippocampus) and 
adipose tissue. Moderate to high density level of A1ARs appear to be present 
on specialized cells of spinal cord, thyroid , kidney, adrenal gland, eye, 
sinoatrial and atrio ventricular  nodal tissue of the heart. Human (h)A1AR are 
expressed in low density in the cardiac ventricles, lung, pancreas, liver and GI 
tract.
6
 Activation of the A1ARs inhibits adenylyl cyclase activity, activates K
+
 
channels, blocks transient  Ca
+ 
channels and increases  intracellular  Ca
+
  and  
inositol-1,4,5-trisphosphate levels by activating phospholipase C (PLC).  
A2A Adenosine receptors (A2AARs).  A2AARs are found in the, spleen, 
thymus and leukocytes in high level, whereas moderate levels are observed in 
the heart and lung.
  
Moreover, the highest concentration of the receptor is 
found in striatum of the brain.
7,8 
Similalry, activation of  A2AARs induces the 
cyclic AMP-protein kinase A (PKA) pathway by conjugating  through  Gs 
protein
5
 in peripheral tissues or Golf protein
9,10
 in the brain. A2AARs interact 
with various neurotransmitters in the brain   and  regulate  the motor, 
psychiatric effects  and  the  sleep-wake cycle. In peripheral tissues, A2AARs 




A2B Adenosine receptors (A2BARs). Among all four adenosine receptors, 
A2BARs are the most adenosine-insensitive receptor which are widely 
expressed, but in low abundance. A2BAR requires micromolar concentrations 
which are rarely achieved under physiological conditions. During conditions 
including  hypoxia, ischaemia, the adenosine level is increased and genetic 
and pharmacological studies have described the functional roles of A2BARs 
including tissue adaptation to hypoxia
12,
 increased ischaemia tolerance
13,14
. 
A3 Adenosine receptors (A3ARs).   Recently, the hA3AR has been cloned and 
characterized pharmacologically.
4
  The amino acid   sequence of the hA3AR is 
61%, 54% and 52% identical in sequence to hA1AR, hA2AAR and hA2BAR 
subtypes, respectively.
15
 The hA3AR shares sequence homology of about 74% 





mRNA of A3AR was  mainly found in various  brain areas  at limited levels, 





mRNA of hA3AR  has  been expressed  in peropherl tissues, with low levels in 
testis and  CNS.
18 
As a consequence, the evaluation of therapeutic 
characteristics  in animal models is hampered due to species dependent tissue 
distribution  and pharmcalogy of A3ARs.
19
 Thorough investigation on A3AR 
suggests that  A3ARs are principally expressed in the liver, lung, and primary 
cells (e.g. macrophages, monocytes, eosinophils) involved in inflammation. 
Whereas, A3AR minor expression is found in kidney, brain, heart, and GIT 
tissues.
5
  In terms of signaling transduction pathways (Figure 4), activation 
 
Figure 4. Schematic representation of  signalling pathways  involved in A3AR  




of the A3ARs results in the (i) inhibition of adenylyl cyclase through the 
interaction with inhibitory Gi protein mediation, followed by decrease in 
cyclic adenosine monophosphate (cAMP) level; (ii) increase in the 





   Other secondary pathways related to A3AR have also been 
reported, such as (iv) activation of ATP sensitive K
+
 channel (KATP) in the 
heart, or (v) activation of  RhoA by A3AR mediation with phospholipase D 
(PLD) and protein kinase C (PKC) stimulations consequently.  These 





 (vi) Similarly, through the activation of  Ras,  A3AR 
regulate phosphoinositide 3-kinase (PI3K) or extracellular signal-regulated 
kinase (ERK1/2) activities.
23
 The phosphoinositide 3-kinase/phospholipase B 
(PI3K/PKB) and mitogen-stimulated protein kinase/extracellular signal 
influenced kinase (MEK1/ERK1/2) pathways are found to be involved in cell 
survival processes and related to A3AR induced preconditioning in cardio 
myocytes from newborn rats during hypoxia or reoxygenation.
24
 Through 
above signalling pathways, the modulation of such receptor is implied in 
cardio protective and cerebro protective functions. Further, due to selective 
activation of A3AR, the  cellular growth is also modulated.
25-28
  
            Similarly, its inhibition by selective antagonists has been described to 
be useful in the treatment of pathologic conditions such as  glaucoma, 
inflammatory diseases and cancer.
29,30
 The wide spread distribution of A3ARs 
in various cells and tissues, could suggest their possible involvement in 
various disease conditions  and the potential use as a selective 
pharmacological target. As such, the A3ARs are deemed promising therapeutic 
targets that propel the research on the development of potential A3AR ligands 
targeting this particular receptor. In fact, a large number of A3 ligands i.e. 
agonists and antagonists, have been investigated, and various classes of 
derivatives indicating good A3 affinity with wide ranges of selectivity towards 
other AR subtypes have been synthesized and tested successfully as A3AR 
ligands. Due to the still enigmatic role of A3AR, we decided to focus our 
studies on this adenosine receptor subtype. Therefore, in the next section, 
pertinent therapeutic applications associated with the modulation of A3AR by 
selective compounds are discussed in more details. 
 
1.3 Pharmacology and therapeutic applications of A3 adenosine receptors 
             The diverse physiological functions of adenosine highlight the 
significant benefits of developing therapeutics for the regulation of adenosine 
receptors. The vast amount of effort invested in adenosine research is driven 
by the therapeutic potential for drugs which elicit their actions at adenosine 
receptors. However, the ubiquitous distribution of adenosine receptors in 
mammalian cell types, the existence of at least four distinct subtypes together 
with the variability of physiological responses mean that exploiting this 
6 
 
potential requires ligands that are highly selective in their action (with respect 
to receptor subtype and tissue type) to be of value as therapeutics. To-date, 
there are increasing studies that indicate the A3 receptor could be involved in 
several patho physiological conditions that occur especially in the central 
nervous, cardiovascular systems, as well as in inflammatory disorders and 
cancer (Figure 5).  
 
Figure 5. Schematic view of the therapeutic application of A3AR ligands in 
various patho physiological conditions 
 
1.3.1 Role of A3 receptor in central nervous system 
            A3ARs are distributed in the central nervous system substantially but at 
low levels with a diminished affinity and the role of A3ARs in various 
pathological conditions is controversial, although they may contribute to 
neurotransmission.
31
 Recently, Chen et al.
30
 examined the  protective role of 
the A3AR agonists in brain cells by in vitro and in vivo study. However, these 
results differ predominantly from those obtained by Von Lubitz et al.,
32
 who 
proved that the intra peritoneal pre-treatment with A3AR agonists before 
ischemia exacerbated the condition in stroke-afflicted mice. In addition, other  
research groups hypothesized about the absence of  this receptor subtype or its 
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mRNA in the CNS, suggesting that the described evidence on A3AR was due 
to the overlapping affinity of A3AR ligands for A1AR.
33
 Subsequent studies 
proved that A3AR activation has different actions depending on the A3AR 
agonists concentration  used: higher concentrations (>10 µM) exhibited a 
cytotoxic effect, whereas lower concentrations  displayed a cytoprotective 
effect. These dual and opposite effects of the A3AR’s activation are observed 
in conditions such as tissue protection in inflammatory cells or in tumoral 
tissues. Studies have shown that chronic pre-treatment with an A3AR agonist 
resulted in remarkable neuro protection of ischemic gerbils.
28
 In contrast, 
neuronal damage was worsened due to acute treatment with an A3AR agonist. 
26
 It has been reported that  the activity  of anti depressant-sensitive serotonin 
transporters (SERTs) is rapidly increased  by A3ARs stimulation.
34
 A3AR-
stimulated SERT activity is primarily mediated by p38 MAPK-linked 
pathways, supporting the potential use of agents that block A3ARs (i.e. 
antagonists) and selectively diminish SERT surface expression and activation. 
Therefore, it is suggested the use of A3AR antagonists for the treatment of 




1.3.2 Role of A3 receptor in the cardiovascular system 
            ARs have been widely distributed  in cardiac myocytes, and A2AR 
subtypes also highly expressed  on endothelial cells.
35
 During increased 
oxygen consumption (e.g. exercise), adenosine is formed and channeled out of 
the cardiac system and further it reaches the interstitial space and carries 
information of cardiac myocytes to smooth muscle of arteriolar for dilatation, 
till the conditions reach the normal ranges. Some studies proved the 
involvement of  A3AR in ischemic preconditioning (IPC), mainly in early 
ischemia (5 min before the onset)
36,37
 and late IPC (24 hr before inducing 
ischemia).
38
 It was noticed that the activation of PKC along with A3AR-




             Interestingly, activation of A3AR by its agonists IB-MECA (2 in 
Figure 6) and Cl-IB-MECA (3) during reperfusion and acute myocardial 
ischemia was also accounted to be related with cardio protection. 
Consequently,  A3AR antagonists  could block  the beneficial effects, which 
8 
 
were observed either before ischemia or during reperfusion.
40
 Nevertheless, a 
few research groups have performed the preclinical studies investigating the 
beneficial effects of adenosine administration 
41
 or the treatment of an acute 
myocardial ischemia reperfusion injury by AR agonist administration.
42
 
Consequently, the results have shown no clear advantages from the infusion of 
such agents, especially in patients without anterior myocardial infarction, 
which could probably be attributed to suboptimal doses or too small clinical 
trials. 
           A multi factorial large arteries disease called atherosclerosis is the 
major reason for heart disease and stroke. It was discovered that 
environmental and genetic risk factors seemed to be involved with  this 
pathology.
43
  Recently, it has been discovered that HIF-1α accumulation by 
activating  ERK 1/2  pathway was stimulated by  adenosine in hypoxic foam 
cells. Further, VEGF secretion in a HIF-1α dependent way was also activated 
by A3ARs. In addition, adenosine induced formation of foam cell is strongly 
reduced A3AR antagonists and by HIF-1α silencing. So as a consequence, 





1.3.3 Role of A3AR in inflammation and other related pathological 
conditions 







 and macrophages 
48
 have been modulated 
by adenosine, thereby it plays a important role in the inflammation process. It 
has been proven that the activation of A3ARs could  be both pro- or anti-
inflammatory, depending  on the cell type investigated or on the animal 
species studied.
49  
Several studies reported that apoptosis and the chemo taxis 
process  of eosinophils are inhibited by A3ARs, present on human 
eosinophils.
50
 It has been exhibited that over expressed A3ARs in 
lymphocytes, Jurkat cells, and a human leukemic cell line caused the  
inhibition  of adenosine cyclase and calcium  modulations.
51
 These effects 
seem to be an indication of an anti-inflammatory effect of this receptor 
subtype produced by A3AR activation of macrophages. 
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             In some studies that are aimed at evaluating the role of ARs in 
inflammatory diseases, for instance asthma, it was observed that mast cells 





 Besides, the A3ARs density on eosinophils  of   
 
Figure 6. Structures of (2) A3 agonist, IB-MECA (3) A3 agonist, Cl-IB-
MECA; (4) QAF805, A2BAR and A3AR antagonist (used for inflammatory 
conditions); (5) MRS1523, (6)cordycepin, (7) pyrazolo[3,4-d]pyrimidine 
(effective in cancer); (8) KF26777 (used for asthma); (9) MRS3558 (used for 
autoimmune  inflammatory  diseases);  (10)   OT-7999,(used for glaucoma).    
 
patients suffering from asthmatic conditions was also found to be elevated.
53
 
On the other hand, in a rabbit model, it was reported that theophylline  counter 
balanced the  broncho constriction stimulated by adenosine, which was a 
natural antagonist of adenosine receptors.
54
  Such observations inferred a vital 





















































































company Novartis developed QAF805 (4, Figure 6), as a dual A2BAR and 
A3AR antagonist and has been proposed as a antiasthmatic agent.
55
 However, 
Phase Ib clinical trials of this asthmatic agent were not successful. 
In the case of another chronic inflammatory disease, namely rheumatoid 
arthritis, it was recently noted that TNF-α inhibition involved also the A3AR;
56
 
in particular, the A3AR agonists were observed to supply a  protective effect 
via inhibition of alpha (MIP-α) and TNF-α secretion, or suppression of 




1.3.4 Role of A3AR in eye disorders  
              A3ARs have been implicated in ocular diseases such as dry eye, 
glaucoma or uveitis.
58
  In the past study, lower  intracellular pressure observed 
in the  the A3AR knockout mouse, suggested the  role for A3AR antagonists in 
glaucoma treatment.
59
 In addition,  A3AR antagonists may be considered  as  a 
substitute for treating ocular hypertension associated with pseudoexfoliation 
syndrome in patients.
60
 On the contrary, in pseudo exfoliation syndrome with 
glaucoma condition, the level  of A3AR mRNA was found to be increased at 
the non pigmented ciliary epithelium of the eye while compared to normal 
eye.
61
 Over expression of  A3AR in retinal ganglion cells, seemed to be 





1.3.5 Significance of A3 receptor in cancer 
              A high concentration of adenosine  is  found  in cancer tissues and 
also in the interstitial fluid related to various tumors, at sufficient 
concentrations to interact with ARs. Moreover, up regulation of  the A3AR 
level  in cancer cells  proved  the important  functions of  A3ARs as biological 
markers or target. In fact such over expression seems to be well correlated 
with the severity of the disease.  More precisely , it is mainly because of  
enhancement  of transcription factor NF-kB and Wnt signaling caused by  
expression of the A3AR.
63
  Primary examples  of A3AR over expressions 
(about 2.3 fold)  are represented  by colon and breast carcinomas  in 
comparison to adjacent normal tissues.  In most cases, at least 1.6  fold 
11 
 
increase of  A3AR density has been observed as compared to normal 
specimens. 
              Moreover, higher concentration of mRNA of A3AR  was also found 
in lymph node metastases suggesting that  disease progression  stage could be 
indicated by A3AR levels.
64 
Notably, overexpression of the the A3AR levels  
also found in remote tumor tissue along with the tumor origin. This seems to 
be associated to TNF-α upregulation, a raise in NF-kB and Wnt signaling. 
Moreover, several studies confirmed that down regulation of A3AR occured 
rapidly after the tumor  removal.
65
 More precisely, inhibition of adenylate 
cyclase by A3AR causes, decrease in  cAMP level, and consequent effects on 
PKA and PKB/Akt, control the cell cycle, which results in arrest of cell 
proliferation and inhibition of tumor growth. In fact, it has been recently 
exhibited that  phosphorylative pathways  such as ERK 1/2, p38, and Akt are 
involved in cell proliferation of glioblastoma cells mediated by A3AR. 
66
 
             The A3AR agonists such as IB-MECA and Cl-IB-MECA, have been 
widely investigated for their proliferation effects on various tumour cells. 
Interestingly co-administration of  such agonists, with 5-fluorouracil,
67
 seem 
to be responsible for the  cytostatic effect towards cancer cells, as indicated by 
cell cycle arrest at the G0/G1 phase.
68 
The cancer cell function was completely 
recuperated  after administration  of  a selective A3AR antagonist (MRS1523, 
5 in Figure 6).
69
 In addition, IB-MECA and Cl-IB-MECA were found to 
exclusively activate  A3ARs  and  inhibit the growth of primary murine 
melanoma tumors,
69
human prostate cancers, or  colon cancers
70
 in in vivo 
experiments.
68
 In addition, these compounds  added value in cancer treatment, 
by promoting (i) chemoprotective effect; 
71
  (ii) up-regulation of IL-12 in 
carcinoma bearing mice,
70
(iii) natural killer cell activity
72
. 
             On the contrary, low concentrations (100nM) of Cl-IB-MECA 
induced the proliferation of cancer cells, as demonstrated by Gessi et al.
73
 
Abbracchio and collaborators have  substantiated these results and observed 
increased Rho expression 
74
 and an enhanced anti-apoptotic protein Bcl-XL 
production. Further, they suggested that A3AR agonists stimulation might 
determine different effects depending on cell type and experimental conditions 
(e.g. concentrations). In fact, both a receptor-dependent or -independent 
inhibitory effect towards cancer cell proliferation through  the arrest at the 
12 
 
G0/G1 phase  was  observed  by  using high concentrations (10-60 μM) of the 
above-mentioned A3AR agonists 
75
 or cordycepin (i.e. 3’-deoxyadenosine, 
6)
76
. Recently, a newly synthesized A3AR antagonist (pyrazolo[3,4-
d]pyrimidine, 7) was shown to counteract the A3AR agonists Cl-IB-MECA 
and IB-MECA-induced proliferation of the glioma cells via inhibition of 
A3AR agonist-regulated ERK 1/2 activation.
77
 This observation was in 
accordance with the studies which exhibited that ERK 1/2, p38 and Akt could 
be the phosphorylative pathways responsible for A3AR regulated cell 
proliferation in glioblastoma. These findings implied that A3AR antagonists  
could be represented as  promising adjuvant  agents in the glioma 
chemotherapy. 
             On the whole, A3AR ligands are a class of therapeutically relevant 
agents that could play an important role in the neuro- and cardio-protection, as 
well as inflammatory diseases and cancer. Nevertheless, issues on the peculiar 
physiological role of A3AR activation, which may produce effects that are 
species-dependent, or produce opposite effects depending on duration and 
level of activation as well as concentration of A3 agonist used, have not yet 
been satisfactorily explained. In spite of these unclear observations, some 
promising A3AR ligands have progressed into the clinical trials, particularly  i) 
adenosine itself (Adenocard), used to treat arrhythmias and supraventricular 
tachycardia; ii) IB-MECA and Cl-IB-MECA (A3 agonists) in Phase II clinical 
studies for arthritis, psoriasis and liver cancer, (iii) QAF805 (A2BAR/A3AR 
antagonist, 4) and KF26777, (A3AR antagonist, 8), indicated for asthma; (iv) 
MRS3558 (CF502, 9  in Figure 6) in preclinical studies for autoimmune 
inflammatory diseases
78
 and (v) OT-7999 (A3AR antagonist, 10)
79
 which is 
expected to enter clinical trials for the treatment of glaucoma. 
 
1.3.6  Role of  Adenosine deaminase 
             Adenosine deaminase (ADA) (EC 3.5.4.4) is considered to be a key 
endogenous enzyme in purine metabolism and catalyzes the irreversible 
deamination of adenosine and 2’-deoxyadenosine to inosine and 2’-
deoxyinosine, respectively.
 
During electrical stimulation or energy depletion, 
adenosine is generated, mostly at the intracellular level, and subsequently 
released by a process involving a transporter.
80
 Subsequently, inactivation of 
13 
 
extracellular adenosine is believed to happen largely by uptake across the cell 
membrane, followed by either rephosphorylation to 5’-AMP, catalyzed by 
adenosine kinase (adenosine 5'-phosphotransferase, EC 2.7.1.20)  or 
deamination to inosine, which is catalysed by adenosine deaminase (adenosine 
aminohydrolase, EC 3.5.4.4). The general pathway of adenosine metabolism is 
depicted in Figure 7.
80
  
Generally, adenosine deaminase (ADA) is ubiquitous in all human tissues and 
plays a vital role in the developement of the immune system and the genetic 
ADA deficiency results in severe immunodeficiency disease  caused by 
damage of lymphoid cells differentiation and maturation.
81
 Consequently, it is 





















       
              ADA abnormalities have also been reported in other diseases, such as 
rheumatoid arthritis and leukemia.
84
 Moreover, it is described that adenosine 
concentration is increased in inflammatory lesions, hence it is considered as an 





























                        Figure 8. Novel class of ADA inhibitors. 
 
              Additionally, ADA has been the focus of interest mainly because its 
congenital defect in humans causes serious combined immunodeficiency 
disease (SCID), in turn resulting in the impairment of both B-cell and T-cell 
development.
86
 Considering the wide therapeutic application, there has been a 
continuous interest in the development of new ADA inhibitors. 
               Numerous ADA inhibitors have been reported in the literature. 
Generally, ADA inhibitors are divided into two classes, namely I) ground-state 
inhibitors
87
 (11, (+)-Erythro-9-(2-hydroxy-3-nonyl)adenine, (+)-EHNA, in  
Figure 8), which have common structure of endogenous adenosine and II) 
transition state inhibitors
88
 (12,  2’-deoxycoformycin,  dCF, in  Figure 8), 
which resembles the structure  of  the tetrahedral transition-state intermediate 
in the deamination process catalyzed by the enzyme. Apart from the natural 
products, i.e. ADA inhibitors such as (+)-EHNA and deoxycoformycin, 
several synthetic heterocyclic compounds have been tested for ADA activity. 
Among them pyrazolo[3,4-d]pyrimidine-4-one, imidazo[4,5-d] pyridazine-7-
one, imidazole-4-amide, 2-hydroxy-3-nonyl-azoles and purine riboside 
analogues are reported to be potent inhibitors of adenosine deaminase.For 
more details on ADA inhibition, please refer to Chapter 10. 
  
1.4 Overview on different classes of ligands as Adenosine Receptor 
Antagonists 
                Over the past  two decades, numerous research groups have made 
intense efforts in exploring suitable ligands for the A3AR subtype. In 
particular, an investigation on  the selective A3AR antagonists was carried out 
enormously because of their potential therapeutic applications, and their  
preferrence for pharmacological characterization of receptors. Most of  the 















11, EHNA 12, dCF
15 
 







 On the other hand, most of the A3AR antagonists 
posses  some common structural features. Mostly, they are planar in nature, 
aromatic, or π-electron-rich heterocycles and it lacks the essential ribose 
moiety, for agonist activity. In contrast to agonists, AR antagonists are novel 
in structure as compared to adenosine. The followig paragraphs demonstrate 
the different classes of A3 antagonists. 
1.4.1 Xanthine derivatives as A3AR antagonists 
              The xanthines (e.g.,caffeine and theophylline) are the classical natural 
adenosine receptor  shows  low affinity for the hA3AR subtypes (in the high 
µM range) and they are inactive at the rat AR.
16
 As a consequence, structural 
modification was carried out on the xanthine nucleus by many research groups 
to improve the affinity at the hA3AR. Consequently,  I-ABOPX (13, Figure 9, 
with Ki hA3AR =15 nM), with increased affinity  for hA3AR  was synthesized 
by the introduction of  8-phenyl substitution and large 3-substituents on the 
purine nucleus.
91
 Similarly, the cyclization of  positions 7 and 8 of the purine 
nucleus led to the improvement of the affinity (14, with Ki hA3AR = 4.0 nM), 
while further addition of a 8-methoxy group increased the affinity at  hA3AR  
and  selectivity against other ARs (15, with Ki hA3AR = 2.2 nM).  
 








































16, K i hA3AR = 3.5 nM
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positions gave rise to a new  highly potent and selective hA3AR antagonists 




1.4.2 Nonxanthine derivatives as A3AR antagonist 
              Several nonxanthine-based poly heterocyclic derivatives have been 
described as potential hA3AR antagonists. These derivatives  are generally 
classified into different subgroups, namely (i) monocyclic scaffolds; (ii) 
bicyclic scaffolds; and (iii) tricyclic scaffolds. 
 
1.4.2.1 Monocyclic scaffolds 
Dihydropyridines and pyridines. The 1,4-dihydropyridine (DHP) 
derivatives, are also found to possess  antagonistic effect  to ARs.
93
  It was 
noticed that sterically bulky groups at the 4-, 5- and 6-positions are favoured 
for the  hA3AR affinity. The combination of  bulky groups such as phenyl 
ethynyl at the 4
th 
position, benzylester at the 5
th 
position, and phenyl group at  
6
th
position (Figure 10, MRS1191, 18, with Ki hA3AR = 31.4 nM) displayed 
the best affinity profile towards hA3AR. Further incorporation of  an electron-
withdrawing  nitro  group at the 4
th
 position of the benzyl ester (MRS1334, 
19, with Ki hA3AR = 2.69 nM, rA1AR /hA3AR=>37174, rA2AAR 
/hA3AR=>37174), led to a compound with improved affinity at hA3AR and 
selectivity against the other subtypes. Simultaneously, the hA3AR affinity of 
the pyridine compounds resulting from the oxidation of 4-dihydropyridines, 




Figure 10. Structures of hA3AR antagonists: Non xanthine-based monocyclic 
structures. 
 
Furthermore, a thioester substitution at the 3-position led to a greater affinity 
at the hA3AR than oxygen analog (MRS1523, 5, with Ki hA3AR = 18.9 nM).
94
  
Thiadiazoles and thiazoles. Analogues of  thiadiazoles (20, with Ki hA3AR = 
0.79 nM) and thiazoles (21, with Ki hA3AR = 2.4 nM)  derivatives have been 
reported  by some research groups as potent and selective hA3AR antagonists.  
From the study , it was observed  that  further incorporation  of a 5-(pyridine-
4-yl) moiety in compound 21 enhanced the affinity and selectivity toward 
hA3AR (22, with Ki hA3AR = 0.4 nM; hA1/hA3 = 425,000; hA2A/hA3 = 
425,000).
95
 On the other hand, this derivative also showed high selectivity at 
rat A3AR in animal studies. Such scaffolds could be useful for the 
development of new potential A3AR antagonists, considering the relatively 
shorter synthetic procedures and polar nature as compared with other bicyclic 
and tricyclic  derivatives. 
 
1.4.2.2 Bicyclic scaffolds 
Flavonoids. Flavonoids were found to be  hA3AR  antagonists  in the 
micromolar concentration from the broad screening of phytochemicals. 
Further, using SAR and molecular docking studies, a structural optimization 


































21, K iA3AR = 2.4 nM
18 
 
hA3AR, = 561 nM), as the most potent and selective compound of the series 
for hA3AR.
96  
Isoquinolines and quinazolines. Ijzerman et al. developed the isoquinoline 
derivatives and the corresponding quinazoline derivatives (with a bio isosteric 
replacement of a carbon by a nitrogen atom at the 4-position) as novel hA3AR 
antagonists.
97
  SAR studies showed that  substitution of meta- or para- pyridyl 
substituent at the 3-position of the bicyclic nucleus increased the hA3AR 
affinity. Moreover, a para-methoxyphenyl ring connected  to  the 1-position 
via an amide or urea spacer group, was important for  high A3AR affinity and 
selectivity. The examples of potent and selective  A3AR antagonists  among 
the isoquinoline and  quinazoline  derivatives are  VUF8504 (24, with Ki 
hA3AR = 17 nM) and VUF5574 (25, with Ki hA3AR = 4 nM) respectively. 
 
 
Figure 11.  Structures of hA3AR antagonists: Non xanthine-based bicyclic 
structures. 
 
Adenosine - and adenine - based derivatives  
Some  studies  have focused on the design of adenosine-based analogues  as 
A3AR antagonists, since adenosine  binds well  to the A3AR  across different 
species. From the molecular modeling studies, it was reported  that the 
flexibility of the 5’-region in the ribose moiety played an essential role in 










































































29, Ki A3AR = 1.66 nM
19 
 
the 5’-region, induced the A3AR’s inhibition, as shown by  potent A3AR 
antagonist MRS1292 (26, with Ki hA3AR =29.3nM).
98
 Subsequently, it was 
observed that  bisalkyl substitution  at 5’-N-uronamide led to the identification 
of selective antagonists; for example, derivatives were obtained by N-
dimethylation (MRS3771, 27, with Ki hA3AR = 29 nM and 28, with Ki 
hA3AR = 9.32 nM) or a removal of 5’-position substituents (29, with Ki 




1.4.2.3 Tricyclic scaffolds 
Triazolo quinazolines. The first tricyclic heterocyles to be discovered as 
promising AR antagonists were the triazoloquinazoline derivatives. Among 
the  different compounds synthesized, CGS15943 (30, Figure 12. with Ki 
hA3AR = 13.8 nM), is a reported as  a non-selective AR antagonist, and served 
as a starting template for futhere developement of potent and selective hA3AR 
antagonists. Notably, the  acylation  of  N
5
 amino group with aryl or aralkyl 
moieties has enhanced  both the hA3AR affinity and selectivity (e.g. 
MRS1220, 31, with Ki hA3AR = 0.65 nM).
100
  
Triazolopurines. Triazolopurine derivatives were developed by incorporation 




 position of the purine nucleus, which led 
to the highly potent and selective hA3AR antagonists (32, Ki hA3AR = 0.18 
nM;  10, Ki hA3AR= 0.95 nM).
79,101
 In addition, introduction of a  bulky 2-
phenyl ring and a butyl chain enhanced hA3AR affinity and the selectivity. 
Moreover, very potent and selective derivative 10 (OT-7999) showed  
lowering of  IOP in animal models, thus indicating a promising application in 
the treatment of glaucoma.  
Triazoloquinoxalines. The triazolo-[4,3-a]quinoxalines (TQX) and triazolo-
[1,5-a]quinoxalines  are examples of class  of  hA3AR antagonists, which also 
share  structural similarities with  a non-selective AR antagonist CGS15943 
(30). In the triazolo[4,3-a]quinoxaline series, the acylation of the 4-
aminogroup with alkyl or aralkyl substituents with subsequent introduction of  









Figure 12. Structures of hA3AR antagonists: Non xanthine-based tricyclic 
structures. 
 
Furthermore, the hA3AR affinity and selectivity was modulated by different 
substituents on the 2-phenyl ring, especially electron withdrawing and 
donating substituents such as para-methoxy, para-methyl, and para-chloro. It 
was observed  that  the  para-NO2  substitution  at the 2-phenyl chain was 
essential  for the  A3AR affinity and selectivity in the 1,4-diones series (33, 
with Ki hA3AR = 0.6 nM). 
Pyrazoloquinolines. The series of pyrazoloquinolin-4-ones and pyrazolo 
quinolines were identified  as  potent and selective hA3AR antagonists 
104,105 
sharing  a  common central nucleus with the TQX series. Similar to the TQX, 
the substituent on the 2-phenyl ring play a crucial role in modulating  A3AR 
affinity, while a nuclear (e.g. oxogroup) or extranuclear (e.g. amide group) 
C=O proton acceptor substitution at the 4-position  led  to potent and selective 
A3AR antagonists. At  the 2-position, the presence of 4-chloro,4-methoxy, 4-








































































hA3AR affinity in the 4-one (34, Ki hA3AR, 2.9 nM). The introduction  of  an 
acyl group and carbamoyl residue (35, with Ki hA3AR, = 2.1 nM) at  the  4-
position,  resulted in retention of  the  hA3AR affinity  and selectivity, 
confirming the significance of the C=O group with the receptor site 
interactions. 
Pyrido-triazolo-pyrazinones. Pyrido-triazolo-pyrazinone is a novel scaffold 
that exhibits SAR similar to  TQXs at the hA3AR receptor.
106
 Also in this 
series, para-methoxy group at the 2-phenyl ring displayed high binding 
affinity in the 4-oxo series (36, with Ki hA3AR = 3.3 nM). Similarly the same 
substitution in the 4-amido series (compound 37, with Ki hA3AR = 4.5 nM) 
showed high affinity, as compared to the unsubstituted 2-phenyl 
derivatives.When the 4 amino group was substituted,  particularly by acyl 





1.5 Overview of structure-activity relationships profile of 
pyrazolopyrimidines as A3AR Antagonists
 
              Pyrazolopyrimidines represent a novel, recently reported series of 
bicyclic scaffold-derived hA3AR antagonists
 
that display improved hA3AR 
affinity and selectivity profiles compared with their isosterically related 
derivatives, the imidazole [1,2-a][1,3,5] triazines. Lenzi et.al synthesised a 
series of 2-phenyl pyrazolo[4,3-d]pyrimidine-7-one derivatives as a result of 
molecular simplification from the tricyclic scaffold of pyrazolo[3,4-
c]quinolin-4-one (38, Figure 13) modified at C
5
 position by different alkyl 
(H,Me, Et) and aryl (Ph,CH2Ph) groups in order to investigate the lipophilicity 





substituents of the bicyclic nucleus were essential for 
hA3AR affinity and selectivity. Small  methyl group substitution at the C
5
-
position  along with para methoxy-substituted  phenyl group at the N
2
-
position (39, with Ki hA3AR = 1.2 nM), afforded the most potent and selective 
hA3AR antagonist in this series of derivatives. However, A3AR binding 
affinity was unfavourable when the C
5















Figure 13.  Molecular simplification of tricyclic pyrazolo[3,4-c]quinolin-4-
one to pyrazolo[4,3-d]pyrimidinone 
 
             Moreover, in another study, the SAR profile of an isomer of this series 
indicated that  amido (40, Figure 14) or ureido moieties (41) at the C
4
-
position, along with a phenyl ring at the C
6
-position at the bicyclic scaffold, 
were key pharmacophoric elements for the recognition at the ARs and 
essential for promoting A3AR affinity and selectivity. As small methyl group 
(40) and bulkier benzyl moiety (41) were well tolerated, it is speculated that 
the N
2
-position is associated with a good degree of steric tolerance. Compound 
40, with low nanomolar affinity at  the A3AR and the high selectivity against 
other AR subtypes (40, Ki hA3AR = 0.18 nM; hA1/hA3 =5,761 nM; hA2A/hA3 
= 17,661 nM and 41, Ki hA3AR = 2.9 nM; hA1/hA3 = 3448; hA2A/hA3 = 
3448), has been suggested as a potential  lead compound  for the development 
of other potent analogues. Subsequent  test of compound 40  on human glioma 
U87MG cells counteracted the A3AR agonist-mediated proliferation of the 
glioma cells via the inhibition of ERK 1/2 activation. Therefore, this 
compound might also represent a potential starting template for the 
development of adjuvant agents in the glioma chemotherapy.
77,108 
 
Figure 14.  Structures of pyrazolopyrimidine and related ligand as as hA3AR  
antagonists.
 





































2-phenyl-2H -pyrazolo[4,3-d]pyrimidin-7(6H)-one2-phenyl-2H -pyrazolo[3,4-c]quinolin-4(5H )-one
OCH3









             A series of [1,2,3]triazolo[4,5-d]pyrimidines, which could be 
considered bioisosteres of pyrazolo[3,4-d]pyrimidines, was synthesized by 
Biagi et al.
109
 From the SAR study, it was noticed that an aryl carbamoyl chain 
at the N
6







- positions in pyrazolo[3,4-d]pyrimidines, respectively) led to 
compound 42 (Ki hA3AR = 6.0 nM; hA1/hA3 =72; hA2A/hA3 =1,341)
109
 that 
was less potent and less selective towards hA3AR when compared with 
pyrazolo[3,4-d]pyrimidine derivatives.  
 
1.6  Overview of structure - activity relationships profile of pyrazolo-
triazolo-pyrimidine as hA3AR Antagonist
 
             The pyrazolo-triazolo-pyrimidines (PTPs) are hybrid molecules 
derived from a hA2AAR antagonist
 
and an A3AR agonist which resembles the 





 When  the N
5
-position of PTP scaffold of a known hA2A 
antagonist was substituted with a para-methoxy phenyl carbamoyl moiety, an 
optimal A3AR affinity was observed. Moreover, such rational design resulted 
in compound 43 (Figure 15, with Ki hA3AR = 0.6 nM),  with very high 
hA3AR affinity and selectivity.
113
 Subsequently, from different studies, methyl 
group at the N
8
-position and unsubstituted phenyl group at the N
5
-position  
were identified as crucial features for hA3AR affinity which was confirmed by 
compound 44 (Ki hA3AR = 0.16 nM).
114,115,116 
Compound 45,  with  water   
solubility of  11mg/ml attianed  by N
5
 pyridinium salt substitution, which also 
significantly improved hA3AR affinity (Ki hA3AR = 0.01 nM).
117
 
             On the contrary, replacement  of the N
5
-phenyl moiety with different 
N
5
-heteroaryl rings resulted in a general loss of hA3AR affinity and selectivity. 
Recently, our group
118
 has synthesized a series of pyrazolo-triazolo-
pyrimidines (PTP) derivatives as potent and highly selective hA3 adenosine 
receptors antagonists. From the binding assay it was confirmed that the 
presence of a free amino group at C
5
 position of  PTP analogue lowered 
hA3AR (50, Ki hA3AR = 75 nM) but it also showed good interaction at both 
hA1 and hA2AAR. Moreover, subsequent  substituents incorporation at the C
5
 




















































































54, K i hA3AR = 25 nM




























51, K i hA3AR = 68 nM
hA1/hA3= 23
hA2A/hA3 = 12
49, K i hA3AR = 6.94nM































48, K i hA3AR =6.88 nM
46, K i hA3AR = 0.345 nM
hA1/hA3= 70700
hA2A/hA3 = >290000
47, K i hA3AR = 5.24 nM
hA1/hA3= 5730
hA2A/hA3 = >19100





































improving the hA3 subtype selectivity. This finding seems to imply that the 
hA3 binding cavity around the C
5
 position is rather spacious accommodating 
extended chains such as benzoyl and phenylacetyl groups. Between these two 
substituents, the longer phenylacetyl group  (e.g. 46, Table 1 and Figure 15, 
with Ki hA3= 0.345 nM, hA1/hA3= 70700; hA2A/hA3>290000) showed 
relatively better binding profile than the shorter benzoyl chain (47, Ki hA3= 
5.24nM, hA1/hA3>5730; hA2A/hA3>19100). Moreover, the vacant NH at C
5
 
was not crucial because substitution with an additional benzoyl chain (as in 
compound 48, with Ki hA3= 6.88 nM and 49, with Ki hA3= 6.94 nM), although 
less favorable than a single chain, still retained  affinity at hA3 receptor and 






















Figure 16. Overview of structure-affinity relationship for the novel series of 
2-aryl-PTP derivatives 
* Replacing 2-furyl ring with 2-aryl ring with N5-NH2, -NHCOPh and -NH-
COCH2Ph  substitution                    improved hA3 affinity and selectivity 
 
* Replacing 2-furyl ring with 2-aryl ring with N
5
-NH- CONHPh                   
decreased hA3   affinity but improved selectivity  
 
• R2 = (4-F/Cl/Br/OMe/NO2/CF3/Ph)-Ph. 
 
             4-F/Cl/OMe are tolerable in all derivatives; 4-F/OMe shows higher hA3 
             affinity; 4-OMe high selectivity, 4-Br or 4-NO2 intolerable 
 
Small alkyl chain (e.g.CH3)          hA3 
affinity and selectivity  
Longer and bulky alkyl chain (e.g. 




-alkyl chain             hA2A affinity. 
R1 = NH2                 moderate affinity at hA3 receptor; low 
selectivity  
NH-COPh              high hA3 affinity and selectivity  
NH-COCH2Ph             best hA3 affinity and high 
                                    selectivity  






This finding again supported the predication that the binding pocket of hA3 
receptor around this C
5
 position was roomy enough to accommodate the bulky 
and branched imide substituent, while there was limited space available for 
such bulky groups at A1 and A2A subtypes and resulted in decrease of affinity. 
         Further in the study, it was found that  C
5 
amino compound 50, with a 
small alkyl group at N
8





 positions. This was further confirmed by the 
introduction of a slightly longer alkyl chain (e.g., an ethyl group in compound 
51, with Ki hA3= 68.7 nM; hA1/hA3= 22.9; hA2A/hA3= 12.3), which still 
showed hA3 antagonism and moderate selectivity. Notably, when the same 




 (as in compound 52,  with Ki 
hA3= 565 nM) the affinity at hA3 receptors dropped by at least 8 fold, with the 
resulting binding affinity profile inclined toward hA2A receptors (Ki hA2A= 
83.8 nM). Conversely, when a group bigger than ethyl was introduced at N
8 
(e.g. phenylethyl group in compound 53,  with Ki hA3= 76.7 nM), a decrease 
of  affinity at hA3 receptor was observed as similar to compound 50. In 
derivatives with free amino group at C
5
 position, the introduction of a 
methoxy group in para position of the phenyl in C
2
 position (54, with Ki 
hA3=25.0 nM) improved the hA3 affinity. 
             Interestingly, when a substitution was introduced at the C
5
 position 
and a small alkyl group was kept in N
8
 position, affinity increased remarkably 
towards the hA3AR. In fact compound 55, with a phenyl at C
2
, a methyl group 
at N
8
 and a phenyl acetamide at C
5
, showed the best hA3 affinity profile of this 
class of compounds (Ki hA3=0.108nM) and good selectivity against the other 
AR receptor (hA1/hA3 =5200; hA2A/hA3 =7200). Figure 16 displays the 
overview of structure-affinity relationship for the novel series of 2-aryl-PTP 
derivatives. On the whole, these results supported the importance of the 
introduction, in the PTP system, of (a) small substituents (e.g. CH3) at the N
8
 
position to maintain affinity and selectivity at hA3AR and (b) a lengthy chain 
such as a phenyl acetyl group at the C
5
 position to obtain a higher affinity and 





1.7 Other therapeutic applications of  pyrazolo[3,4-d]pyrimidines  
             Pyrazolopyrimidines are popular synthetic pharmacophores with 
numerous reported biological activities partially because of their structural 
similarity to purines. Purine-containing small molecules (such as ATP and 
GTP) are widely distributed in nature, and can be recognized by various 
proteins such as kinases and GTPases.
 
Consequently, pyrazolopyrimidines 
have been exploited as adenosine deaminase inhibitors
119
, ATP competitive 
inhibitors of kinases (mTOR, EGFR and CDK2)
120-122





1.7.1 Pyrazolo[3,4-d]pyrimidines as adenosine deaminase (ADA) 
inhibitors  
             The synthesis of a number of 1- and 2-alkyl derivatives of the 4-amino 
pyrazolo[3,4-d]pyrimidine (APP) nucleus and their evaluation as inhibitors of 
ADA from bovine spleen was reported by Da Settimo et al.
119
 From the 
pharmacological assay, the 2-substituted amino pyrazolopyrimidines proved  
to be  potent ADA inhibitors and  most of them exhibited  Ki values in the 
nanomolar range. The inhibitory activity of  this series was enhanced with the 
increase in  alkyl chain length, attaining a maximum with the n-decyl 
substituent at the N
1
 position. Insertion of a 2’-hydroxy group in the n-decyl 
chain led to compound 56  (Figure 17), which displayed the highest inhibitory 
potency of the series (56,  Ki = 0.053 nM). 
 
1.7.2 Pyrazolo[3,4-d]pyrimidines as ATP-Competitive inhibitors of 
kinases  
1.7.2.1 The mammalian target of rapamycin (mTOR) 
               Recently, Verheijen et al.
120
 reported a series of 4-morpholino-6-
aryl-1H-pyrazolo[3,4-d]pyrimidines  as potent and selective  mTOR inhibitors. 
In this study, the 6-aryl substituent  of the scaffold was extensively modified 
to obtain inhibitors of  mTOR with subnanomolar inhibitory concentrations. 
Subsequent, 6-arylureidophenyl substituents resulted in potent mixed 
inhibitors of  mTOR and phosphatidylinositol 3-kinase R (PI3K-R). However, 




Figure 17.  Structures of  pyrazolo[3,4-d]pyrimidines  as various enzyme 
inhibitors 
 
Similarly,  6-alkylureidophenyl  groups were combined with  1-carbamoyl 
piperidine substitution (e.g. 57, IC50 = 0.2 nM) resulted in  potent mTOR 
inhibitor with  IC50 in subnanomolar range and selectivity of 1000-fold over 
PI3K-R. In addition, several 6-arylureidophenyl-1H-pyrazolo[3,4-
d]pyrimidines were substituted at the 4-position of the arylureido moiety with 
water solubilizing groups as a result of structure based drug design approach. 
Subsequently, these compounds displayed potent mTOR inhibition (IC50<1 
nM) with novel cellular proliferation activity in assays (IC50<1 nM). 
1.7.2.2  EGF-R PTK Inhibitors 
              Pyrazolo[3,4-d]pyrimidines class  was designed based on a 
pharmacophore model for ATP-competitive inhibitors which  interact with 
epidermal growth factor receptor (EGF-R) protein tyrosine kinase (PTK) 











































































pyrazolo[3,4-d]-pyrimidines as potent EGF-R tyrosine kinase inhibitors. 
Moreover, the derivatives of 4-(phenylamino)-pyrazolopyrimidines were 
shown to be selective tyrosine kinase inhibitors with potent  in vitro and 
cellular activity  and  combined in vivo efficacy.
121
  Mostly, compounds  of  
this  series  showed inhibition  with  IC50 values of below 10 nM. Among  
them,  compound 58  showed  highest activity of  1nM against EGF-R PTK. In 
addition, compounds 59  and  60  showed satisfactory oral bioavailability in 
mice and  presented improved  in vivo efficacy  at  doses  of  12.5 and 50 
mg/kg using  EGF-R overexpressed A431 cell line in a nude mouse tumor 
model.  
 
1.7.2.3 CDK inhibitors with antiproliferative activity 
              A  new series of pyrazolo[4,3-d]pyrimidine  scaﬀold  as potent  
CDK2 inhibitor was reported by  Jorda et al.
122
 Compound 61 was prepared 
using a known CDK inhibitor roscovitine (62) as bioisotere. In several 
biochemical and biological assays, the eﬀects of compound 61 were compared 
with those of its bioisoster, roscovitine. These analyses showed similar kinase 
selectivity proﬁles of roscovitine (62) and compound 61, yet apparently higher 
eﬃciency of the latter compound. The overall molecular and cellular eﬀects of 
compound 61 were consistent with its ability to inhibit CDKs and  
furthermore, exhibited  evidence for a role of CDKs in maintenance of  DNA 
repair by homologous recombination (HR); The data suggest that blocking 
HR-mediated  repair by compound 61 and perhaps also by other CDK 
inhibitors could potentially  be  exploited  in cancer. Importantly, enhanced 
anticancer activities were observed for  pyrazolo[4,3-d]pyrimidine 61 
compared to  its bioisostere roscovitine (62). Hence, the reported compound 
61 could be preferred for cancer treatment. 
 
1.7.3 Pyrazolo[3,4-d]pyrimidines as DNA polymerase inhibitors 
                Ali et al reported a series of  6-anilino substituted pyrazolo[3,4-
d]pyrimidin-4-ones  as inhibitor of  enzyme  DNA polymerase III replication 
in staphlococcus aureus. The scaffold was considered as a novel  dGTP 





enhance the potential of these  inhibitors as antimicrobials, further  structure-
activity relationship studies was performed  on this scaffold  involving  
substitutions at the 2, 4, and pyrazolo NH positions. All  the  new inhibitors  
were  investigated  for  their  ability  to inhibit  S.aureus-DNA pol III and Gr
+
 
bacteria in culture. Consequently, substitution of  2-anilino groups along with 
meta or para position substitution  of  small hydrophobic groups (63, MIC= 8 
µg/ml) enhanced both antipolymerase and antimicrobial activity. These 
pyrazolo[3,4-d]pyrimidine derivatives resulted  in  development of  a new 
class of  antimicrobials with promising Gr
+
 bacteria antagonistic activities. 
 
1.8  Molecular Modeling on hA3AR and its ligands 
             Presently, most of the  drug discovery process involves the 
combination of computational strategies with coventional synthetic 
procedures. Generally, computational strategies identifies the  structural 
features of  ligands attributing to biological activity, and  guiding to  the   
optimization of lead compounds. Moreover,  these theoretical methodologies 
unveil the important  atomic level  ligand-receptor interactions. Several 
molecular modeling studies such as  quantitative structure–activity 
relationship (QSAR),  homology modeling  and molecular docking have been 
performed on the hA3AR and its ligands. Among these modeling studies, the 
molecular docking simulations and QSAR studies performed on the pyrazolo 
pyrimidine (PP) and pyrazolo-triazolo-pyrimidine (PTP) derivatives as hA3AR 
antagonists are discussed in the following sections. 
 
1.8.1 Quantitative structure-activity relationship (QSAR) studies 
              QSAR has been a useful technique for improving  drug discovery of  
hA3AR ligands. In such a computational approach, molecular descriptors 
(different structural features) are chosen to build  a theoretical model.The 
molecular recognition of hA3AR is depend on the descriptors. Topological and 
electrostatic potential descriptors are examples of such molecular descriptors 
which comprise of related information particular to an individual 
compound.
124
  Moreover, such a constructed  model could also assist in the 
structure optimization of the lead compounds and in the discovery of new 
potent adenosine ligands.
125,126
 The following sections illustrate some 
31 
 
examples of QSAR studies performed on pyrazolo-triazolo-pyrimidine 
derivatives as potent hA3AR antagonists. 
Pyrazolo-triazolo-pyrimidines. Moro et al recently proposed a receptor-
based and ligand-based drug design  approach to  define a  pharmacophore  for 
PTP derivatives . 
115
 In this study, QSAR was performed using docking-based 
structure super imposition for the PTPs through Comparative Molecular Field 
Analysis (CoMFA). CoMFA model  produced good correlation coefficients 
(non-crossvalidation r
2




pred). Similarly, the 
steric and electrostatic contour plots seemed to be consistent with the ligands 
hypothetical binding interactions of molecular docking simulations. CoMFA 
suggested that, sterically bulky substituents  are  favoured  for  affinity  as  a 
green polyhedron (favours bulky groups) was observed around N
5
-aryl 
carbamoyl moiety. Similarly, a N
5
-phenyl ring  was surrounded  by  blue 
polyhedron (favours electron positive groups). Both of these contours 
surrounding the N
5
-substituents  were complementary to the surrounding 
nonpolar residues such as Ile98, Ile186, and Leu244. Moreover, N
8
-
substituents and the N
5
-carbamoyl moiety  were  surounded by red polyhedra 
which in turn reflected by surrounding  polar residues  Ser175, His95, Ser247, 
and His272 in the docking study.  
            On the other hand, Tafi et al. 
127
 defined  the pharmacophore map 
using  ligand-based structural alignment to obtain the hA3 antagonists via the 
catalyst program. The docking simulation for the PTP  derivatives was later 
performed  based on the best catalyst-driven pharmacophoric frame work. The  






- positions, an 
aromatic appendage at the tricyclic core and a H-bond acceptor at the amidic  
group were  vital  for the hA3 receptor antagonism. 
            Similarly, Cheong et al
128
 elucidated a pharmacophore model for the 
novel series of 2-aryl-PTP derivatives. A ligand-based pharmacophore was 
obtained for a new series of 2-unsubstituted  and 2-(para-substituted)phenyl-
pyrazolo-triazolo-pyrimidines as potent  antagonists of  hA3AR. CoMFA  







positions of the tricyclic nucleus, with more emphasis given to the 
unprecedentedly explored C
2
-position. According to the CoMFA model,  blue 
contour was observed  in close proximity to the C
2
 position phenyl ring in the 
32 
 
tricyclic nucleus. It was deduced that the delocalization of electrons towards 
the pseudo aromatic tricyclic core has exerted its effect on the phenyl ring, 
thus rendering the surrounding region to be more electron deficient. Similarly, 
the green contour was seen  around  the  phenyl ring at both the N
5
-positions 
of the tricyclic nuclei, indicating that bulky groups were tolerable around this 
region.  
             Consistently, a  red  contour was seen at the para-position of such N
5
-
phenyl ring in the PTP derivatives (Figure 18-B). This observation was 
further substantiated by the good hA3 affinity profile of compounds ranging 
from 0.2 to 0.4 nM, which bear electro negative groups at the para-position.  
Similarly, the presence of p-F or p-OMe on the phenyl ring of N
5
-
arylcarbamoyl chain in the newly synthesized  2-aryl-PTPs  was  found  
favourable for the hA3 affinity as well. A small patch of   yellow contour was 
found between the meta and para-positions of  the phenyl ring in PTP 
derivatives bearing the aryl carbamoyl chain, suggesting that only substituents  
of certain size were acceptable at these two positions. Likewise, a red contour 
was also seen around the CONH- group at N
5 
position of the scaffold, 
indicating that the presence of  an electro negative group (e.g. carbonyl group) 
was favoured for  hA3 affinity. Interestingly, electron-withdrawing effect of  
 
 
Figure 18. A. Distribution of steric and electrostatic effects in the 2-aryl-
pyrazolo-triazolopyrimidine derivative. The distances (Å) among the three 







aryl ring are indicated. B. Combined steric and electrostatic contour plots 






para-substituents at phenyl ring and delocalization of electrons in the nearby 





              Moreover, a green contour observed around the substituent at N
8
-
position of PTPs (Figure 18-B) implied that incorporation of the less bulky 
methyl group was more favourable at the N
8
-position as compared to the bulky 
alkyl chains such as phenyl ethyl group to provide good affinity at hA3 
receptors. Obviously, an inverse relationship was observed between the 
binding affinity and  the molecular volume (MV) of  the substituent  at  
position  N
8
.  In addition, N
7
 of the pyrazole ring in PTPs was surrounded by a 
red contour. On the other hand, N
8
-position of  PTPs was covered by a small 
blue contour. The electrostatic effect at this position seemed negligible; 
whereas the steric effect at this position was assumed to determine a essential 
role towards the hA3 affinity.  
             Overall, the CoMFA-based model confirmed that steric effect was 




-positions and at the para-position of 2-phenyl ring 
(Figure 18-A). In addition bulkygroups  were unfavorable at both the N
8
-
position and  para-position of  2-phenyl ring, while the N
5
-position of the 
tricyclic nucleus favour the bulky groups. For the electrostatic effect, para-
position of amidic group at  N
5 





-positions favour  the electropositive group. Overall, the steric 
effect was found to be relatively more predominant than electronic effect for 
antagonists interaction to the hA3 receptor.
129
 
             Although CoMFA methodology has been widely  used in the research 
field, yet CoMFA posesses some weaknesses. The most challenging is its 
input requirement that each ligand structure can be represented as a 3D model, 
by selecting an absolute orientation of a single conformational alignment. 
Sometimes, the alignment can yield excellent models with superior predictive 
ability.
130
 However, only one method exists for validating the alignment 
procedure, which is the maximization of various q
2





 This averages the internal predictive accuracy  for every structure-
activity observation. Similarly, the other major difficulty  of  the CoMFA  
method  is  in  its  results application. These two CoMFA difficulties is  
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addressed by “Topomer  CoMFA” a completely objective and universal 
methodology for generating a alignment  for structural fragment, both a 
conformation and its orientation in a cartesian space. By definition, structural 
fragments contain a common feature. Topomer CoMFA is a 3D-QSAR tool  
which automatically generates a model  for predicting the biological activity 
or properties of compounds.
132,133
 Basically, structural  fragments posesses a 
common features such as  “open valence” or “attachment bond”. The topomer 
methodology overlaps this common feature to offer an absolute orientation for 
any fragment. A single fragment conformation is then generated from a 
standardized  3D model by rule based adjustments  to acyclic single bond  
torsions and chiralities.Topomer CoMFA has been applied to the  four 
different cases, where  structure/activity observations are converted into sets 
of  mutually comparable fragments. These are  
[i] A purely congeneric series, for example, a combinatorial  library sharing  a 
common nucleus. Differing  portions  of  the structures  contribute to the 
differences in activity. Consequently, the variables responsible for the 
differences in potency, can be  removed from the common core, to become the 
set(s) of topomerically modeled  fragments.  
[ii] A roughly homologous series, with each individual structure  consisting of 
more than one large group connected by one or more acyclic bonds, but within 
one of those large groups identical throughout  the  series.  
[iii] A roughly homologous series containing only one large group, which is 
similar though not identical across the series.  
[iv] Series having negligible homology. In the absence of recognizable 
commonalities, it may be helpful to identify subseries, each having both a 
structural commonality.  
 
1.8.2  Homology modeling of hA3 receptor 
             Characterzation of the GPCRs are  usually hamperd by the technical 
difficulties in X-ray crystallography  and NMR experiments. Due to that 
reason 3D structure of  the  hA3AR has not been elucidated yet. Nevertheless, 
construction of hA3 receptors have been performed using a computational 
approach. This hA3 receptor model, through molecular docking analysis aid in 
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the potential binding pocket predictions and also plays an essential role in the 
structure-based drug design. 
1.8.2.1 Progress of hA3AR homology modeling 
            Moro et al.
134
 constructed the human A3 adensoine receptor models 
utilizing low resolution electron density maps (EDM) of rhodopsin, via the 
“cross-docking” methodology.  The high resolution  crystal structure  of  
bovine  rhodopsin (PDB Code: 1F88) at 2.8 Å was discovered in the year 
2000. Since then, the homology  model of hA3AR  are constructed using  such 
a template.
106
 Although the  transmembrane systems are similar as that of    
adenosine receptors, very limited sequence  identity  was observed for  the 
bovine rhodopsin  with  A3  receptors  (less than 20% sequence ID).
135
 
Recently, the crystallographic structure of  human beta2 (β2)-adrenergic GPCR 
(PDB Code: 2RH1) 
136
 and  human A2A receptor (PDB Codes: 3EML)
113
 at 2.4 
Å and 2.6 Å has been resolved respectively. Subsequently, hA3 receptor 
homology models  are constructed using  these alternative templates. 
77
Interstingly, due to  relatively high percentage of about 43% of sequence 




              Evers et al. introduced ligand assisted homology modeling as an 
alternative to conventional homology modeling, where the binding site is 
incorporated with ligand molecules to model a  GPCRs by homology.
138
 In 
this approach, accurate geometries of the protein binding sites are obtained by 
keeping the ligand molecules  bound to the models as restraints. Recently, 
Moro and his co-workers  applied a similar strategy, namely ligand-based 
homology modeling (LBHM), on the hA3AR.
139 
In this study  multi-
conformational space  of  the  antagonists  were explored along with  ligand 
binding inducing possible  receptor reorganization.  Validation of this method 
was carried out by  analysis of  more than  200  known  hA3AR antagonists  in 
the corresponding  putative  ligand  binding site. Through  this multi-
conformational  states  approach, a consensus  binding  motif among all 
known antagonists  has been found, and a novel ‘Y-shaped’ 3D- 
pharmacophore  has  been  deduced  by obtaining a concensus binding motif  
based on this multi-conformational states approach. Applying such receptor-
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based pharmacophore, the potential hit could be screened from the available 
compound database. 
 
1.8.2.2  hA3AR models 
             In general, the TM regions of GPCRs comprise of the same overall 
topology and the most conserved residues in each helix  guide the sequence 
alignment.
 
Nonetheless, the loops constitute the most variable regions. 
Particularly, the extracellular loop 2 (ECL2) is of  particular interest in 
homology modeling of adenosine receptors. The highly conserved disulfide 
bond formed between the cysteine 166 (ECL2) and cysteine 83 (TM3) plays a 
important role in ligand recognition. The formation of disulfide bond is  
considered critical for determining the conformation  of the ligands binding 
pocket. To-date, a number of A3AR models have been built based on the 
bovine rhodopsin template (Figure 19 (A)) which  describe the hypothetical 




             Recently, the A3AR models  have also been  constructed based on  the  
human β2-adrenergic receptor (Figure 19 (B)) and the hA2AAR receptor 
(Figure 19 (C)) template.
77, 137  
Among  these models, the main differences 
were observed at the ECL2, ICL3 and extracellular end of  TM1.
137
 As the 
ECL2 is deemed essential for  ligand recognition, differences in the ECL2  
between the models widely affect the structure based drug design. The bovine 
rhodopsin-based  homology model consists  of  a  seven-helical bundle with a 
central cavity surrounded by helices 3, 5, 6 and 7. The access  of  the ligands 
into the central cavity is governed by the ECL2, which  possesses  a  β-sheet 
secondary structure. As mentioned earlier, this model has been widely used to 
identify putative ligand-receptor interactions  and  rationalize the structure-
affinity relationship of  known  hA3AR  antagonists  and  agonists. For  the 
human β2-adrenergic receptor-based  homology model, the location  of  the 
hA3AR antagonist is found similar between  the  models  obtained  from  the  
rhodopsin  and  the  β2-adrenergic receptor, despite the fact that there are 
structural differences in the ligand binding  sites  between  the two models. 
The presence of a α-helix on ECL2 in models (opened to extracellular site) 
























   
 
 
Figure 19. Topology of (A) bovine rhodopsin-based hA3 homology model (B) 
human β2 adrenergic receptor-based hA3 homology model (C) hA2A adenosine 




measurement  difficult. They are measured as 1620 Å
3
 and 1930 Å
3
 
respectively.  However, these  models  are not comparable  to the  model 
which enables the accessibility of ligands into the central  binding  sites. In the 
hA2AAR-based homology model, the helical arrangement is similar to other 
homology models. Nevertheless, the helices are shifted, and the differences 





binding  pocket  of  ligands for such a model shifted closer to the TM6 and 
TM7 and open to the extracellular side. With regards to the volume of  binding  
site, both A3AR  bovine rhodopsin-based model, where the binding site is 




1.8.2.3  Evaluations of hA3AR model 
             Evaluation of  hA3 receptor model is a crucial factor in confirming the 
accuracy of homology modeling. The commonly employed strategies are: 
(i) Checking the  protein  stereochemistry using  Ramachandran Plot, χ plot, 
clash contact reports, and Dope Score
141
 
(ii) the concordance with data from site-directed  mutagenesis of hA3AR; the 
residues that mutagenesis studies have been identified to play a significant role 




(iii) the affinity and selectivity profile of newly synthesized derivatives should  
be rationalized by models through analysis of the hypothetical binding 
interaction between the ligand and the respective residues in the docking 
studies.
142 
Based on such receptor-based structural information, new 
compounds are rationally designed and synthesized; 
(iv) the model  should also be able to suggest the mutation of  residues that the 
model predicts to be important  for ligand-receptor interaction, which is then 




1.8.3 Molecular Docking Simulations 
             Molecular docking simulations relies mainly on the interactions of 
ligands with the receptor target in a three dimensional environment.  For 
hA3AR, the affinity of the hA3 ligands to such a receptor is a result of 
structural and chemical complementarities, which can be determined through 
identification  of  binding modes and interactions of  ligands inside the 
receptor cavity. All the docking studies are performed on a hA3 receptor 
homology model, since the crystal structure of  hA3 receptor has not been 
resolved yet. Through the hA3 models, the binding modes of different 
scaffolds of  hA3 ligands are depicted and experimental hA3 binding affinities 
of these ligands are therefore rationalized. The majority of these hA3 models 
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are based on the bovine rhodopsin template based homology models, with 
increasing number of models constructed from the recently resolved hA2A 
receptor crystal structure. The following sections illustrate  some examples  of  
molecular docking studies carried out on pyrazolo- pyrimidine (PP) and 
pyrazolo-triazolo-pyrimidine (PTP) derivatives that have been described as 
potent hA3AR antagonists. 
 
1.8.3.1 Pyrazolo[4,3-d]pyrimidinones 
             Lenzi et al performed the  molecular docking  simulation  for the  
series of  pyrazolopyrimidinone derivatives (compound 39) using hA2AAR 
crystal structure based homology model.
107
 In  the  docking experiments, it 
was observed that carbonyl group at the 7-position  and the N atoms  of  the  
pyrazole  ring interacted with aminoacid residue Asn250(TM6) by stabilizing 
hydrogen bonding interactions. Moreover the ligand made various 
hydrophobic interactions with binding residues, especially , the  aromatic π–π 
stacking interaction was observed between 2-phenyl ring and Phe168(ECL2). 
Similarly,  pyrazolopyrimidi-7-one core made hydrophobic interaction with 
highly conserved residue   Trp243 (TM6). It was also noticed that  small  
electron donor groups such as methyl and methoxy  at  para  position  of  2-
phenyl  moiety  strengthened  the    π–π  stacking interaction  of  2-phenyl 
group with receptor.  
 
1.8.3.2 Pyrazolo[3,4-d]pyrimidines 
             The docking studies were performed for the pyrazolo[3,4-
d]pyrimidine derivatives (compound 40) on an hA3AR model derived from the 
homology modelling using hA2AAR crystal structure as template.
77
 It was 
noted that  the methyl group of the scaffold was  pointed  towards the 
extracellular membrane and made potential interaction with  with 
Phe168(ECL2) and Leu246(TM6). Subsequently  acyl chain  at N
4
-position 
was enclosed in the cleft between TM2 and TM3, and  its branch 6-phenyl 
ring was accomadated inner side of the TM5 and TM6. As expeccted, the 
pyrazolo pyrimidine scaffold  was interacted with Phe168 by a π–π  stacking 





nitrogens and the Asn250 (TM6) of  receptor. Moreover, the 6-phenyl ring  
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and  acyl moiety of the ligand were sited in the hydrophobic clefts and made 
essential hydrophobic interactions with nearby residues. 
 
1.8.3.3 Pyrazolo-triazolo-pyrimidines 
             Baraldi et al explored  the binding modes and interactions of  PTPs 
scaffold as a class of  hA3AR antagonists.
114
 From the study, it was 
hypothesized that these derivatives of PTP mainly  interacted with residues  
belong  to  TMs 3, 5, 6, and 7.  The C
2
-furan ring of the scaffold pointed 
towards extracellular side and interacted with Asn250 (TM6) via  π–π  
interaction. The carbamoyl moiety of the N
5
-position was  surrounded in the 
middle of  TM6 and TM7, and forms a stabilizing H bonding interaction with 
Ser275 (TM7).The N
5
-substituents were surrounded  by  the  small binding 
pocket with hydrophobic residues  like Val235 (TM6), Leu236 (TM6) and 
Asn278 (TM7). Therefore, the para and meta  positions of the N
5
-phenyl ring 
seemed to be invloved with stringent steric control. Similarly, the N
8
-alkyl 
group made important  hydrophobic  interactions  with  residues  such  as 
Leu90 (TM3), Phe182 (TM5), Ile186 (TM5), and  Leu190 (TM5). Maconi et 
al.
117
 reported that the furan ring at C
2
 position was seemed to interact with 
Phe168 (ECL2) and Phe182 (TM5) through a π–π  interaction, whereas  the 
carbamoyl group was  interacted with His95 (TM3) and Ser247 (TM6) via H-
bonding. The N
5
-substituents were located in a hydrophobic region and made 
hydrophobic interactions with nonpolar residues such as Ile98 (TM3), Ile186 
(TM5), and Leu244 (TM6). Conversely, Tafi et al.
127
 suggested  that  the  PTP 
core nucleus was  stabilized  by  π–π  stacking interactions with  Trp243 
(TM6). Similarly, the carbonyl of  the amidic group at  N
5
  position formed an 





-furan ring  and  phenyl ring at N
5
- of PTP were defined by three lipophilic 
pockets,  composed  of  Phe239, Trp243, His272 (HYD1), Leu102(HYD2), 
His95, Phe182,Trp185 and Tyr254 (HYD3) respectively. Moreover, it was 
deduced  that  the H-bond present between the N
5
-pyridyl ring  and the residue 
Tyr254 (TM6) mainly favoured  hA3AR affinity and selectivity. 
             
            Very recently,  our group has performed the  docking simulation of  2-
(para-substituted) phenyl-PTP derivatives as a new class of  potent  hA3 
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antagonist on A3AR homology model, based on the crystal structure of the 
hA2AAR .
118
 In this study, the ligand-receptor recognition mechanism was 
analysed in quantitative manner using interaction energy calculation. 
Moreover, binding interactions of various substitutents at the different position 
of the tricyclic scaffold was analysed. 
 
Binding interactions at the tricyclic nucleus and C
2
-position of PTP 
             The tricyclic core of the PTP scaffold was shown  to interact mostly 
with the nonpolar residues such as Leu246 (TM6) and Phe168 (ECL2) through 
hydrophobic packing and π-π interactions, respectively. The immediate phenyl 
ring at C
2
-position of the tricyclic nucleus in N
5
-amine sat inside a 
hydrophobic pocket surrounded by the side chains of  non-polar residues  at 
TMs 6, 7 and ECL2, such as Ile253, Leu264, Tyr265 and Val169 (Figure 20). 
Nevertheless, the bulky side chains of  these  non-polar residues limited the 
hydrophobic  pocket  size  around the phenyl ring, and only certain 
substituents  with  appropriate sizes were allowed  at the 4th  position of  2-
phenyl ring. Therefore, the introduction  of  bulky substituents, such as NO2, 
CF3 and phenyl at the para-position has resulted in relatively low affinity at 
the hA3 receptor mainly due to the steric hindrance imposed by these bulky 
groups. In addition, van der Waals interactions were also observed between 
the 2(para-(un)substituted)-phenyl ring and the Gln167 on ECL2.  
 
Binding interactions at N
5
-position of PTP 
             The free  NH2, -CONH, -NHCONH groups (of  benzamide, 
phenylacetamide, phenylcarboamyl) at the N
5
-position formed H-bond with 
nearby -C=O or NH- group on the side chain of Asn250(TM6),which was 
highly conserved among all the adenosine receptors.This amino acid was 
shown to be a crucial residue involved in antagonist recognition at adenosine 
receptors, as determined from site-directed mutagenesis experiments.
 
In 
addition, the side chain of Asn250 was also likely to interact with the N
5
-
amino or amide group via van der Waals forces. The phenyl ring of benzamide 




































































     Residue: Involved in Hydrogen bonding                      
     Residue: Involved in Hydrophobic interaction 
     Residue: Involved in π-π stacking interaction 
     Residue: Van der Waals interaction 
 
Figure 20. Hypothetical binding interactions of new series of 2-aryl-PTPs                                                                   
 
(Figure 20), which is considered to be an important residue in adenosine 
receptor activation  and  antagonist  recognition. The corresponding  phenyl  
ring also accommodated within  the  boundary of  a hydrophobic  pocket  
formed  by a group of non-polar residues at TM3 (Leu91) and TM5 (Ile186, 
Phe182, Met177) and  interacted with those residues through typical  
hydrophobic forces. Among these residues, Met177 and Phe182 were 
exhibited to be essential for the hA3 receptor antagonist recognition. The 
presence of the hydrophobic interactions  around the N
5
-position appeared 
crucial for the hA3 receptor recognition. In addition, the N
5
-phenylacetamide 
chain of the PTP made hydrophobic interactions with  residues like 
Leu246(TM6), Ile253(TM6), Val169(ECL2) and Met174(TM5). Similarly, 
phenyl ring of the N
5
-arylcarboamyl moiety also formed the hydrophobic 
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interactions with Val169, Met174(ECL2) Leu249, Ile253 (TM6), 
Val259(ECL3) and Leu264(TM7).   
 




-positions of PTP 
             N
8
-position of the pyrazole ring with methyl and phenylethyl  
substitution were situated within the boundary of  hydrophobic pocket 
consisting of  a group of  hydrophobic residues at TM2 (Leu68, Ala69), TM3 
(Leu90), TM5(Val165) and TM7(Tyr265, Ile268). All the important 






-substituents of  2-aryl-PTPs  and the 
corresponding residues in hA3 receptor were summarized in the Figure 20. 
Generally, the binding interactions found between the ligands and the residues 







-substituents and residues deemed crucial  for conferring  hA3 affinity; 











on pyrazole  ring in engaging H-bond with nearby residues; (iii) aromatic 
moieties like triazolo/pyrimidine ring on the tricylic nucleus and phenyl  ring  
of  benzoyl group at N
5 
position  form  π-π interaction  with the nearby 
aromatic residues; (iv) van der waals interaction (e.g. dipole-dipole) between 
the polar moiety (such as amidic  group  at  N
5
, polar substituents at para-















Chapter 2  Statement of Purpose 
 
             In the last 15 years, intensive efforts in medicinal chemistry to design 
and synthesize new derivatives able to interact with adenosine receptors have 
led to the discovery of potent and selective ligands (with either agonistic or 
antagonistic properties) for the A1, A2A, A2B and A3 ARs.  More precisely, 
while various agonists and antagonists for the A1 and A2A receptor subtypes 
have been reported, the role of A2B and A3 receptors has not been elucidated 
yet. The reason at the basis of such phenomenon could be attributed to the fact 
that A2B  and A3 receptors are the latest to be discovered, hence less research 
has been conducted on these receptor subtypes. Nevertheless, selective  
inhibition  of  human A3 adenosine receptor (hA3AR) by potent antagonists 
has been shown to have promising application in the treatment of several 
pathological conditions, including glaucoma, inflammatory diseases and 
cancer.
30, 31, 74
 Therefore, the identification of  new compounds able to 
selectively inhibit this adenosine receptor subtype  is  deemed crucial   in 
improving several pathological conditions. On the basis of these observations, 
the focus of this thesis is to explore new A3AR antagonists, with the purpose  
of  providing a better understanding  of  this still unknown receptor towards 
promising biomedical applications.  
Recent research by our group on the  pyrazolo-triazolo-pyrimidine (PTP) 
scaffold, centered on the replacement of the conventional furan ring at position 
C
2







  led to the identification of potent and selective analogues at 
human A3AR. However, also in the case of the PTP scaffold and in the most 
of the tricyclic heterocyclic derivatives described previously in the literature, 
these compounds have a number of limitations such as   
(i) complex structure of the ligands make the synthetic preparation difficult 
(due to more steps involved), time consuming and expensive;  
(ii) low yields (15-17%), undetected side products and problems in 
purification; 
(iii) critical steps in the synthesis of PTPs involve high temperature reactions 
(160°C & 260°C) for long time;  
45 
 
(iv) some of the PTP compounds show deviation from the Lipinski’s rule of  
five such as high molecular weight and high lipophilicity. Moreover, these 
problems may affect the ADME properties of the compounds, causing poor 
pharmacokinetic profiles (solubility & permeability).
143, 144
 As such, these 
observations have suggested the need to further investigate simplified 
heterocyclic structures in order to improve the ADME properties as well as to 
maintain or improve the affinity and selectivity towards the hA3AR.
107, 145, 146
  
A recent study on a molecular simplification of complex tricyclic structures to 
bicyclic structures resulted in simplified analogues with  potent activity in the 
nanomolar range with improved selectivity towards the hA3AR as compared to 
the parent compound. Overall, this study proved the significance of simplified 
structures, which can act as hA3AR antagonists to the same extent as more 
complex structures, while overcoming several limitations including higher 
propensity for metabolic instability and more complicated syntheses.
118
   
             Moreover, from SAR  and molecular modelling studies of  previously 
synthesized PTP derivatives, we observed that the pyrazolo [3,4-d] pyrimidine 
(PP) nucleus represents the core domain in the interaction with A3AR’s 
binding site, suggesting that its presence is critical in affecting the binding of 
this structure to the receptor of interest.  Therefore, PP scaffold was chosen as 
pharmacophore for this thesis, which is based on a simplified structure of  PTP 
compounds. In addition, we  also deduced that certain features included in the 
new PP scaffold  could  improve or preserve the hA3 receptor antagonistic 
activity, while maintaining the selectivity towards other receptor subtypes. 
Moreover, we postulated that our PP derivatives would be able to bind equally 
well to the hA3AR in comparison to the PTP counterparts, by preserving the 
key interactions with the same crucial amino acids. The rationale at the basis 
of such selection is explained in more detail in  Chapter 3. 
Hypothesis 1: 
             Therefore,  based on the above mentioned structural benefits, it is 
hypothesised that the molecular simplifications of tricyclic PTP to bicyclic PP, 






-positions of the bicyclic 




positions, and to the triazole ring, 
respectively, of the PTP parent scaffold) will ultimately maintain affinity and 
selectivity at this receptor subtype, while reducing the synthetic procedures 
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and potentially improving the physico-chemical properties of the derivatives 
in comparison to the parent compounds (for more details, please refer to 
Chapter 3, Chart 1).  
 
Hypothesis 2: 
             It is also hypothesized that pertinent molecular modeling 
investigations can be used to rationalize the experimental data obtained from 
the pharmacological characterization of new PP derivatives by providing new 
insights on (i) important structural features associated with their selective 
inhibition of  hA3AR (via QSAR analysis) and (ii) essential binding 
interactions between ligands and specific residues responsible for the hA3 
affinity (through molecular docking simulations on the hA3AR homology 




 position of the tricyclic nucleus. 
 
Main objectives     
To test these hypotheses, the following investigations were planned and 
carried out: 
a) Design, synthesis and characterization of a new series of 4 chloro-
pyrazolo [3,4-d] pyrimidine derivatives bearing a chloro functional 
group  at the C
4





-positions of the bicyclic scaffold as simplified analogues 
of PTPs (Chapter 3).  
b) Pharmacological investigation of the importance of structural 
parameters at each position of PP bicyclic nucleus towards the affinity 
and selectivity profile at the hA3AR through binding affinity assays at 
the hA1, hA2A and hA3 receptors as well as functional assays at the 
hA2B (Chapter 4). 
c) Detailed analyses of the SAR for the new series of 4 chloro-pyrazolo 
[3,4-d] pyrimidines towards hA3AR subtype (Chapter 4). 
d) Rationalization of the experimental binding affinity data through 
molecular modeling investigations, including quantitative structure 
activity relationship analysis (Chapter 5), hA3AR homology 
modeling and docking simulations (Chapter 6)  of the new series of 4 
chloro-pyrazolo [3,4-d] pyrimidine derivatives (Chapter 4). 
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Chapter 3 Design, Synthesis, Pharmacological and Molecular 
Modeling Evaluation of a Novel Series of 4-chloro-
Pyrazolopyrimidine Derivatives  
*Pharmacological assays were performed by our collaborator, Professor Karl-
Norbert Klotz, at the Institute for Pharmacology and Toxicology, University of 
Würzburg, Germany. 
* QSAR was performed by our collaborator Asst. Prof. Yap Chun Wei at the 
Dept of Pharmacy, National university of Singapore.  
 
3.1 Introduction 
           This section describes the rationale for the design, synthesis, 
pharmacological and pharmacological evaluation of a new series of 
pyrazolo[3,4-d]pyrimidines bearing  a  chloro substitutent  at the C
6
-position 
(based on the hypothesized structural modification as mentioned in Chapter 2 





-positions of the tricyclic nucleus. The discussion will first elaborate on the 
factors influencing the design of the library, followed by chemical 
considerations  of  the synthetic routes and   the   binding   affinities of  the 
novel series of  pyrazolo[3,4-d]pyrimidines  at  the  human A1, A2A and A3 
adenosine receptor subtypes and molecular modelling evaluations of 4-chloro-
pyrazolopyrimidine derivatives. 
 
3.2 Rationale of drug design  
             Based on the details and information available from literature as 
described in the previous chapter, a new series of  adenosine antagonists, 
particularly targeted at hA3 receptors, has been designed (Figure 21). In our 
previous work, we have synthesized various tricyclic pyrazolo triazolo 
pyrimidine (PTP) derivatives as hA3AR antagonists.
118
 Among those PTP 
derivatives, we have found that some of them showed high affinity towards 
hA3 receptor in the nM range. Molecular modeling studies of those compounds 
showed that the introduction of some substituents in the original scaffold 
could be vital for potency. Thus, to develop a new class of compounds 
targeting the A3 receptor, we performed a molecular simplification of the 
tricyclic PTP structure to a bicyclic pyrazolo[3,4-d]pyrimidine (PP) bearing 
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key substituents, hoping that these new compounds could preserve their 
pharmacological profile at the hA3AR while simplifying the synthetic 
procedures. 
             From the structure-activity relationship (SAR) studies of previously 
synthesized PTP derivatives
118, 128
 we deduced the following features that 
could be vital for the hA3AR antagonistic activity:  
I) The pyrazolo[3,4-d]pyrimidine (PP) nucleus has shown to represent the core 
domain in the interaction with AR’s binding sites, suggesting that its presence 
is critical in affecting the binding of this structure to the receptor of interest. 
Therefore, we proposed a new series of hA3AR antagonists, in which the core 
PP domain was kept intact (Chart 1).  
II) The size of the substituents at N
2
 position of the PP bicyclic nucleus 
(corresponding to N
8
 position of the PTP scaffold) could play an important 
role in determining the affinity and selectivity towards A3AR. Our previous 
studies showed that small alkyl groups (e.g., methyl or ethyl) are well 
















 Hence, we introduced various substituents with 
different lipophilicity and steric hindrance such as alkyl (methyl 81, isopropyl 
82, and neopentyl 83) and phenyl ethyl (84) functions at N
2
 position.  
III) Assuming that substituents  at  C
6 
position (correspondent to position C
5
 of 
PTP scaffold) are essential for retaining the selectivity and potency,
128
 various 
hA3 Selectivity & 
Potency 
Essential for  selectivity 
















Essential for Activity 
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acyl groups (benzoyl, para substituted benzoyl and phenyacetyl) were 
substituted at C
6
 position in the new series of analogues. In fact, these moieties 
have given rise to potent hA3AR antagonists when introduced at the C
5
 
position of the PTP scaffold. 
IV) Differently from the previous triazole ring in the PTP series, a small group 
needed to be introduced at C
4
 position to keep the scaffold simple and, at the 
same time, enabling a further point of functionalization. To reiterate, we 
proposed a lipophilic chloro functional group at the C
4
 of the bicyclic nucleus 
to maintain the steric constraints unaltered at this position, which could also 
help the nucleus to attain the same binding pose as PTP due to restricted 
rotation of C
4
 position. Moreover, this group enables the easy introduction of 
different chains and functionalities if additional structural modification is 
deemed essential for further improvement of activity. 











Chart 1. Rationale for the design of 2-(alkyl and aralkyl substituted)-2H-
pyrazolo[3,4-d]pyrimidine derivatives (Molecular simplification of  PTP into 
PP, R denotes N
2




              On the basis of the potential structural benefits of the simplified PP 
derivatives, a novel structure-affinity relationship evaluation was conducted 
through the rational design and synthesis of a new series of pyrazolo[3,4-
d]pyrimidines (compounds 81-84, Chart 1 and Table 2). 
 
 
R = CH3 (81),   
(CH3)2CH (82), 
CH2C(CH3)3 (83), 
CH2CH2 C6H5 (84) 
R1 = NH2 (81-84),  NHCOPh (101,105,109,113), 
NHCOPh (p-F) (102,106,110,114),  NHCOPh (p-
CF3) (103,107,111,115), NHCOPh (p-CH3) 






























































 position,  alkyl groups with different steric effects, ranging from a 
small methyl and isopropyl  to  a  long and  bulky groups like neopentyl and  
phenylethyl chain, were incorporated. At the C
4
-position, a chloro group was 
introduced. At the N
6
, a free amine or different lengths of amide moieties, for 
instances (bis-) benzamide, phenylacetamide and substituted benzamide with 
para-substituents of different electronic effects, for examples those with 
electron-withdrawing effect (e.g. 4-F, 4-CF3) as well as groups with electron-
donating effect (e.g. 4-CH3) were substituted at such position. 
 
Compound Substitutents at R Substitutents at R1 
81 CH3 NH2 
82 CH(CH3)2 NH2 
83 CH2C(CH3)3 NH2 
84 CH2CH2C6H5 NH2 
101 CH3 NHCOPh 
102 CH3 NHCOPh (p-F) 
103 CH3 NHCOPh (p-CF3) 
104 CH3 NHCOPh (p-CH3) 
105 CH(CH3)2 NHCOPh 
106 CH(CH3)2 NHCOPh (p-F) 
107 CH(CH3)2 NHCOPh (p-CF3) 
108 CH(CH3)2 NHCOPh (p-CH3) 
109 CH2C(CH3)3 NHCOPh 
110 CH2C(CH3)3 NHCOPh (p-F) 
111 CH2C(CH3)3 NHCOPh (p-CF3) 
112 CH2C(CH3)3 NHCOPh (p-CH3) 
113 CH2CH2C6H5 NHCOPh 
114 CH2CH2C6H5 NHCOPh (p-F) 
115 CH2CH2C6H5 NHCOPh (p-CF3) 
116 CH2CH2C6H5 NHCOPh (p-CH3) 
117 CH3 N(CO-Ph)2 
118 CH(CH3)2 N(CO-Ph)2 
119 CH2C(CH3)3 N(CO-Ph)2 
120 CH2CH2C6H5 N(CO-Ph)2 
121 CH3 NHCOCH2Ph 
122 CH(CH3)2 NHCOCH2Ph 
123 CH2C(CH3)3 NHCOCH2Ph 














3.3 Chemical Considerations 
            The new series of the 6 amino- 4 chloro-pyrazolo[3,4-d]pyrimidine 
derivatives  81-84 & 101-124 were prepared following  two synthetic 
pathways, as depicted in Schemes 1&2. Scheme 1 illustrates the synthesis of 







































Reagents: (a) RI or RBr/ K2CO3/ DMF, 90
°
C, 10h; (b) MeOH/ 
HCl(g), 0-10
 °
C, 18h; (c) C2H5OCONCS/ TEA /DCC /DMF, rt,18h; (d) 2M 
NaOH/ MeOH, 60
°
C, 12h; (e) POCl3/ dimethylaniline, 110
°
C reflux, 24h; (f)  
conc.H2SO4, 0
°
C to rt, 5h; (g) C6H5CONCS/ acetone, reflux, 12h; (h) CH3I/ 
0.1N NaOH, rt, 3 h; (i) 2% aq.NH3/ DMF, 120
°
C sealed tube, 3 h; (j) 1N 
NaOH, 110
°
C reflux, 12 h.  
Cpd R 
81       CH3 
























































































3.3.1 Synthesis of 4-chloro-2-(ar)alkyl-2H-pyrazolo[3,4-d]pyrimidin-6-
amine (81-84), N-(4-chloro-2-2-(ar)alkyl-2H-pyrazolo[3,4-d]pyrimidin-6-
yl)benzamide (101-116), N-benzoyl-N-(4-chloro-2-(ar)alkyl -2H-
pyrazolo[3,4-d]pyrimidin-6-yl)benzamide (117,118),  and N-(4-chloro-2-
(ar)alkyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)-2-phenylacetamide (119-122)   
             Alkylation of  3(5)-amino-4-cyano-pyrazoles was performed by 
Baraldi et al.
114





alkylated 3(5)-amino-4-cyano-pyrazoles derivatives were synthesized using a 
strong base NaH. As according to the reported procedure, the 3(5)-amino-4-
cyano-pyrazole was dissolved in dimethylformamide (DMF) and alkylated 
through a reaction with iodoalkane or bromoalkane and sodium hydride (NaH) 
under ice bath condition. The  NaH, which is a strong base, promotes 
deprotonation of the acidic proton on the nitrogen atom of the pyrazole ring. 
As a result, the electron rich nitrogen atom readily attacks the electron 
deficient alkyl group on the iodoalkane or bromoalkane with ensuing 





 regioisomers in a 1:1  ratio. Inorder to improve 
the yield of the product, it was decided to use the weak base such as K2CO3 
instead of NaH. Subsequently, the intended N
2
 regioisomer (65-68) was 
obtained as major product (Chart 2) with  good yield by under standard 
heating condition. Among them, compounds 65&68 were already reported by 
our group.
118, 147
 In addition, compound 66 was also reported in the literature 







                  
                 Chart 2. Proposed mechanism of formation of 65-68  
Subsequently, the nitrile group was transformed into carbimidate by 
nucleophilic addition reaction as estabilished by Shrivastava et al.
149
 
Corresponding nitrile derivatives 65-68 were treated with dry hydrogen 
 chloride in dry methanol at 0°C for one hour, followed by stirring at the same 













K2CO3 RI or RBr
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care was taken for maintaining the temperature at 0°C, as any drastic change 
in the reaction temperature during the course of the reaction, resulted in the 
decomposition of the product. The resulting product was unstable and was 
directly taken to the subsequent reaction without any further purification. 
 
              
Chart 3. Proposed mechanism for the formation of compounds 73-76 
 
 Intermediate compounds (69-72) were cyclized to corresponding carbamates 
(73-76) derivatives using mild alkoxycarbonylisothionate/DCC annulation 
methodology.
150
 Alkylcarbonyl isocyanates are highly reactive reagents and 
the reaction of an ortho-substituted heterocyclic amine with such a reagent 
(Chart 3),  affords a 3-(alkoxycarbonyl)-1-thio-uriedo-substituted derivative 
(69a-72a), which undergoes cyclodesulfurative conditions and finally 
transformed into the annulated heterocyclic compounds.  
In this reaction, intermediates (69-72) were condensed with ethoxy 
carbonylisothiocyante in DMF at room temperature to obtain a desired  




















































































cyclodesulfurization was effected by addition of dicyclohexylcarbodiimide 
(DCC) at room temperature and continuous stirring for 18 h under the same 
temperature resulted in the annulated carbamates (73-76). These carbamates 
(73-76) were readily hydrolyzed to corresponding amines 77-80 under basic 
conditions in methanol at 60°C for 12 hours (steps (a)-(d) in Scheme 1). The 
ethoxy carbonyl protecting group was easily cleaved under standard 
conditions. 
             The yield of compounds 73-76 (from 15% to 20%) and 77-80 (from 
24 % to 28%) were quite low. As mentioned earlier, PTP compounds were 
obtained with low yield and the objective of this new design was to obtain all 
the intermediates and final compounds in good yields. Ssince the library of 
these new PP derivatives consists of a large number of compounds, it was 
deemed unfeasible to continue subsequent reactions with these low yields. 
Hence, a new synthetic route (steps (f)-(j) in Scheme 1) was further developed 
to obtain the target bicyclic derivatives 81-84 in good yields. In this method, 
3-amino-N
1
-substituted-4-pyrazolocarbonitriles (65-68) were hydrolyzed to 
corresponding carboxamides (85-88) under acidic conditions at cold 
temperature for 30 minutes, followed by stirring at ambient temperature for 5 
hours. The conversion of nitrile to amide was confirmed by H
1
 NMR analysis 
and two broad singlets were observed for CONH2 proton as specified in the 
literature.
151, 152
 Among the carboxamide derivatives (85-88), compound 85 
was already reported in the literature 
153 
and compound 86 was commercially 
available. 
             Yamazaki et.al
154
 synthesized  guanosine derivatives by condensation 
of 5-amino-4-imidazole-carboxamide  with benzoyl isothiocyanate followed 
by methylation and ring closure. Similalrly, subsequent steps of the synthetic 
scheme were performed using these established procedures with some 
modification. As per literature method, the carboxamide was allowed to react 
with benzoylisothiocyanate in water at room temperature, but the 
corresponding benzoylthioureido derivatives were not obtained. When the 
reaction was carried out in 50% aqueous acetone at elevated temperature (80-
100°C), thiouriedo derivatives were obtained with low yield, probably because 
of partial decomposition of benzoyl isothiocyante in aqueous condition. 
Hence, the reaction was performed in dry acetone followed by condensation 
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with benzoylisothiocyante under reflux condition for 12 hours. Upon cooling, 
the benzoylthioureido (89-92) was obtained as yellow solids with good yield.  
             It is known that methylmercapto group activated by the electron-
attracting tendency of benzoyl group would be more reactive. Hence, the 
methylation reaction was performed by treating  intermediate compounds 89-
92 with a methyliodide in aqueous sodium hydroxide solution at ambient 
temperature for 3 hours to obtain a methylthio derivatives (93-96). After 
adjusting the pH to 6, the corresponding carbamidothioates (93-96) were 
obtained as white solid.  
             Subsequently, the nucleophilic substitution of SCH3 group by NH2 
was carried out with vigorous heating in a sealed tube. As expected the 
electron poor carboamyl carbon was easily attacked by nucleophile NH2. In 
this reaction, the methyl mercapto derivatives 93-96 were heated in DMF 
containing 2% ammonia at 120°C for 3 hours in a sealed tube to afford 
benzoylguanidino derivatives 97-100 and completion of the reaction was 
confirmed by the odour of methy mercaptan from the reaction vessel. 
Interestingly, the synthesized compounds 97-100 were insoluble in any of the 
solvent. Hence, they were directly taken to the next reaction. Afterwards, 
benzoyl guanidinos 97-100 were easily cyclized to  amine derivatives 77-80 
upon treatment with 1 N sodium hydroxide under reflux condition. Upon 
cooling, the pH of the  reaction mixture was adjusted to 6 to obtain a 
precipitate. As expected, the nitrogen atom of the carboamyl group attacked 
the carbon atom of the methenamine group followed by elimination of 
ammonia and benzoic acid from the reaction. The traces of benzoic acid was 
easily separated by stirring the product in hot ethanol. Interestingly, 
compounds 77-80 were obtained with higher yields (from 68 to 81 %) than 
those obtained from the synthetic route 1. 
             Chlorination of the heterocyclic amide has been reported by several  
researchers. Among them, combination of  reagents such as POCl3 and N,N’-
dimethylaniline or diethylaniline has been widely used in the field of 
chemsitry.
155, 156
 POCl3 is considered to be one of the strong chlorinating agent 
for the heterocycle compounds. Hence, chlorination of the 6-amino-2-alkyl-
2H-pyrazolo[3,4-d]pyrimidin-4(5H)-ones (77-80) was carried out with 

















Scheme 2. Reagents:  (a)  substituted benzoyl chloride/DIPEA/toluene, 
120°C, reflux, 24 h ; (b) phenyacetyl chloride /DIPEA/toluene, 120°C, reflux, 
24 h. 
 
reflux condition for 24 hours. After completion of the reaction the excess 
POCl3 was carefully removed and the crude product was purified by column 
chromatography to obtain the corresponding chloro analogues (81-84) as solid. 
Among them, compound 81 was already reported in the literature in low yield 
using different procedures.
157
 All the corresponding final compounds 81-84 




C NMR, HMQC and  mass spectra (ESI) 
analysis.
 
              Later, acylation of the free heterocyclic amine was carried out with 
little modification to the  already established procedure.
118  
In this reaction 
 R R1 R2  R R1 R2 
81  CH3 - - 111 CH2C(CH3)3 H CF3 
82 (CH3)2CH - - 112 CH2C(CH3)3 H CH3 
83 CH2C(CH3)3 - - 113 CH2CH2C6H5 H H 
84 CH2CH2C6H5 - - 114 CH2CH2C6H5 H F 
101 CH3 H H 115 CH2CH2C6H5 H CF3 
102 CH3 H F 116 CH2CH2C6H5 H CH3 
103 CH3 H CF3 117 CH3 C6H5CO H 
104 CH3 H CH3 118 (CH3)2CH C6H5CO H 
105 (CH3)2CH H H 119 CH2C(CH3)3 C6H5CO H 
106 (CH3)2CH H F 120 CH2CH2C6H5 C6H5CO H 
107 (CH3)2CH H CF3 121 CH3 - - 
108 (CH3)2CH H CH3 123 (CH3)2CH - - 
109 CH2C(CH3)3 H H 123 CH2C(CH3)3 - - 
































 alkyl and phenyethyl group (81-84) were dispersed in 
toluene and treated with two equivalents of benzoyl chloride and substituted 
benzoyl chlorides (Scheme 2)  to obtain the mono-benzoyl derivatives (101-
116) and phenyl acetyl derivatives (121-124), respectively. Di-substituted 
benzoyl derivatives (117-120) of analogues  81-84 were prepared under this 
standard condition using 4 equivalents of the benzoyl chloride and DIPEA. 
The solvent was removed under reduced pressure and subjected to column 
chromatography to obtain desired compounds 101-124. In addition, the amide 
formation was confirmed by observing the absence of  NH2 peak between 6.1 
to 7.2 ppm in 
1
H NMR and presence of amide (CONH) peak between 11.1 to 
11.7 ppm in the 
1
H NMR spectra. Further, CONH formation was confirmed  





C NMR  analysis were performed for one compound in each N-
alkyl (ar-alkyl) substituted  and C
6
 acylated derivatives. 
 
3.3.2   Experimental Methods 
3.3.2.1 Chemistry  
             Reactions were routinely monitored by thin-layer chromatography 
(TLC) on silica gel plate (precoated 60 F254 Merck plate). Column 
chromatographies were performed using silica gel 60 (Merck,70-230 mesh). 
Melting points were determined on a Gallenkamp instrument and were 
uncorrected. Compounds were dissolved in HPLC (high performance liquid 
chromatography) grade methanol for determination of mass to charge m/z on a 
LCQ Finnigan MAT mass spectrometer (source of ionization: Electron spin 
ionization (ESI) probe). Purity of the compounds were determined by HPLC 




C NMR spectra were determined in 
the deuterated dimethylsulfoxide (DMSO-d6) solutions on Bruker DPX 
ultrashield NMR (400 MHz) spectrometers, with chemical shifts given in parts 
per million (δ) downfield relative to tetramethylsilane (TMS) as internal 
standard, and J values (coupling constants) given in hertz. The following 
abbreviations were used: s, singlet; d, doublet; t, triplet; sep, septet; m, 
multiplet; br, broad. 
HPLC Studies. The purity of the compounds were determined using 
analytical HPLC using HITACHI, version 3.1.8b on a Phenomenex Gemini 
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5U C18 (5 μM, 110 Å, 150mm × 4.60 mm i.d.) column at room temperature  
at a flow rate of 1.0 mL/min with two different mobile phase eluent  systems 
at 254 nm UV detection. The isocratic elution was followed and the analysis 
was carried out using two different  mobile  phase systems, eluent 1; 
ACN(60%): H2O, eluent 2; MeOH (50%): H2O. 
3.3.2.2 General procedure for the synthesis of 3-amino-1-alkyl or aralkyl-
1H-pyrazole-4- carbonitriles (65-68).  To a solution of 3-amino-1H-
pyrazole-4-carbonitrile (1.08 g, 0.01 mol) in anhydrous DMF (5 mL), 
anhydrous potassium carbonate (1.65 g, 0.012  mol, 1.2 equiv) was added at 
0°C and the resulting mixture was stirred at the same temperature for 45 min. 
Appropriate (ar) alkyl iodide or bromide (0.012 mol, 1.2 equiv) was added 
slowly over 15 min and the reaction mixture was heated at 90°C for 10 h. 
Then the resulting reaction mixture was cooled, poured over ice cold water 
and the aqueous phase was extracted with EtOAc (3x10 mL), the combined 
organic layers were dried over Na2SO4, filtered, and the solvent was removed 
under reduced pressure to give a oily residue which was purified via column 
chromatography eluting with a mixture of hexane/ethylacetate (1:1) to obtain 
the desired products (65-68) as solids. 
3-amino-1-methyl-1H-pyrazole-4-carbonitrile (65): Yield: 67%; pale 
yellow solid, mp 125-127 °C; 
1
H NMR (400 MHz, DMSO-d6): δ 3.52 (s, 3H, 
N-CH3), 6.53 (s, 2H, NH2), 7.51 (s, 1H, pyrazole-H).
 13
C NMR (400 MHz, 
DMSO-d6): δ 35.0 (N-CH3), 72.6 (C-CN), 115.7 (CN), 140.3 (CH), 151.9 (C-




3-amino-1-isopropyl-1H-pyrazole-4-carbonitrile (66):Yield : 69%; pale 
yellow solid, mp 120-122 °C; 
1
H NMR (400 MHz, DMSO- d6): δ 1.33 (d, J= 
6.64 Hz, 6H, 2CH3), 4.24 (sep, J=6.64 Hz, 1H, CH), 5.52 (s, 2H, NH2), 8.10 




3-amino-1-neopentyl-1H-pyrazole-4-carbonitrile (67): Yield: 71%; pale 
yellow solid, mp 123-125 °C; 
1
H  NMR (400 MHz, DMSO- d6): δ 0.89 (s, 9H, 
3CH3), 3.67 (s, 2H, CH2), 5.50 (s, 2H, NH2), 8.04 (s, 1H, pyrazole-H). LC-MS 





3-amino-1-phenethyl-1H-pyrazole-4-carbonitrile (68): Yield: 76%; pale 
yellow solid, m.p 132-134 °C; 
1
H NMR (400 MHz, DMSO- d6): δ 3.03 (t, 
J=7.16 Hz, 2H, CH2), 4.11 (t, J=7.12 Hz, 2H, CH2), 5.57 (s, 2H, NH2), 7.13-
7.29 (m, 5H, Ar-H), 7.92 (s, 1H, pyrazole-H). LC-MS (ESI) analysis (m/z) 






3.3.2.3 General procedure for synthesis of methyl 3-amino-1-(alkyl or 
aralkyl)-1H-pyrazole-4-carbimidates hydrochloride (69-72). Dry hydrogen 
chloride was bubbled for an about 60 min through a solution of carbonitriles 
65-68 (0.005 mol) in 4 ml anhydrous methanol at 0°C. The mixture was then 
stirred for 18 h at the same temperature. After flushing with N2, the reaction 
mixture was dried under vacuum. The unstable carbimidates were used for the 
next reaction without further purification. 
Methyl 3-amino-1-methyl-1H-pyrazole-4-carbimidate hydrochloride (69): 
Yield : 52%; White solid. 
Methyl 3-amino-1-isopropyl-1H-pyrazole-4-carbimidate hydrochloride 
(70): Yield : 49%; White solid. 
Methyl 3-amino-1-neopentyl-1H-pyrazole-4-carbimidate hydrochloride 
(71): Yield : 53%; White solid. 
Methyl 3-amino-1-phenethyl-1H-pyrazole-4-carbimidate hydrochloride 
(72): Yield: 57%; White solid. 
 
 3.3.2.4  General procedure for synthesis of ethyl 2-(alkyl or aralkyl)-4-
oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-6-ylcarbamates  (73-76). A 
suspension of carbimidates 69-72 (0.01mol) in 10 ml of anhydrous DMF 
under nitrogen was treated with ethoxy carbonylisothiocyanate (0.011 mol, 1.1 
equiv). The reaction mixture was stirred for an hour under N2 and then 
triethylamine (0.01 mol) was added to it and stirring was continued  for 
another 1 h. After that dicyclohexylcabodiimide (0.013 mol, 1.3 equiv) was 
added to the mixture and stirred for 18 h. After flushing with N2, the reaction 
mixture was dried under vacuum and the crude residue was purified by 
column chromatography (hexane/EtOAc, 1:1) to obtain the desired product 




(73): Yield: 19%; white solid, mp 191-193 °C; 
1
H NMR (400 MHz, DMSO-
d6): δ 1.20 (t, J=6.64 Hz, 3H, CH3), 3.57 (s, 3H, N-CH3), 4.08-4.10 (m, 2H, 
CH2), 7.79 (s, 1H, pyrazole-H), 10.45 (s, 1H, NH). LC-MS (ESI) analysis 




one (74): Yield: 15%; white solid, mp 180-182 °C; 
1
H NMR (400 MHz, 
DMSO-d6): δ 1.25 (t, J= 7.12 Hz, 3H, CH3), 1.40 (d, J= 6.64 Hz, 6H, 2CH3), 
4.18 (q, J1= 7.04 Hz, J2= 14.16 Hz, 2H, CH2), 4.46 (sep, J= 6.64 Hz, 1H, 
CH), 8.54 (s, 1H,  pyrazole-H), 9.89 (s, 1H, NH), 10.56 (s,1H, NHCO). LC-







one (75): Yield: 20%; white solid, mp 210-212 °C; 
1
H NMR (400 MHz, 
DMSO-d6): δ 0.90 (s, 9H, 3CH3), 1.25 (t, J= 7.04 Hz, 3H, CH3), 3.88 (s, 9H, 
CH2), 4.19 (q, J1= 7.1 Hz, J2= 14.24 Hz, 2H, CH2), 8.46 (s, 1H, pyrazole-H), 
9.89 (s, 1H, NH), 10.55 (s, 1H, NHCO). LC-MS (ESI) analysis (m/z) calcd for 






one (76): Yield: 18%; white solid, mp 193-195 °C; 
1
H NMR (400 MHz, 
DMSO- d6): δ 1.28 (t, J=7.16 Hz,3H, CH3), 3.12 (t, J=7.28 Hz, 2H, CH2), 4.22 
(q, J1= 7.1 Hz, J2= 14.24 Hz, 2H, CH2), 4.34 (t, J=7.16 Hz, 2H, CH2), 7.19-
7.34 (m, 5H, Ar-H), 8.37 (s, 1H, pyrazole-H), 9.95 (s, 1H, NH), 10.60 (s, 1H, 







 3.3.2.5  General procedure for synthesis of 6-amino-2-(alkyl or aralkyl)-
2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (77-80). To a solution of ethyl 2-
(alkyl or aralkyl)-4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-6-
ylcarbamates  73-76 (0.0012 mol) in 4 mL of  methanol, 2M sodium 
hydroxide solution (4 mL) was added. The reaction mixture was heated with 
stirring at 60°C for 12 h. The mixture was cooled and acidified at pH 6 with 
acetic acid. The solid was collected by filtration, washed with water and 
recrystallized from methanol to obtain the desired products (77-80) as solids. 
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6-amino-2-methyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (77): Yield: 
24%; white solid, mp >300 °C; 
1
H NMR (400 MHz, DMSO- d6): δ 3.69 (s, 
3H, N-CH3), 6.69 (s, 2H, NH2), 7.73 (s, 1H, pyrazole-H), 10.58 (s, 1H, 




6-amino-2-isopropyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (78): Yield: 
28%; white solid, mp >300 °C; 
1
H NMR (400 MHz, DMSO- d6): δ 1.42 (d, J= 
6.52 Hz, 6H, 2CH3), 4.50 (sep, J= 6.52 Hz, 1H, CH), 7.64 (s, 2H, NH2), 8.11 
(s, 1H, pyrazole-H), 10.61 (s, 1H, NHCO). LC-MS (ESI) analysis (m/z) calcd 




.   
6-amino-2-neopentyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (79): Yield: 
24%; white solid, mp >300 °C; 
1
H NMR (400 MHz, DMSO-d6): δ 0.97 (s, 9H, 
3CH3), 3.96 (s, 2H, CH2), 6.18 (s, 2H, NH2), 8.23 (s, 1H, pyrazole-H), 10.40 






6-amino-2-phenethyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (80): Yield 
27%; white solid, mp >300 °C; 
1
H NMR (400 MHz, DMSO-d6): δ 3.13 (t, 
J=7.12 Hz, 2H, CH2), 4.35 (t, J=7.12 Hz, 2H, CH2), 6.17 (s, 2H, NH2), 7.15-
7.29 (m, 5H, Ar-H), 8.07 (s, 1H, pyrazole-H), 10.33 (s, 1H, NHCO). LC-MS 







3.3.2.6 General procedure for synthesis of 3-amino-1-(alkyl or aralkyl)-
1H-pyrazole-4-carboxamide (85-88). Carbonitriles 65-68 (0.03 mol) were 
dissolved in 7 mL conc.H2SO4 at 0°C and stirred at room temperature for 5 h. 
Then the reaction mixture was poured into ice cold water and neutralized to 
pH 7 with 28% NH3 solution. The white precipitate was formed which was 
further washed with cold water and dried under vacuum to obtain the desired 
products (85-88) as solids. 
3-amino-1-methyl-1H-pyrazole-4-carboxamide (85): Yield: 83%; white 
solid, mp 155-157 °C; 
1
H NMR (400 MHz, DMSO-d6): δ 3.50 (s, 3H, N-CH3), 
6.12 (s, 2H, NH2), 6.64 (br s, 1H, NH), 7.16 (br s, 1H, NH), 7.60 (s, 1H, 
pyrazole-H).
 






3-amino-1-isopropyl-1H-pyrazole-4-carboxamide (86): Yield: 85%; white 
solid, mp 159-161 °C; 
1
H NMR (400 MHz, DMSO-d6): δ 1.34 (d, J= 6.52 Hz, 
6H, 2CH3), 4.18 (sep, J=6.64 Hz, 1H, CH), 5.33 (s, 2H, NH2), 6.69 (br s, 1H, 
NH), 7.16 (br s,1H,NH), 7.94 (s,1H, pyrazole-H). LC-MS (ESI) analysis (m/z) 
calcd for C7H12N4O  (168.20): found 169.0 [M+H]
+
.  
3-amino-1-neopentyl-1H-pyrazole-4-carboxamide (87): Yield: 78%; white 
solid, mp 161-163 °C; 
1
HNMR (400 MHz, DMSO-d6): δ 0.90 (s, 9H, 3CH3), 
3.64 (s, 2H, CH2),  5.32 (s, 2H, NH2), 6.72 (br s, 1H, NH), 7.21 (br, 1H, NH),  
7.85 (s, 1H, pyrazole-H). LC-MS (ESI) analysis (m/z) calcd for C9H16N4O 
(196.25): found 197.1 [M+H]
+
.  
3-amino-1-phenethyl-1H-pyrazole-4-carboxamide (88): Yield: 90%; white 
solid, mp 166-168 °C; 
1
HNMR (400 MHz, DMSO-d6): δ 3.08 (t, J=7.16 Hz, 
2H, CH2), 4.12 (t, J=7.16 Hz, 2H, CH2), 5.44 (s, 2H, NH2), 6.24 (br s, 1H, 
NH), 6.73 (br s, 1H, NH), 7.19-7.35 (m, 5H, Ar-H), 7.80 (s, 1H, pyrazole-H). 







3.3.2.7  General procedure for synthesis of 3-(3-benzoylthioureido)-1-
(alkyl or aralkyl)-1H-pyrazole-4-carboxamide (89-92). To a solution of 
carboxamides 85-88 (0.015 mol) in dry acetone  (10 mL), benzoyl 
isothiocyante (0.0165 mol, 1.1 equiv) was added and refluxed at 60°C for 12 
h. The reaction mixture was cooled. The resulting yellow solid was filtered, 
washed with acetone and dried under vacuum. The crude product was further 
recrystalized from methanol to obtain the desired products (89-92) as solids. 
3-(3-benzoylthioureido)-1-methyl-1H-pyrazole-4-carboxamide (89): Yield: 
61%; yellow solid, mp 218-220 °C; 
1
H NMR (400 MHz, DMSO-d6): δ 3.61 (s, 
3H, N-CH3), 7.17 (br s, 1H, NH), 7.46-7.60 (m, 5H, Ar-H), 7.73 (d, J= 
7.04Hz,  2H, CONH2), 7.78 (s, 1H, pyrazole-H), 11.47 (br s, 1H, NH). LC-MS 




Yield: 63%; yellow solid, mp 212-214 °C; 
1
H NMR (400 MHz, DMSO-d6): 
1.42 (d, J= 5.76 Hz, 6H, 2CH3), 4.44-4.50 (m, 1H, CH), 7.07 (br, 1H, NH), 
7.58-7.68 (m, 5H, Ar-H), 8.00 (d, J=6.8Hz, 2H, CONH2), 8.31 (s, 1H, 
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pyrazole-H), 11.06 (br s, 1H, NH). LC-MS (ESI) analysis (m/z) calcd for 




Yield: 60%; yellow solid, mp 215-217 °C; 
1
H NMR (400 MHz, DMSO-d6): δ 
0.91 (s, 9H, 3CH3), 3.91 (s, 2H, CH2), 7.09 (br s, 1H, NHCO),  7.57-7.70 (m, 
5H, Ar-H), 8.00 (d, J= 7.52 Hz, 2H, CONH2), 8.18 (br s, 1H, pyrazole-H). 





Yield: 71%; yellow solid, mp 208-210 °C; 
1
H NMR (400 MHz, DMSO-d6): δ 
3.11 (br s, 2H, CH2), 4.34 (br s, 2H, CH2), 7.08-7.27 (m, 5H, Ar-H), 7.37-7.69 
(m, 5H, Ar-H), 7.99 (d, J= 7.04Hz,  2H, CONH2), 8.01 (s, 1H, pyrazole-H), 
11.51 (br s, 1H, NHCO), 12.7 (br s, 1H, NH). LC-MS (ESI) analysis (m/z) 




3.3.2.8  General procedure for synthesis of (E)-methyl N'-benzoyl-N-(4-
carbamoyl-1-(alkyl or aralkyl)-1H-pyrazol-3-yl) carbamimidothioate (93-
96). To a solution of benzoylthioureidos 89-92 (0.003 mol) in 10 mL of 0.1 N 
NaOH, methyl iodide (0.0036 mol, 1.2 equiv) was added at room temperature 
and the resulting mixture was stirred for 3 h. The white suspension was 
observed and it was adjusted to pH 6 with glacial acetic acid.  The white 
precipitate was obtained, which was filtered and washed with cold water and 
finally dried under vacuum to obtain the desired products (93-96) as solids. 
(E)-methyl-N'-benzoyl-N-(4-carbamoyl-1-methyl-1H-pyrazol-3-yl) 
carbamimidothioate (93): Yield: 75%; white solid, mp 196-198 °C; 
1
H NMR 
(400 MHz, DMSO-d6): δ 2.44 (s, 3H, SCH3), 3.57 (s, 3H, N-CH3), 6.99-7.52 
(m, 5H, Ar-H), 7.70 (br s, 1H, pyrazole-H), 7.78 (d, J= 4.76 Hz,  2H, 
CONH2), 11.52 (br s, 1H, NH). LC-MS (ESI) analysis (m/z) calcd for 




carbamimidothioate (94): Yield: 67%; white solid, mp 223-225 °C; 
1
H NMR 
(400 MHz, DMSO-d6): 1.45 (d, J=6.52 Hz, 6H, 2CH3), 2.42 (s, 3H, SCH3), 
4.59 (br s, 1H, CH), 7.39-7.91(m, 5H, Ar-H), 8.02 (d, J= 5.92Hz, 2H, 
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CONH2), 8.25 (s, 1H, pyrazole-H), 13.09 (br s, 1H,NH). LC-MS (ESI) 
analysis (m/z) calcd for C16H19N5O2S (345.42): found  346.0 [M+H]
+
.                                                                                                                            
(E)-methyl-N'-benzoyl-N-(4-carbamoyl-1-neopentyl-1H-pyrazol-3-yl) 
carbamimidothioate (95) : Yield: 56%; white solid, mp 219-221 °C;
 1
H 
NMR (400 MHz, DMSO-d6): δ 0.89 (s, 9H, 3CH3), 2.42 (s, 3H, SCH3), 4.02 
(s, 2H, CH2), 7.40-7.95 (m, 5H, Ar-H),  8.02 (d, J= 7.40 Hz, 2H, CONH2), 
8.17 (s, 1H, pyrazole-H). LC-MS (ESI) analysis (m/z) calcd for C18H23N5O2S 




.                                                                                                                                                     
(E)-methyl-N'-benzoyl-N-(4-carbamoyl-1-phenethyl-1H-pyrazol-3-yl) 
carbamimidothioate (96) : Yield: 63%; white solid, mp 235-237 °C;
 1
H 
NMR (400 MHz, DMSO-d6): δ 2.42 (s, 3H, SCH3), 3.13 (t, J=7.04 Hz, 2H, 
CH2), 4.45 (t, J=6.64, Hz, 2H, CH2), 7.12-7.25 (m, 5H, Ar-H), 7.40-7.88 (m, 
5H, acyl-H), 8.03 (d, J= 7.16 Hz,  2H, CONH2), 8.14 (s, 1H, pyrazole-H), 
13.12 (br s, 1H, NH). LC-MS (ESI) analysis (m/z) calcd for C21H21N5O2S 






3.3.2.9  General procedure for synthesis of (Z)-3-(2-benzoylguanidino)-1-
(alkyl or aralkyl)-1H-pyrazole-4-carboxamide (97-100). 
Carbamimidothioate derivatives 93-96 (0.003 mol) were dissolved in dry 
DMF (5 mL) containing 2% ammonia (5 ml) and heated to 120°C for 3 h in a 
sealed tube. At the end of the reaction the odor of methyl mercaptan was 
recognized, cooled and poured over ice water mixture. The resulting white 
precipitate was washed with water and dried under vacuum to obtain the 
desired products (97-100) as solids. 
(Z)-3-(2-benzoylguanidino)-1-methyl-1H-pyrazole-4-carboxamide (97): 


















3.3.2.10  General procedure for synthesis of 6-amino-2-(alkyl or aralkyl)-
2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (77-80). A suspension of 
benzoylguanidino derivatives 97-100 (0.0035 mol) in 1N NaOH (10 mL) was 
refluxed at 110°C for 12 h. The resulting milky white mixture was adjusted to 
pH 6 with acetic acid. A mixture of benzoic acid and free amine derivatives 
were obtained which was washed with water and dried. Finely divided powder 
was suspended in hot ethanol with stirring to remove benzoic acid and filtered 
hot. The resulting ethanolic portion was evaporated to dryness to obtain a pure 
desired product (77-80) as white solid.  
6-amino-2-methyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (77): Yield: 
72%; white solid.
 1
H NMR (400 MHz, DMSO- d6): δ 3.69 (s, 3H, N-CH3), 
6.64 (s, 2H, NH2), 7.73 (s, 1H, pyrazole-H), 10.49 (s, 1H, NHCO).   
6-amino-2-isopropyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (78): Yield: 
75%; white solid. 
1
H NMR (400 MHz, DMSO- d6): δ 1.45 (d, J= 6.52 Hz, 6H, 
2CH3), 4.53 (sep, J= 6.52 Hz, 1H, CH), 7.66 (s, 2H, NH2), 8.13 (s, 1H, 
pyrazole-H), 10.63 (s, 1H, NHCO).  
6-amino-2-neopentyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (79): Yield: 
68%; white solid.
 1
H NMR (400 MHz, DMSO-d6): δ 0.97 (s, 9H, 3CH3), 3.71 
(s, 2H, CH2), 6.25 (s, 2H, NH2), 7.68 (s, 1H, pyrazole-H).  
6-amino-2-phenethyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (80): Yield: 
81%; white solid. 
1
H NMR (400 MHz, DMSO-d6): δ 3.13 (t, J=6.92 Hz, 2H, 
CH2), 4.35 (t, J=7.16 Hz, 2H, CH2), 6.15 (s, 2H, NH2), 7.16-7.29 (m, 5H, Ar-
H), 8.07 (s, 1H, pyrazole-H), 10.30 (s, 1H, NHCO).  
3.3.2.11  General procedure for synthesis of 4-chloro-2-(alkyl or aralkyl)-
2H-pyrazolo[3,4-d]pyrimidin-6-amine (81-84).  A mixture of 6-amino-2-
(alkyl or aralkyl)-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-ones (77-80) (0.005 
mol), phosphoroyl trichloride (0.1 mol, 20 equiv) and N-N dimethylamine ( 
0.005 mol, 1 equiv)  was refluxed at 110°C for  24 h. Then the reaction 
mixture was cooled and the excess phosphoroyl chloride was removed under 
reduced pressure. The resulting red oil was poured onto ice mixture slowly, 
stirred for 10 min. The aqueous part was extracted with EtOAc (3x10ml). The 
combined organic layers were dried over Na2SO4, filtered, and the solvent was 
removed under reduced pressure to give a oily residue which was purified by 
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column chromatography eluting with a mixture of hexane/ethyl acetate (5:5) to 
obtain pale yellow solids as desired products (81-84). 
4-chloro-2-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-amine (81): Yield: 65%; 
pale yellow solid, mp 247-249 °C; 
1
H NMR (400 MHz, DMSO-d6): δ 3.99 (s, 
3H, N-CH3), 6.91 (s, 2H, NH2), 8.43 (s, 1H, pyrazole-H). 
13
C NMR (400 
MHz, DMSO-d6): δ 33.9 (N-CH3), 106.5(C), 132.2 (CH-pyrazole), 153.9(C-







. HPLC purity (254 
nm); eluent 1: 98.2%, 
t
R = 2.2 min, eluent 2:  99.6%, 
t
R = 2.5 min. 
4-chloro-2-isopropyl-2H-pyrazolo[3,4-d]pyrimidin-6-amine (82): Yield: 
67%; pale yellow solid, mp 151-153 °C; 
1
H NMR (400 MHz, DMSO-d6): δ 
1.48 (d, J= 6.64 Hz, 6H, 2CH3), 4.53 (sep, J=6.52 Hz, 1H, CH), 6.19 (s, 2H, 
NH2), 8.30 (s, 1H, pyrazole-H). 
13
C NMR (400 MHz, DMSO-d6): δ22.0 
(CH3), 48.5 (CH-alkyl), 106.7 (C), 132.1 (CH-pyrazole), 153.8 (C-Cl), 155.2 
(C-NH2), 166.6 (N-C-N-). LC-MS (ESI) analysis (m/z) calcd for C8H10ClN5 




  HPLC purity (254 nm); eluent 1: 96.8%, 
t
R = 
3.3min, eluent 2:  99.5%, 
t
R = 3.2 min.                                                                                                                                                                  
4-chloro-2-neopentyl-2H-pyrazolo[3,4-d]pyrimidin-6-amine (83): Yield: 
77%; pale yellow solid, mp 154-156 °C; 
1
H NMR (400 MHz, DMSO-d6): δ 
0.96 (s, 9H, 3CH3), 4.01 (s,2H,CH2), 7.29 (s, 2H, NH2), 8.02 (s,1H, pyrazole-
H).
13
C NMR (400 MHz, DMSO-d6) : δ 28.2 (CH3), 33.8 (C-alkyl), 57.4 
(CH2), 106.2 (C), 132.2 (CH-pyrazole), 153.9 (C-Cl), 156.9 (C-NH2), 161.9 
(N-C-N-). LC-MS (ESI) analysis (m/z) calcd for C10H14ClN5 (239.70): found  
240.0[M+H]
+
. HPLC purity (254 nm); eluent 1: 100%, 
t
R = 6.0 min, eluent 2:  
99.5%, 
t
R = 6.3 min. 
4-chloro-2-phenethyl-2H-pyrazolo[3,4-d]pyrimidin-6-amine (84): Yield: 
72%; pale yellow solid, mp 146-148 °C; 
1
H NMR (400 MHz, DMSO-d6): δ 
3.13 (t, J= 5.56 Hz,  2H, CH2), 4.40 (t, J= 6.04 Hz,  2H, CH2), 7.13 - 7.26 (m, 
5H, Ar-H), 7.28 (s, 2H, NH2), 7.99 (s, 1H, pyrazole-H). 
13
C NMR (400 MHz, 
DMSO-d6): δ 35.0(CH2), 47.9 (N-CH2), 106.5 (C), 126.8 (CH), 128.8 (CH), 
129.0 (CH), 132.5 (CH-pyrazole), 138.6 (CH), 153.8 (C-Cl), 156.1 (C-NH2), 
161.8 (N-C-N-). LC-MS (ESI) analysis (m/z) calcd for C13H12ClN5 (273.72): 
found 272.0 [M-H]
+
. HPLC purity (254 nm); eluent 1: 99.3%, 
t
R = 5.5 min, 
eluent 2:  99.5%, 
t
R = 5.8 min. 
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3.3.2.12  General procedure for synthesis of N-(4-chloro-2(alkyl or 
aralkyl)-2H-pyrazolo[3,4-d]pyrimidin-6-yl) benzamide (101-104, 105-108, 
109-112, 113-116). To a suspension of 4-chloro-2-(alkyl or aralkyl)-2H-
pyrazolo[3,4-d]pyrimidin-6-amines 81-84 (0.001 mol) in toluene, 
diisopropylethylamine (0.002 mol, 2 equiv) and benzoyl chloride or 
substituted benzoyl chlorides (0.002 mol, 2 equiv) were added. The mixture 
was heated under reflux at 120°C for 24 hours. The solvent was removed 
under reduced pressure and the resulting residue was purified by column 
chromatography (hexane: EtOAc, 5:5) to obtain the desired products (101-
104, 105-108, 109-112, 113-116) as solids. 
N-(4-chloro-2-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)benzamide (101): 
Yield: 36%; White solid, mp 165-167 °C;  
1
H NMR (400 MHz, DMSO-d6): δ 
3.99 (s, 3H, N-CH3), 7.51-7.64 (m, 3H, Ar-H), 7.99 (d, J= 7.52 Hz, 2H, Ar-H), 
8.34 (s,1H, pyrazole-H), 11.42 (s, 1H, NH).
 13
C NMR (400 MHz, DMSO-d6): 
δ 34.6 (N-CH3), 103.2 (C), 129.0 (CH), 129.7 (CH), 132.6 (CH-pyrazole), 
133.3 (CH), 134.9 (C), 150.2 (C-Cl), 152.5 (N-C-N), 156.6 (C-NH), 169.8 





. HPLC purity (254 nm); eluent 1: 97.8 %, 
t
R = 
2.9 min, eluent 2:  100 %, 
t
R = 3.0 min. 
N-(4-chloro-2-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-
fluorobenzamide (102): Yield: 43%; White solid, mp 140-142 °C;  
1
HNMR 
(400 MHz, DMSO-d6): δ 3.99 (s, 3H, N-CH3), 7.33-7.37 (m, 2H, Ar-H), 8.05-
8.09 (m, 2H, Ar-H), 8.35 (s, 1H, pyrazole-H), 11.46 (s, 1H, NH). LC-MS 





. HPLC purity (254 nm); eluent 1: 99.4%, 
t
R = 3.3 min, eluent 
2:  96.6%, 
t
R = 3.7 min.  
N-(4-chloro-2-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-
(trifluoromethyl)benzamide (103): Yield: 57%; White solid, mp 145-147 °C;  
1
H NMR (400 MHz, DMSO-d6): δ 3.98 (s, 3H, N-CH3), 7.88-7.91 (m, 2H, Ar-
H), 8.15-8.17 (m, 2H, Ar-H), 8.35 (s, 1H,  pyrazole-H), 11.67 (s, 1H, NH). 





. HPLC purity (254 nm); eluent 1: 99.8%, 
t
R = 5.7 
min, eluent 2:  99.6%, 
t




methylbenzamide (104): Yield: 42%; White solid, mp 149-151 °C; 
1
H NMR 
(400 MHz, DMSO-d6): δ 2.39 (s, 3H, CH3), 3.99 (s, 3H, N-CH3), 7.31-7.93 
(m, 4H, Ar-H), 8.33 (s, 1H, pyrazole-H), 11.32 (s, 1H, NH). LC-MS (ESI) 
analysis (m/z) calcd for C14H12ClN5O (301.73): found 302.0 [M+H]
+
. HPLC 
purity (254nm); eluent 1: 99.4 %, 
t
R = 3.8 min, eluent 2:  99.5 %, 
t
R = 3.7 
min. 
N-(4-chloro-2-isopropyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)benzamide 
(105): Yield: 28%; White solid, mp 151-153 °C;   
1
H NMR (400 MHz, 
DMSO-d6): δ  1.50 (d,  J= 6.76 Hz,  6H, 2CH3), 5.01 (sep, J= 6.52 Hz, 1H, 
CH), 7.51-7.99 (m, 5H, Ar-H), 8.35 (s, 1H, pyrazole-H), 11.39 (s, 1H, NH). 





. HPLC purity (254nm); eluent 1: 100%, 
t
R = 4.2, 
eluent 2:  100.0%, 
t
R = 4.6 min.  
N-(4-chloro-2-isopropyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-
fluorobenzamide (106): Yield: 40%; White solid, mp 120-122 °C; 
1
H NMR 
(400 MHz, DMSO-d6): δ  1.51 (d, J= 6.76 Hz,  6H, 2CH3), 5.02 (sep, J= 
6.76Hz,  1H, CH), 7.48-7.85 (m, 4H, Ar-H), 8.37 (s, 1H, pyrazole-H), 11.49 
(s, 1H, NH).
 13
C NMR (400 MHz, DMSO-d6): δ 22.0 (CH3), 48.5 (CH-alkyl), 
106.8 (C), 116.2 (CH), 132.1 (CH), 132.5 (C), 134.3 (CH-pyrazole), 153.8 (C-
Cl),  154.9 (N-C-N), 158.2 (C-NH),  161.6 (C-F), 166.8 (CO). LC-MS (ESI) 





.  HPLC purity (254 nm); eluent 1: 95.5%, 
t
R = 4.2 min, eluent 2:  
95.1%, 
t
R = 4.7 min.  
N-(4-chloro-2-isopropyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-
(trifluoromethyl)benzamide (107): Yield: 38%; White solid, mp 146-148 °C; 
1
H NMR (400 MHz, DMSO-d6): δ  1.47 (d, J= 6.8 Hz, 6H, 2CH3), 4.96 (sep, 
J= 6.64 Hz, 1H, CH), 7.86-8.15 (m, 4H, Ar-H), 8.35 (s,1H, pyrazole-H), 11.65 





. HPLC purity (254nm); eluent 1: 99.6 
%, 
t
R = 7.3 min, eluent 2:  99.4%, 
t
R = 7.2 min.  
N-(4-chloro-2-isopropyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-
methylbenzamide (108): Yield: 34%; White solid, mp 131-133 °C;  
1
H NMR 
(400 MHz, DMSO-d6): δ 1.50 (d, , J= 6.64 Hz,  6H, 2CH3), 2.39 (s, 3H, CH3), 
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5.00 (sep,  J= 6.64 Hz,  1H, CH), 7.32 (d,  J= 8.04 Hz,  2H, Ar-H), 7.91 (d,  J= 
8.12Hz,  2H, Ar-H),  8.34 (s,1H, pyrazole-H), 11.31(s, 1H, NH). LC-MS (ESI) 





.  HPLC purity (254 nm); eluent 1: 95.7%, 
t
R = 5.2 min, eluent 2:  
95.1%, 
t
R = 5.9 min. 
N-(4-chloro-2-neopentyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)benzamide 
(109): Yield : 44%; White solid, mp 135-137 °C; 
1
H NMR (400 MHz, 
DMSO-d6): δ 0.95 (s, 9H, 3CH3), 4.16 (s, 2H, CH2), 7.51-8.0 (m, 5H, Ar-H), 
8.38 (s,1H, pyrazole-H), 11.38 (s, 1H, NH). 
13
C NMR (400 MHz, DMSO-d6): 
δ 28.1(CH3), 33.8 (C-alkyl), 58.2 (CH2), 110.0 (C), 128.8 (CH), 128.9 (CH), 
132.5 (CH-pyrazole), 132.7 (CH), 134.5 (C), 154.1 (C-Cl),  155.2 (N-C-N), 
155.3 (C-NH),  166.2 (CO).  LC-MS (ESI) analysis (m/z) calcd for 




. HPLC purity 
(254 nm); eluent 1: 97.8%, 
t
R = 7.2 min, eluent 2:  97.4%, 
t
R = 7.9 min. 
N-(4-chloro-2-neopentyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-
fluorobenzamide (110): Yield: 54%; White solid, mp 132-134 °C;  
1
H NMR 
(400 MHz, DMSO-d6): δ 0.95 (s, 9H, 3CH3), 4.15 (s, 2H, CH2), 7.33-8.05 (m, 
4H, Ar-H), 8.37 (s, 1H, pyrazole-H), 11.42 (s, 1H, NH). LC-MS (ESI) analysis 





HPLC purity (254nm); eluent 1:  98.3%, 
t
R = 8.0 min, eluent 2:  99.6%, 
t
R = 
8.4 min.  
N-(4-chloro-2-neopentyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-
(trifluoromethyl)benzamide (111): Yield: 39%; White solid, mp 129-131 °C; 
1
H NMR (400 MHz, DMSO-d6): δ 0.92 (s, 9H, 3CH3), 4.10 (s, 2H, CH2), 
7.87-8.13 (m, 4H, Ar-H), 8.38 (s, 1H, pyrazole-H), 11.63 (s, 1H, NH). LC-MS 





. HPLC purity (254 nm);  eluent 1: 95.4%, 
t
R = 10.9 min, 
eluent 2:  98.1%, 
t
R = 11.5 min.  
N-(4-chloro-2-neopentyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-
methylbenzamide (112): Yield: 35%; White solid, mp 134-136 °C; 
1
H NMR 
(400 MHz, DMSO-d6): δ 0.94 (s, 9H, 3CH3), 2.36 (s, 3H, CH3), 4.15 (s, 2H, 
CH2),  7.28-7.91 (m, 4H, Ar-H), 8.34 (s, 1H, pyrazole-H), 11.28 (s, 1H, NH). 







.  HPLC purity (254 nm); eluent 1: 98.4%, 
t
R = 8.3 
min, eluent 2:  97.8%, 
t
R = 8.5 min.  
 N-(4-chloro-2-phenethyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)benzamide 
(113): Yield: 45%; White solid, mp 140-142 °C; 
1
H NMR (400 MHz, DMSO-
d6): δ 3.23 (t, J= 7.28 Hz, 2H, CH2), 4.60 (t, J= 7.04 Hz, 2H, CH2), 7.17-7.26 
(m, 5H, Ar-H), 7.51-7.99 (m, 5H, acyl-H),  8.34 (s, 1H, pyrazole-H), 11.39 (s, 
1H, NH).
 13
C NMR (400 MHz, DMSO-d6): δ 35.3 (CH2), 48.3 (CH2), 103.2 
(C), 126.9 (CH), 128.8 (CH), 128.9 (CH), 129.03 (CH), 129.08 (CH), 132.6 
(C), 133.7 (CH), 135.1 (CH-pyrazole), 138.6 (C), 150.1 (C-Cl), 152.4 (N-C-N-
), 156.6 (C-NH), 169.8(CO). LC-MS (ESI) analysis (m/z) calcd for 




. HPLC purity 
(254 nm); eluent 1:  99.7%, 
t
R = 6.7 min, eluent 2:  99.5%, 
t
R = 6.4 min.  
 N-(4-chloro-2-phenethyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-
fluorobenzamide (114): Yield: 37 %; White solid, mp 127-129 °C; 
1
H NMR 
(400 MHz, DMSO-d6): δ 3.23 (t, J=7.44 Hz,  2H, CH2), 4.61 (t, J= 7.04 Hz, 
2H, CH2), 7.15-7.19 (m, 5H, Ar-H), 7.22-7.26 (m, 2H, acyl-H), 8.05-8.08 (m, 
2H, acyl-H),   8.35 (s, 1H, pyrazole-H), 11.43 (s, 1H,NH). LC-MS (ESI) 





. HPLC purity (254nm); eluent 1: 99.6%, 
t
R = 7.3 min, eluent 2:  
95.8%, 
t
R = 7.5 min.  
 N-(4-chloro-2-phenethyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-
(trifluoromethyl)benzamide (115): Yield: 51%; White solid, mp 137-139 °C; 
1
H NMR (400 MHz, DMSO-d6): δ 3.20 (t, J= 7.28 Hz, 2H, CH2), 4.59 (t, J= 
7.16 Hz,  2H, CH2), 7.16-7.25 (m, 5H, Ar-H), 7.86-8.15 (m, 4H, acyl-H),  8.34 
(s,1H, pyrazole-H), 11.64 (s, 1H, NH). LC-MS (ESI) analysis (m/z) calcd for 




. HPLC purity 
(254nm); eluent 1:  98.7%, 
t
R = 9.2 min, eluent 2:  96.3%, 
t
R = 9.0 min. 
N-(4-chloro-2-phenethyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-
methylbenzamide (116): Yield: 40 %; White solid, mp 131-133 °C; 
1
HNMR 
(400 MHz, DMSO-d6): δ 2.39 (s, 3H, CH3), 3.22 (t, J= 7.16 Hz, 2H, CH2), 
4.60 (t, J= 7.04 Hz, 2H, CH2), 7.17-7.25 (m, 5H, Ar-H), 7.31-7.91 (m, 4H, 
acyl-H),  8.33 (s, 1H, pyrazole-H), 11.29 (s, 1H,NH). LC-MS (ESI) analysis 
(m/z) calcd for C21H18ClN5O (391.85): found 392.0 [M+H]
+
. HPLC purity 
(254 nm); eluent 1: 97.6%, 
t
R = 6.9 min, eluent 2:  95.0%, 
t
R = 6.9 min. 
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3.3.2.13  General procedure for synthesis of N-benzoyl-N-(4-chloro-2-
(alkyl or aralkyl)-2H-pyrazolo[3,4-d]pyrimidin-6-yl) benzamide (117-120). 
To a suspension of 4-chloro-2-(alkyl or aralkyl)-2H-pyrazolo[3,4-d]pyrimidin-
6-amines 81-84 (0.001 mol)  in toluene, diisopropylethylamine (0.004 mol, 4 
equiv) and benzoyl chloride (0.004 mol, 4 equiv) were added. The mixture 
was heated under reflux for 18 hours .The solvent was removed under reduced 
pressure and the resulting residue was purified by column chromatography 
(hexane:EtOAc, 5:5) to obtain the desired products (117-120) as solids. 
N-benzoyl-N-(4-chloro-2-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-
yl)benzamide (117): Yield : 61%; White solid, mp 163-165 °C;  
1
H NMR 
(DMSO-d6): δ  3.88 (s, 3H, N-CH3), 7.53-7.89 (m, 10H, Ar-H), 8.53 (s,1H, 
pyrazole-H). LC-MS (ESI) analysis (m/z) calcd for C20H14ClN5O2 (391.81): 
found 392.1 [M+H]
+
. HPLC purity (254 nm); eluent 1: 99.9%, 
t
R = 4.5 min, 
eluent 2:  98.4%, 
t
R = 4.8 min.  
N-benzoyl-N-(4-chloro-2-isopropyl-2H-pyrazolo[3,4-d]pyrimidin-6-
yl)benzamide (118): Yield : 57%; White solid, mp 153-155 °C; 
1
H NMR 
(DMSO-d6): δ  1.22 (d, J= 6.8 Hz, 6H, 2CH3), 4.71 (sep, J= 6.64 Hz,  1H, 
CH), 7.48-7.83 (m, 10H, Ar-H), 8.45 (s,1H, pyrazolo-H). LC-MS (ESI) 





.  HPLC purity (254nm); eluent 1: 99.4%, 
t
R = 7.2 min, eluent 2:  
97.6%, 
t
R = 6.9 min. 
N-benzoyl-N-(4-chloro-2-neopentyl-2H-pyrazolo[3,4-d]pyrimidin-6-
yl)benzamide (119):Yield: 52%; White solid, mp 161-162 °C; 
1
H NMR (400 
MHz, DMSO-d6): δ 0.61 (s, 9H, 3CH3), 4.01 (s, 2H, CH2), 7.48-7.83 (m, 10H, 
Ar-H), 8.52 (s, 1H, pyrazole-H). LC-MS (ESI) analysis (m/z) calcd for 




.  HPLC purity 
(254 nm); eluent 1: 100.0%, 
t
R = 11.6 min, eluent 2:  99.1%, 
t
R = 10.9 min. 
N-benzoyl-N-(4-chloro-2-phenethyl-2H-pyrazolo[3,4-d]pyrimidin-6-
yl)benzamide (120): Yield: 46%; White solid, mp 134-135 °C; 
1
H NMR (400 
MHz, DMSO-d6): δ 2.79 (t, 7.0Hz, 3H, CH3), 4.45 (t, J= 7.04 Hz, 2H, CH2), 
6.86-7.20 (m, 5H, Ar-H), 7.49-7.82 (m, 10H, acyl-H), 8.41 (s, 1H, pyrazole-





.   HPLC purity (254 nm); eluent 1: 98.6%, 
t
R = 
12.3 min, eluent 2:  97.5%, 
t
R = 11.6 min. 
72 
 
3.3.2.14  General procedure for synthesis of N-(4-chloro-2-(alkyl or 
aralkyl)-2H-pyrazolo[3,4-d]pyrimidin-6-yl)-2-phenylacetamide (121-124). 
To a suspension of 4-chloro-2-(alkyl or aralkyl)-2H-pyrazolo[3,4-d]pyrimidin-
6-amines 81-84 (0.001 mol)  in toluene, diisopropylethylamine (0.002 mol, 2 
equiv) and phenyl acetyl chloride (0.002 mol, 2 equiv) were added. The 
mixture was heated under reflux for 12 h. Subsequently, another 0.001 mol 
equivalent of diisopropylethylamine and phenyl acetyl chloride were added 
and refluxing continued for 12 h again. The solvent was then removed under 
reduced pressure and the resulting residue was purified by column 
chromatography (hexane: EtOAc, 5:5) to obtain the desired products (121-
124) as solids. 
N-(4-chloro-2-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)-2-
phenylacetamide (121). Yield : 42%; White solid, mp 147-149 °C;  
1
H NMR 
(DMSO-d6): δ  3.83 (s, 2H, CH2), 3.94 (s, 3H, N-CH3), 7.25-7.34 (m, 5H, Ar-
H), 8.29 (s, 1H, pyrazole-H), 11.23 (s, 1H, NH). LC-MS (ESI) analysis (m/z) 




.     
HPLC purity (254 nm); eluent 1: 96.2%, 
t
R = 4.2 min, eluent 2:  99.4%, 
t
R = 
4.9 min.  
N-(4-chloro-2-isopropyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)-2-
phenylacetamide (122). Yield: 43%; White solid, mp 146-148 °C; 
1
H NMR 
(DMSO-d6): δ 1.47 (d, J= 6.76 Hz,  6H, 2CH3), 3.84 (s, 2H, CH2), 4.98 (sep, 
J= 6.64 Hz, 1H, CH), 7.25-7.34 (m, 5H, Ar-H), 8.30 (s, 1H, pyrazole-H), 
11.21 (s, 1H, NH). LC-MS (ESI) analysis (m/z) calcd for C16H16ClN5O 




. HPLC purity (254 nm); eluent 
1:  99.5%, 
t
R = 5.3 min, eluent 2:  95.1%, 
t
R = 6.0 min.  
N-(4-chloro-2-neopentyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)-2-
phenylacetamide (123). Yield: 45%; White solid, mp 155-157 °C; 
1
H NMR 
(DMSO-d6): δ 0.93 (s, 9H, 3CH3), 3.85 (s, 2H, aryl-CH2), 4.12 (s, 2H, alkyl-
CH2), 7.24-7.34 (m, 5H, Ar-H), 8.33 (s, 1H, pyrazole-H), 11.19 (s, 1H, NH). 





. HPLC purity (254 nm); eluent 1:  98.3%, 
t
R = 10.0 
min, eluent 2:  99.3%, 
t
R = 10.6 min.  
N-(4-chloro-2-phenethyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)-2-





(DMSO-d6): δ 3.20 (t, J= 7.16 Hz, 2H, CH2), 3.85 (s, 2H, CH2),  4.57 (t, J= 
6.88 Hz, 2H, CH2), 7.12-7.22 (m, 5H, Ar-H), 7.25-7.35 (m, 5H, acyl-H), 8.30 
(s, 1H, pyrazole-H), 11.17 (s, 1H, NH). LC-MS (ESI) analysis (m/z) calcd for 




. HPLC purity 
(254 nm); eluent 1:  99.5%, 
t
R = 7.9 min, eluent 2:  97.4%, 
t
R = 8.4 min. 
 
3.3.3 X-ray crystallographic studies 
             Further, inorder to confirm the N
2
 alkyl(ar-alkyl) substitution, crystals 
of the compound 81 were grown by vapor diffusion of diethyl ether into a 
saturated solution of MeOH. The detailed key crystallographic parameters can 
be found in Table A1 & A2 under Appendix. The X-ray crystallographic 
results confirmed the successful substitution of the substituent (methyl group) 
at N
2








Figure 22.  X-ray crystal structure of compound 81 (CCDC-937929). All the 
atoms are represented by spheres of arbitrary radii. 
 
            X-ray data were collected from Bruker AXS SMART APEX 
diffractometer using Mo-Kα radiation at  223(2) K with the SMART suite of 
Programs.
[30] 
Lorentz and  polarization effects and absorption effects of data 







Further SHELXTL suite of programs
[33] 
were  used to carry out 
structural solution and refinement. The structure was solved by Direct 
Methods. Non-hydrogen atoms were located using difference maps and were 
given anisotropic displacement parameters in the final refinement. All H 
atoms were put at calculated positions using the riding model. CCDC-937929 




3.3.4  Conclusion   
              The synthesis of  28 new 4-chloro-pyrazolopyrimidine derivatives 
was successfully achieved using optimized synthetic procedures as described 




C NMR and mass spectrometry (ESI). Additionaly, final compounds 81-84 
and derivativves 101, 106, 109 & 113 were confirmed by 2D NMR (HMQC). 
The purity of the compounds was determined by HPLC analysis (HPLC data 
of newly synthesized compounds 81-124 were tabulated in Table A3 under 
appendix), and all of  the compounds showed the purity of  95% and above, 
which were considered to be pure for biological evaluation. 
 
3.4 Pharmacological Evaluation of a Novel Series of  4-Chloro-
PyrazoloPyrimidine Derivatives  
 
3.4.1 Introduction 
             The binding affinities of the novel series of pyrazolo[3,4-
d]pyrimidines at the human A1, A2A and A3 adenosine receptor subtypes and 
the adenylyl cyclase activity of the derivatives at the human A2B receptor  are 
described in this chapter. In addition, the selectivities were also assessed by 
comparing the binding affinity values (Ki) against the hA3 receptor with  Ki 
values against the hA1 and hA2A receptors.  
 
3.4.2 Binding affinity towards human A1, A2A and A3 adenosine receptors 
             The displacement of selective radioligands towards respective 
adenosine receptors (expressed in Chinese Hamster Ovary cells (CHO) for 
hA1, hA2A, hA3 receptors),
158-160
 was measured to evaluate the binding 
affinities of the synthesized compounds. There is inverse proportion for the 
amount of   tested compounds against affinity of the compound for a particular 
receptor subtype (i.e. the lower is the amount of a compound required to 
displace the radioligands, the higher is the affinity of the compound). In this 















H]-2-hexyn-1-yl-N(6)-methyl adenosine) at the hA3 
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receptors  were evaluated. The  Ki (dissociation constant) value of the data was 
calculated  from  the Cheng and Prusoff equation (Ki = IC50 / (1 + [C*] / KD*), 
where [C*] denotes the concentration of the radioligand and KD* indicates the 
dissociation constant of the radio ligand),
161
 with the geometric means of at 
least 3 experiments, including 95% confidence intervals. 
 
3.4.3 Adenylyl cyclase activity at human A2B adenosine receptors 
             The potency  of  compounds  81-84 & 101-124  at  the  hA2B  receptor 
(expressed in CHO cells) was determined in adenylyl cyclase experiments, 
because of the lack  of  a  suitable  radioligand  for hA2B receptor  in binding 
assay. The experiment was carried out through the procedure reported 
previously by Klotz et al. with some modifications.
158, 159
 In this assay, a 
known concentration of non-selective adenosine agonist, NECA, was 
subjected to inhibitory effect of tested compounds. Consequently, the 
activation of hA2B receptor led to stimulation of  adenylyl cyclase, followed  
by  conversion  of ATP into cAMP. When the antagonists bind to the hA2B  
receptor, the stimulation  of  adenylyl cyclase  induced by the agonist NECA 
is blocked, resulting in decrease of the cAMP production. Similarly, different 
levels of cAMP accumulation were obtained based on the different 
concentrations of tested compound. As mentioned earlier, Cheng and Prusoff 
equation was used to calculate the Ki  values, which corresponded to the IC50  
for each compound by applying geometric means of at least  three  
experiments, including 95% confidence intervals.  
 
3.4.4  Experimental Methods 
3.4.4.1 Preparation of CHO membrane 
             The procedures for radioligand binding experiments, which involve 
pharmacological methods with membrane preparation, were  performed  as  
described in Klotz et al.
158
 A two-step procedure was employed to prepare a 
membrane  for  radioligand binding  from cells stably transfected with the 
human adenosine receptor subtypes (hA1, hA2A, hA2B  and hA3 expressed on 
CHO cells). Firstly, using the low-speed step (1,000 x g for 4 min), the cell 
fragments and nuclei were removed, and then crude membrane  fraction  from 
the supernatant was sedimented at 100,000 x g for 30 min. Subsequently, the 
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membrane pellet was resuspended in the specific buffer, frozen in liquid 
nitrogen and stored at -80°C. However, one step centrifugation method was 
used for the measurement of the adenylyl cyclase activity, in which the 
homogenate was  sedimented for about 30 min at 54,000 x g. Finally, the 
obtained crude membrane pellet was resuspended in 50 mM Tris/HCl, pH 7.4 
and used for the adenylyl cyclase assay immediately. 
3.4.4.2 Binding assay of human cloned A1, A2A, A3 adenosine receptor  
             Klotz et al. and Lohse et al. described the binding of  [
3
H]-CCPA to 
CHO cells transfected with the  human  recombinant  A1 adenosine receptors 
and subsequent  binding assay was performed as reported. 
158, 159, 162
As  per  
the  procedure, displacement  experiments  were  carried out  for  3 h  at  25°C  
in  200 μL of  buffer containing  1 nM [3H] CCPA, 0.2 U/mL adenosine 
deaminase, 20 μL of diluted membranes (50 μg of protein/assay) in 50 mM 
Tris/HCl, pH 7.4 and tested compounds  in different concentrations. Similarly, 
1 mM theophylline was used to determine the nonspecific binding.
  
In the 
same manner, binding of [
3
H]-NECA to CHO cells transfected with  the  
human recombinant A2A adenosine  receptors was  performed.
158, 159 
In this 
experiments, samples containing a protein concentration of 50 μg/assay in 
buffer, 30 nM [
3
H]-NECA and assayed compound in different concentrations 
were  incubated for 3 h at 25°C. Likewise, 100 μM R-PIA (R-N6-phenyl 
isopropyl adenosine) was used to determine the nonspecific binding.
160
 
Additionally, binding of  [
3
H]HEMADO to CHO cells transfected  with the 
human  recombinant  A3  adenosine  receptors  was  carried out as described 
earlier.
158, 159, 163
 The  displacement  experiment  was  carried out  for  3 h  at  
25°C  in  buffer solution containing 10 nM [
3
H]-NECA, 20 μg membrane 
protein in 50mM Tris-HCl, 1 mM EDTA(ethylene diamino tetraacetate), 10 
mM  MgCl2,  pH 8.25  and  tested compound in different  concentrations and 





 Moreover, filtration of assay mixture was 
carried out to seperate bound and free radioactivity, through Whatman GF/B 
glass-fiber filters  using  a Micro-Mate 196-cell harvester (Packard  Instrument  
Company). The filter bound radioactivity was calculated on Top Count 





bovine albumin as a reference standard was employed to measure the protein 
concentration. 
 
3.4.4.3 Adenylyl cyclase activity assay 
            The potency of the compounds at hA2B receptor (expressed in CHO 
cells) was determined in adenylyl cyclase experiments. All these experiments 
were performed as described previously with minor modifications.
158, 159
 
In this assay, the  hA2B receptor  transfected  with  membranes were incubated 
with 100 nM NECA, followed by 150,000 cpm of  [α-32P]ATP and tested 
compounds  in different concentrations were treated for  20 min  in the 
incubation mixture as described 
158, 159
 without  EGTA (ethylene glycol 
tetraacetic acid) and NaCl. The IC50 values were calculated for concentration-
dependent inhibition of   NECA -mediated adenylyl cyclase activity caused by 
antagonists. 
 
3.4.4.4  Data analysis 
             In the assay, a non-linear curve  fitting  method  implemented in the 





H]-NECA (IC50) produced by concentration of  the tested 
compounds, as described by De Lean et al.
160
 This assay was performed with 
different concentrations of  tested compounds, as triplicate experiment. In 
addition, the dissociation constant (Ki) values  were calculated  from  IC50  as 
per  the  Cheng and Prusoff equation.
161
 Moreover, a  non-linear regression 
analysis using the equation for sigmoidal concentration-response curve was 
applied to calculate the IC50 values of adenylyl  cyclase activity assay. This 
experiment was performed with different concentrations of tested compounds, 
each performed in triplicate.  
 
3.4.5 Results and Discussion 
3.4.5.1 Structure-affinity relationships 
             Pharmacological evaluation was performed for the novel series of 
pyrazolo[3,4-d]pyrimidine to examine their binding affinities  at all the four 
adenosine receptors. The receptor binding affinities of compounds   81-84 & 
101-124   were determined at the human A1, A2A, A3 receptors and the 
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corresponding   adenylyl cyclase activity in CHO cells which expressed the 
human A2B receptors are summarized in Table 3. 
In this work, we proposed to modify our previously synthesized tricyclic 
pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidines (PTPs)
118
 into a bicyclic 
pyrazolo[3,4-d]pyrimidine (PP) scaffold by considering the significance of 
simplified structures
107, 145, 146 
that can act as promising antagonists, hopefully 
with similar or even improved affinity and selectivity  at the hA3 receptor. 
Towards that purpose, a new series of 2-(alkyl and aralkyl substituted)-2H-







were successfully synthesized and characterized. The binding assay results 
indicated that the reported molecular simplification of the PTP structure, 
although with a remarkable drop (10000 fold decrease) in the Ki values, still 
enabled the binding at the hARs (Table 3). This result seems very promising, 
considering that the PP represents a much smaller scaffold which posesses low 
molecular weight (183-420) as compared to  PTP (265-552) for the hA3AR 
(The smaller scaffold compounds into a better range of mol.wt for an orally 
available compound). Indeed, most of the pyrazolo[3,4-d]pyrimidines were 
able to maintain moderate affinity at hA3 receptors as indicated by the  low 
micromolar range (1.5-33.5 µM) of  Ki values but  showed significant drop in 
selectivity towards the other receptor subtypes. 
 
 Effect of  N
2
 substitution on affinity of PP scaffold 
             To examine the impact of the alkyl group substitutions at N
2
 position 
towards the pharmacological profile, we compared the binding assay results of 
the analogues bearing various alkyl substitutions (i.e. R= methyl, isopropyl & 
neopentyl) or a phenylethyl at this position. The alkyl substitutents (methyl, 
isopropyl & neopentyl) at N
2
 position (Table 3) of the pyrazolo ring were 
found to modulate the affinity at hA3AR to a certain extent. Among them, N
2
 
isopropyl substituted analogues showed the lowest binding affinity (105-108, 
118 & 122, with Ki hA3 values between 6.7 and 27.1 µM, although with a few 
exceptions showing  Ki hA3>100 µM) towards A3AR, followed by N
2
 methyl 




             In contrast, N
2
 isopropyl presented better hA2A affinity (105-108, 118 
& 122, with Ki hA2A values between 0.8 and 4.7 µM and Ki hA3 values 
between 6.7 and >100 µM). Interestingly, neopentyl substituted analogues 
(109-112 & 119, 123) exerted a relatively more favourable effect at the 
hA3AR receptor, and also displayed a 6-7 fold increased affinity in 
comparison with the N
2
 methyl derivatives. Among all the N
2
 alkyl substituted 
derivatives, compound 112 showed the best affinity at the hA3AR (Ki hA3 = 5 
µM). Moreover, derivative 111 & 119 of the same series exhibited equal 
potency (111, Ki hA3 = 6.6 µM and 119, Ki hA3 = 6.5 µM) and the highest 
selectivity towards other receptor subtypes (hA1/A3 >15; hA2A/A3  >15). 
              In addition, the presence of a phenyl ethyl group at N
2 
position 
resulted in a significant (8-10 fold) increase of hA3 affinity (113-116, 120 & 
124, Ki hA3 values between 1.5 and 8.6 µM) and better selectivity in 
comparison to the other N
2
 alkyl counterparts (101-112, 117-118 & 121-122, 
Ki hA3 = 5.0 - <100µM). This result indicates that the  phenylethyl group at N
2
 
position played  a more essential role in the binding at the hA3 receptor; in 
fact, it suggests that the steric hindrance far from N
2
 position is more 
favourable  for the bulky phenyethyl group to orient itself inside the binding 
cavity, in comparison with steric hindrance in close proximity of N
2
 position 
(i.e. methyl 81 & isopropyl 82). However, these findings are in contrast with 
the PTP scaffold, where small substituents (e.g., CH3) at N
8
 position are 
preferable than larger alkyl and arsubstituents.
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Effect of   C6 substitution on affinity of  PP scaffold 
Analogues bearing a free amino group at C
6
 position (81-84) showed no 
measurable towards the hA3 receptor (Ki hA3 >100 µM), while they showed 
better affinity towards the hA2A (Ki hA2A = 3.3-9.1 µM) and the hA1 receptor 
(Ki hA1 = 4.3 - 29.7 µM) subtypes. This was somehow expected, as it was 
already observed that PTPs with a free amino group at C
5
 position are able to 
bind A1 and A2A ARs better than A3ARs. Therefore, further studies will assess 
the influence of acyl substitutions at the C
6




                    Table 3. Binding affinity (Ki) of synthesized compounds at hA1, hA2A, and hA3 adenosine receptors
[a] 
and  







R R1 R2 















>20 >100 > 0.29 >0.09 





>10 >100 >0.09 0.03 














>20 >100 >0.04 >0.03 






> 4.2 1.0 
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106 CH(CH3)2 H F 




>20 >60 >0.05 > 0.02 














>20 >100 >0.04 0.01 

































































































                         [a] Adenylyl cyclase activity of synthesized compounds at the hA2BAR. [b] Displacement of specific [
3
H]-CCPA 
                         binding at human A1 receptors expressed in Chinese hamster ovary (CHO) cells (n=3–6). [c] Displacement of  
                         specific[
3
H]-5’Nethylcarboxamido adenosine (NECA) binding at human A2A receptors expressed in CHO cells 
                         (n=3–6).[d]Ki values for inhibition of NECA-stimulated adenylyl cyclase activity in CHO cells (n=3–6). 




-methyl adenosine (HEMADO) binding at human A3  
                         receptors expressed in CHO cells (n=3-6).
Com 
pound 
R R1 R2 


































C6H5CO H >100 5.4 >100 2.9 >34.5 2 










































            In addition, analogue 117, bearing a dibenzoyl group at C
6
 position, 
displayed a moderate affinity at the hA3 subtype (Ki hA3=7.1µM) and a 3 fold 
improvement in comparison with the mono-acylated analogue (101, with Ki  



























Figure 23. Overview of structure-affinity relationship (SAR) profile for the 











Smaller alkyl chain (e.g. CH3)   disfavoured hA3 
affinity. 
Slightly small group (e.g. CH(CH3)2 preferred for 
hA2A affinity. 
Longer and bulky alkyl chain (e.g. CH2C(CH3)3, 
PhCH2CH2) conferred good hA3 affinity. 
 
Cl group might be replaced with 
hydrophilic functional groups (e.g.CONH2 
or COOC2H5) inorder to improve the 
affinity. 
R1 =  NH2                     Poor affinity at hA3 receptor. 
 
R1 =  NH-COPh                Slightly improved affinity at  hA3 receptor. 
 
R1 =  NH-COCH2Ph                Moderate affinity at hA3 receptor. 
 
R1 =  NH-COPh (p-F)               uncertain affinity at hA3 receptor. 
 
R1 =  NH-COPh (p-CF3, p-CH3 )              High hA3 affinity and  moderate 
                                                                selectivity against hA1, hA2AAR 
                                                                 within the series.                                                             
a
R1= N(COPh)2              High hA3 affinity and selectivity at hA1AR 
                                       within the series.                                                             
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This affinity was maintained when the C
6
 group was replaced by a slightly 
longer phenyl acetyl group (121, with Ki hA3=6.6 µM). This indicates that 
binding cavity is spacious enough to accommodate the bulky diacyl group and 
longer phenylacetyl group at C
6
 position. In contrast, shorter chains like single 
benzoyl groups seemed less favourable. 
As seen in Table 3, C
6
 acyl substituents of  N
2
-isopropyl derivatives (105-108, 
118 & 122) shifted the affinity towards the hA2A receptor; in fact the best 
result was observed for the di-acylated analogue (118, with Ki
hA2A=0.8 µM). This derivative was also about 7-8 times more selective 
towards the other receptor subtypes. Also, the presence of an additional 
electron donating methyl group at the para position of the C
6
-benzoyl 
substituent maintained the affinity (108, with Ki hA2A=1.1 µM) and 
remarkably increased the selectivity against the hA3 receptor subtype (hA3/ 
hA2A =91). Likewise, electron withdrawing groups (e.g. para-F as in 106, with 
Ki hA2A=1.6 µM, and hA3/ hA2A >37) were more favourable towards hA2AAR 
than hA3AR. Moreover, it was noted that high affinity towards the hA2A 
subtype was reflected in the whole N
2
 isopropyl series. Nevertheless, affinity 
switched towards hA3AR for the neopentyl series. Although the free amino 
group of neopentyl prompted a better affinity at the hA2AAR (83, with Ki hA2A 
= 4.1 µM and Ki hA3> 60 µM), corresponding acyl substitution improved the 
affininity at  hA3 ARs (e.g. 109, with Ki hA1 = 11.0 µM; Ki hA2A = 3.5 µM and 
Ki hA3 = 30 µM). This indicates the importance of an acyl group at C
6
 position 
for hA3 affinity profile. Notably, para substitutions (e.g., F, CF3) at  C
6
 
benzoyl groups slightly ameliorated the affinity towards the hA3AR (e.g. 110, 
with Ki hA3 = 5.9 µM & 111, with Ki hA3 = 6.6 µM). Interestingly, compound 
112 (with an electron donating  p-toluoyl group) showed the best affinity at 
the hA3AR (Ki hA3 = 5.0 µM) in the neopentyl series, its para-CF3 analogue 
111 displayed the highest selectivity (hA1/A3 >15, hA2A/A3 >15). This 
indicates the different contributions of electron donating and electron 
withdrawing groups at the para position of the benzoyl group at C
6
. Similarly, 
compound 119 with dibenzoyl substitution displayed the highest selectivity 
(hA1/A3 >15.3,  hA2A/A3 >15.3) in the among the  N
2
 alkyl series derivatives.    
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              In the N
2
-phenylethyl series, para unsubstituted benzoyl (113, with Ki 
hA3 = 8.6 µM) and chain lengthened phenylacetyl (124, with Ki hA3 = 11.4 
µM) at the C
6
 position, appeared to reduce moderately the affinity of the PP 
scaffold at the hA3 receptor in comparison with the para substituted benzoyl 
derivatives. Similarly, para-F group (114, with Ki hA3 = 100 µM) in the acyl 
chain diminished affinity to a great extent at the hA3AR, however, it showed 
good affinity towards hA2A receptor subtype (Ki hA2A = 2.06 µM). On the 
other hand, analogue  116, with the electron donating  p-toluoyl substituent  at 
C
6
 position displayed substantial increase of the affinity towards the hA3AR 
(Ki hA3 = 1.5 µM) and it also imparted a 6 to 8 fold increment in affinity in 
comparison with corresponding  C
6
 unsubstituted and C
6
 lenthy phenylacetyl 
compounds 113 & 122, respectively. Further, p-CH3 substituted compound 
(116) displayed almost 4 fold increment in the affinity as compared to N
2
-
neopentyl counterpart (112, with Ki hA3 = 5.0 µM). Similarly, analogue 115, 
with electron withdrawing  para-CF3 benzoyl group, also exhibited 
comparable affinity at the hA3 receptor (Ki hA3 = 2.8 µM). Interestingly, a 36 
fold increase in affinity was observed for the derivative with para-CF3 
substituent in comparison to the  para-F analogue, overall indicating that 
bulky, either electron-donating or electron acceptor functional groups, are 
preferred over less bulky groups for a better affinity at the hA3AR. SAR on the 
fluoro derivatives at R2 seems to be reversed when R is changes from 
isopropyl to phenylethyl. When R was Isopropyl, R2 seems to have no activity, 
when R group was replaced by less rotatble neopentyl the activity was 
reversed. Incontrast, another  rotatable phenylethyl at R2 showed no activity, 
this again explains that multiple rotatable bonds not preferred for the activity.  
Interestingly, compound 120 with dibenzamide chain at C
6
 position displayed 
the potency which is comparable to that of compound 115. In addition, 
compound 120 was around 35 fold selective towards the hA1AR and 2 fold 
selective towards hA2AAR. 
 
Comparison of  binding affinity PP to PTP  
             Figure 23 summarizes the structure-affinity relationship (SAR) 
profiles observed in this new series of 4-Chloro-pyrazolopyrimidine 
derivatives (81-84 & 101-124).  We  noticed a slightly different   trend   of   
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substitution. Despite the fact that these compounds still maintained good hA3 
affinity in the low micromolar range (1.5-33.5 µM), it was found that the 
molecular simplification from the tricyclic PTP to bicyclic PP resulted in 
several logs decrease of affinity and selectivity towards the hA3 receptor.  
Moreover, it was noticed that N
2
 substituents in the main scaffold caused a 
somehow opposite binding  affinity  for  PP and PTP. In PTP, non bulky 
methyl group at N
8
 position displayed higher affinity than N
8
 phenyl ethyl 
substituted derivatives. On the contrary, lengthy and bulky groups such as 
neopentyl and  phenylethyl at N
2
 position of  PP showed  high binding affinity 
than methyl substitution. Considering the wide space of the hA3 receptor, the 
complex  PTP structure  occupied the most of the space in the receptor centre 
and  needed  sterically less constraints  methyl group in order to accommodate 
the whole PTP structure within the binding cavity, whereas  simpler  PP 
analogues,  which  localize  at  the  centre  of the binding pocket, needed 
lengthy bulky groups to make potential interaction with the corresponding 
residues. In addition, the C
6
 substitution in PP (corresponding to N
5
 
substitution in  PTP) showed a lot of difference in the affinity between PTP 
and PP derivatives. Generally, in PP scaffolds susbtituted benzamide chain 
displayed stronger activity than unsubstituted benzamide and the lengthy 
phenylacetamide chain, whereas in PTP scaffold benzamide chain showed 
weaker activity than pheylacetamide chain.  
 
3.4.6 Conclusion 





positions play a key role in modulating the binding 
affinity at the adenosine receptors. First, at the N
2
 position, lengthy and bulky 
groups such as neopentyl and phenylethyl substitution showed favourable 
effect on the affinity at hA3 receptor. In addition, we also evaluated the 
electronic effect of  para-substituents on the acyl chain towards the affinity 
profile at the hA3 receptors. Based on the binding results, it was confirmed that 
the substituents (e.g., F, CF3, CH3) at the para-position of the C
6
-benzamide 
chain were found to modulate the affinity at hA3AR to a great extent. In 
particular, among the substituents introduced at the para-position of the 
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phenyl ring, both the CF3 and CH3 groups have exerted relatively more 
favourable effect on the affinity at hA3 receptor. 
            Overall, our results demonstrated the importance of the contemporary 
introduction in the PP system of a) large lipophilic substituents (e.g., 
neopentyl and phenylethyl) at N
2
 position to maintain the potency at hA3 
receptor; b) sterically bulky electron donating or electron withdrawing para 
substituted acyl chains at C
6
 position to increase the affinity and selectivity 
towards hA3 receptor; c) a slightly smaller chain (i.e. isopropyl) at N
2
 to 
confer the affinity towards the hA2A receptor, if further study is intended on 
hA2A receptor; d) Electron deficient functional groups (e.g., CF3, Cl, Br, etc.) 
substituted acyl chains at C
6
 position to increase the selectivity at hA3 
receptor. 
            Among the newly synthesized PP derivatives, analogue  116, with a 
phenyl ethyl substitution  at N
2
 position and a para-methylbenzamide at C
6
 
position, possessed the best hA3 affinity profile (Ki hA3 = 1.5 µM) and about 7 
fold selectivity at the hA1 and hA2A ARs. Instead analogues 115 & 120 of the 
same series emerged for their high selectivity (115, hA1/A3= 21, hA2A/A3= 6 
and 120, hA1/A3= 35, hA2A/A3= 2 ) against the other adenosine receptors, 
while displaying almost equal (115, Ki hA3 = 2.8 µM & 120, Ki hA3 = 2.9 µM) 
affinity at the hA3AR. Similarly, in the N
2





 p-toluamide substitutents showed the best affinity at the 
hA3AR (Ki hA3 = 5.0 µM) and its para-CF3 analogue 111 displayed the 
highest selectivity (hA1/A3 >15, hA2A/A3 >15) in the whole series. Compound 
111, which has a CF3 at the 4
th
 position of the benzamide chain, showed high 
selectivity towards other receptor subtypes. A similar trend is also observed 
with compound 115, also bearing  a para CF3 substitution at position 4 as 
well. The presence of sterically bulky (high ClogP, Table A4, Appendix) 
electron withdrawing  groups at the para  position  shifted the affinity towards 
the hA3AR. However, compound  112, having   para-CH3 in the benzamide 
ring, is sterically weaker (low ClogP) than para-CF3 and showed less 
selectivity towards other receptor subtypes. This trend is observed clearly only 
in the N
2
 neopentyl and phenylethyl series because the bulky group at N
2
 
position favoured the hA3 affinity. Hence, it is concluded that such electron 





, is needed at the para position of C
6
 benzamide to improve the 
selectivity. 
             The molecular simplification of the tricyclic pyrazolo-triazolo-
pyrimidine has led to the identification of a novel series of bicyclic 
pyrazolo[3,4-d]pyrimidine derivatives as hA3AR  antagonists. The present 
study has highlighted that the pyrazolopyrimidine moiety is an potential 
scaffold and suggest ways to progress it for obtaining  novel  hA3AR 
antagonists. Although there is a remarkable drop in the affinity, still it could 
be considered as a starting point for further investigations. Consequently, the 
affinity and selectivity could be enhanced to a certain extent, upon analyzing 
the structural features responsible for the drop in affinity by molecular 
modeling studies. 
From the comparison of  SAR of PP analogues with PTP analogues, the 
following features are derived. 
N
2
 position long chain such as neopentyl and phenylethyl are favourable in PP 
analogues, whereas in PTP analogues at N
2
 position small alkyl groups are 
prefferable(e.g. CH3) than longer bulky group. 
Similalry, at C
6 
position acylaated group favoured for affinity at hA3AR for 
both PTP and PP analogues.  
In addition, the steric chloro group didnot show much impact on the affinity 
apart from providing some lipophilicity to the scaffold. Hence, the C
4 
position 
could be substituted by some rotatable hydrogen bond donor or acceptor group 
in opposite to steric group to explore more about this position. 
 
3.5 Quantitative Structure-Activity Relationship (QSAR) Study on a New 
Series of PyrazoloPyrimidine Derivatives 
 
3.5.1 Introduction 
             In this chapter, Topomer CoMFA study has been performed to 
identify pharmacophoric units and to establish the contributions of each of  the 
identified R groups in the data set. Topomer CoMFA is a 3D-QSAR tool that 
automatically generates a model for predicting the biological activity or 
properties of compounds.
165
 Similarly, topomer CoMFA differs from 
conventional CoMFA by using topomers, which are molecular fragments with 
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standardized internal geometries. This enables the topomer CoMFA 
methodology to do away with structural alignments, which is the most difficult 
and subjective step of the conventional CoMFA methodology. Mostly, all the 
steps in topomer CoMFA are automated and thus the methodology is entirely 
objective. In addition, conformation and orientation of a molecular fragment 
were described by a topomer and it was generated based on 2D structure 
without any involvement of a receptor site or other ligands.  The SAR of the 
new series of 4-chloro-pyrazolopyrimidine derivatives was quantitatively 
elucidated and the structural features essential for the inhibition of   hA3AR 




 position of the bicyclic nucleus was proposed. 
Topomer 3D models are constructed for each fragment automatically, using a 
probe atom around the 3D grid. Subsequently, the steric and electrostatic 
fields (“CoMFA column”) are generated for each set of  topomers. Therefore, 
the corresponding biological activity was correlated with both the steric and 
electrostatic properties of a derivative’s chemical structure. 
 
3.5.2  Experimental Methods 
3.5.2.1 Selection and preparation of dataset 
            The structures of the 6 amino-4chloro-pyrazolo[3,4-d]pyrimidine 
derivatives (26 compounds) and their respective biological data are given in 
Table 3 (see chapter 4). SYBYL-X 1.3 program (Tripos Associates Inc.)
166 
was used to perform the QSAR experiment using windows operating system 
version. A molecule sketch program was used for the molecule building. All 
ionisable groups were drawn in their uncharged forms. Derivatives with  Ki 
hA3 >60 µM or >100 µM were assigned an arbitrary high Ki of  1000 µM for 
topomer CoMFA.
132
 Firstly, a standard Tripos molecular mechanics force field 
of 0.05 kcal/ (mol·Å) was used to minimize the molecular geometry of each 
compound. In addition, Gasteiger-Huckel MMFF method was used to 
compute the charges.
167, 168
 Powell Method of 100 iterations were used for 
energy minimization of the atom and prior to that, atomic charges were 
assigned to each atom.  
Training set structures were separated into two sets of fragments (also referred 















Table 4. Fragments of training sets of 4-chloro-pyrazolopyrimidine 
derivatives 
 
 This was achieved by specifying multiple acyclic single bonds to cut within 
each complete structure, since they all shared identical substructure (i.e., 
constant core). Subsequently, after  the fragmentation, the input structures 
were standardized, normalized and the topomers generated. After the model 
was created, the following values were reported in the Topomer CoMFA 







) value for the specified number of components; 
conventional r
2
 value; y-intercept for the PLS analysis; fragment contributions 
of R-group to the predicted activity (adding the sum of the fragment 
contributions with the PLS intercept value gives the predicted activity value). 
These results are summarized in Table 5. The model generated was successful 
(since q
2
 > 0.2), and it was therefore used to predict the activity of other 
structures. 
 
3.5.3 Results and discussion 
The final topomer CoMFA model had a q
2
 of 0.325 and r
2
 of 0.561 using two 
components. These results are comparable to those for some of the datasets 
used to assess the topomer CoMFA methodology.
132
 The topomer CoMFA 
model had an intercept of 2.85 and the contributions of the different 






CH2C(CH3)3 NHCOPh (p-F) 
CH2CH2C6H5 NHCOPh (p-CF3) 

















                 Table  5. Results of the Topomer  CoMFA analysis. 
 It can be seen that substituents at R1(C
6
) position had a much larger effect on 
















Table  6. Average pIC50 value contributions of different substituents for R and 
R1 group   at pyrazolopyrimidine derivatives in topomer CoMFA with an 





















y intercept 2.85 
R    pIC50 
Contribution 
R1      pIC50 
Contribution 
CH3 -0.03 NH2 0.04 
CH(CH3)2 -0.22 NHCOPh 1.69 
CH2C(CH3)3 0.17 NHCOPh (p-F) 1.66 
CH2CH2C6H5 0.04 NHCOPh(pCF3) 2.04 
  NHCOPh(pCH3) 1.78 
  N(CO-Ph)2 1.80 




















        Figure 24. The steric and electrostatic effects at  
        the N
2
 position in     compound 116 (green region  






Figure 25. The steric and electrostatic effects at the C
6
 position in compound 
116 (green region denotes steric effects, blue and red regions denotes 





             Topomer CoMFA produced large green contours around N
2
 position 
(phenyl ethyl group of compound 116 as representative example), as shown in 
Figure 24, indicating that presence of a bulky lengthy chain was needed for 
biological activities. Similarly, pIC50 value seems to be correlating with 
contour plots analysis, as hydrophobic neopentyl groups displayed the highest 
pIC50 followed by phenyl ethyl groups. Subsequently, the negative pIC50 value 
obtained for the methyl and isopropyl derivatives proves the less importance 
of non bulky groups. The electrostatic map around the N
2
 position was not as 




             As shown in the table 6, free amino groups at C
6
 position showed 
lowest pIC50 value, which in turn was indicated by the absence of contour plot 
surrounding this region. When the free amino group was acylated, pIC50 











SAR of the compounds and pIC50 values: as the hydrophobicity increases, 
pIC50 value also increases. SAR showed that limited activity for the C
6
 
benzamide analogues followed by para-F benzamide derivatives. The same 
trend was observed for pIC50 value of corresponding substitutions. Similarly, 
electron withdrawing substitution such as at para-CH3 group possessed 
maximum activity followed by para-CF3 substitution, as seen in the Table 3. 
Moreover, chain elongated phenylactyl and bulky dibenzoyl groups displayed 
almost equal pIC50 and the same trend was followed for the binding affinity of 
the compounds.  
             Similarly, the contour map analysis of R
1 
groups showed that there is 
also a large green region around the phenyl ring of acyl chain at C
6
 position 
(Figure 25), indicating that the presence of bulky substituents should improve 
the biological activities. Similarly, the presence of both blue and red contours 
signifies the necessity of having electronic properties substituents at the para 
position of the acyl chain. This was indicated by the electrostatic maps, in 
which substituents with both positive and negative groups near to the C
6
 
position are deemed vital for activity. 
 
3.5.4 Conclusion  
             Topomer CoMFA has been established as a 3D QSAR tool that 
creates the model for bio activity prediction of compounds. The 3D QSAR 
model exposed the important sites for chemical modifications to improve the 
affinity. The new insights on the steric and electrostatic factors that are 
important in modulating the hA3 affinity for the new series of 4-chloro-PP 




position of the bicyclic nucleus, were 
obtained from the topomer CoMFA methodology. From QSAR analysis, it 
was noticed that the large green region around N
2
 position favoured bulky 
substituents (e.g., neopentyl, phenyl ethyl). Similarly, a large green region 
around the C
6
 position suggests that bulky acyl substituents (e.g., substituted 
benzoyl groups) are favoured at this position. The electrostatic map at C
6
 
position shows that substituents with both positive and negative groups in 
para (e.g. para-CF3, para-F, para-CH3) at the C
6
 position are important for 
activity. These results additionally support  the SAR fact that N
2
 bulky 
groups(e.g. neopentyl and phenylethyl) and C
6
 benzoyl with different  para 
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and meta substituted electronic groups (e.g.CF3, CH3, Br, Cl etc.) are needed 
to improve the affinity. Overall, the hA3 receptor antagonistic activity has 






3.6 Homology modeling of human A3 adenosine receptor and molecular 
docking evaluation of 4-chloro-pyrazolopyrimidine derivatives  
 
3.6.1 General Introduction 
             In this chapter, homology modeling of human A3 adenosine receptor  
was carried out and using the built homology based human A3 model, a 
molecular docking simulation on PP derivatives was further carried out to 
examine the binding modes and vital interactions between the ligands and 




3.6.2 Homology Modeling of Human A3 Adenosine Receptor 
3.6.2.1 Introduction 
             Recently, the crystal structure of hA2AAR, bound with a selective and 
potent antagonist (ZM241385) was identified
169
 and it shares moderate 
sequence identity of about 43% with the hA3AR. Moreover, this structure 
serves as an alternate template for the construction of hA3 homology model 
applied for docking studies.
77, 107, 140
 In the present study, we have developed 
the single template-based homology modeling of  A3 receptor. 
 
3.6.2.2 Experimental Methods 
Construction of hA3 homology model 
              The high affinity antagonist ZM-241385 (PDB code: 3EML),
169
 
which are complexed with humanA2A adenosine receptor crystallographic 
structure, was recently resolved and a new alternative template to perform 
homology modeling of other GPCRs, especially  the adenosine receptors, was 
provided. The template of the human hA2AAR
169
 protein sequence (PDB code: 
3EML) was obtained from PDB, whereas the protein sequence of hA3 receptor 
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                     Figure 26. General flow chart of  homology modeling. 
 
obtained  from  Unit Prot Database.
170
 For the construction of  hA2AAR-based  
homology model, the alignment between the template and the hA3 target 
sequence  was  carried out  through  align 2d  command of  Modeller 9.11 
program
171-174
 and Clustal Omega program was used to countercheck the   
alignment.
175
 Similarly, the sequence alignments were directed by highly 
conserved amino acid residues such as LAXAD, DRY and NPXXY motifs in 
TM2, TM3 and TM7 respectively, and the 3 proline residues in TMs 4, 5 and 
6 (Figure A1 in Appendix).
142 
 A HMM profile-profile techniques and  
seeded guide trees were used by Clustal Omega program to generate 
alignments. Subsequently, the developed model was validated using 
Ramachandran Plot from Procheck and Richardson Lab's Molprobity in 




 All graphical manipulations 
1. Template 
Selection 
2.Sequence alignment with hA3                                                                                               
Target Sequence 
 
A3AR                                                                               
3. Model Building                                                                                                                    
4. Evaluation of  Model                                                                                    
 





and visualizations were performed by means of  PyMOL Molecular Graphics 
System.
177
 Figure 26 depicts the general steps involved in the homology 
modeling. 
 
3.6.2.3 Results and Discussion 
 
Evaluation of hA3 homology models 
             The overall sequence identity between the hA2A template and the 
target sequence of   hA3AR was found to be ~43%. Consistently, the model 
based on the hA2AAR (Figure A1 in Appendix) has shown better parameters 
(% of residues in the most favoured regions = 93.9%, G factor = 0.34, Table 
7) in the Ramachandran Plot (Figure A2 in Appendix) than previous results 
from our lab.
118
 Moreover, none of the residues were observed in the 
generously allowed and disallowed regions. As described by the previous  
 
Table  7. Ramachandran Plot Summary from Procheck 
  












hA3 Model 96.5% 3.5% 0.0% 0.0% 
 










Raw Score -0.17 -0.04 0.48 0.34 90.72 


















n % n % n % n % 
0.48 
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Table 10. RMS deviations of  hA3 Model and its respective templates 
 
findings, 80% of Cα-atoms can be expected to be within 3.5 Å of their true 
position,  for 30-50% of sequence identity, whereas significant errors are 
expected for less than 30% sequence identity.
177,178 
In addition, 96.5% of 
residues was observed in the Richardson Lab's Molprobity analysis (Table 8). 
Interestingly, observations of current study were in agreement with previous 
studies.
118, 140
 All of these findings proposed that the hA3 model based on 
hA2AAR was stereochemically more precise and accurate. 
             After a model building, it was checked for possible errors. Mainly, the 
quality of the model is predicted by the sequence similarity between the target 
and the template (Figure A1 in Appendix). Above 30% of sequence identity 
is deemed as a predictor of the model accuracy. Evaluation is usually 
performed by two types. “Internal” evaluation of self-consistency is able to 
confirm whether a model meets the restraints used to calculate it. 
“External” evaluation depends on information which are not used in the 
calculation of the model.  Programs such as PROCHECK
179
 (internal 
evaluation)  is often used to assess the stereochemistry of  models (e.g. bonds, 
dihedral angles, bond angles, and non-bonded atom lengths). Main advantage 
of PROCHECK is that a large error such as alignment errors are easily 
detected by cluster of stereochemical errors obtained from the evaluation. A 
small  RMSD (< 2.5 Å) value  of  bond length and bond angles of  binding 
pocket residues were observed between  A3AR model and  hA2A template 
(Table 10).This indicates that hA3 homology model closely resembles  hA2A 
template  in terms of  binding pocket. Hence, this model could be deduced  as 
efficient model for the prediction of ligand binding. However, the molecular 
docking study will be further investigated (Section 6.3) to identify the 
predictive comparable binding modes and interactions ability of the hA2A-
based model with ligands. 
 
 
Number of close 
contacts (within 2.2 
Å) 
RMS deviation for 
bond angles: 
RMS deviation for 
bond lengths: 
hA3 Model 0 2.1 ° 0.019 Å 
98 
 
3.6.3 Molecular Docking Simulations 
3.6.3.1 Introduction 
             This section describes the hypothetical binding interactions of newly 
synthesized 4-Chloro-PPs (81-84 & 101-124) through the hA3 ‘hybrid’ 
homology model. The derivatives were docked through the hA2AAR-based 









 substituted derivatives. 
Moreover, the binding modes and interactions of the most potent 2-aryl-PTP 
and the potent PP analogues (116) inside the hA3AR were also evaluated to 
compare the  binding pose with PTP analogues and rationalize the results.  
A molecular docking study was performed on the novel 2-(alkyl and aralkyl 
substituted)-2H-pyrazolo[3,4-d]pyrimidine derivatives (81-84 & 101-124) to 
identify the hypothetical binding mode at the hA3 adenosine receptor and to 












             Figure 27. General topology of the hA3 ‘hybrid’ homology model 
 
Especially, molecular docking studies were carried out on both hA3  and  hA2A 
adenosine receptors. Different docking softwares have been evaluated for their 
ability to reproduce the crystallographic pose of  ZM241385 inside the binding 
cavity of hA2A receptor. Among the different programme, MOE gave the 
lowest RMSD value, hence we decided to use MOE as a docking programme 
for the pose inspection of the novel pyrazolo[3,4-d]pyrimidine derivatives in 
both hA2A and hA3 receptors. All the newly synthesized pyrazolo[3,4-
99 
 
d]pyrimidine derivatives were docked into the orthosteric trans-membrane 
(TM) binding cavities of  both adenosine receptors. On top of that, ligand-
receptor interactions were analysed using  ligand vs receptor residues binding 
interaction energy calculation. 
Ligands were energy minimized to obtain highly populated docked 
conformations and used for interpretation of binding mode inside the binding 
cavity of hA3 homology models as well as hA2AAR. Subsequently, docking 
results were analyzed and the results of the pharmacological evaluation were 
correlated to the binding assay results. 
             Generally, this section emphasized on the binding orientation of the 
new 4-chloro PP derivatives within the binding pocket of homology hA3 
model and hA2AAR. Concomitantly, it allowed us to: (i) explore the amino 
acid residues involved in the binding interactions, which are essential for the 
hA3 antagonist recognition; (ii) investigate the factors responsible for the 
difference in the activity between the 4-chloro-PP derivatives and the 
corresponding 2-aryl-PTP analogues. Therefore, the key residues and 




 and at C
4
-positions of the bicyclic 
nucleus could be delineated via docking study. 
 
3.6.3.2 Experimental Methods 
Computational Methodologies  
             All modeling studies were carried out on a Intel(R) Core[TM] 2 Quad 
CPU Q9550, 2.83 GHz, 3.25 GB RAM system. Docking simulation, energy 
calculation and the analyses of docking poses were performed using the 
Molecular Operating Environment (MOE, version 2010.10) suite.
180
 The  
software  package Hooman’s  IF-E 6.0 181 implemented in the MOE suite, was 
utilized to calculate all interaction energy. PyMOL molecular Graphics system 
was used for graphical visualizations and manipulations.
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MOE-builder tool as a part of  the MOE suite was used to build a ligand 
structures
180
 and were subjected to MMFF94x energy minimization until the 
rms of conjugate gradient was <0.05 kcal mol
-1
 Ǻ-1.  







 and  PLANTS.
185  
Using different 
docking algorithms and scoring functions, ZM-241385 was redocked into the 
100 
 
crystal structure of the hA2A adenosine receptor (PDB code:3EML). 
Considering the lowest rmsd value, the lowest mean rmsd value and the 
highest number of poses with rmsd value <2.5Ǻ, the MOE-Dock was chosen 
as docking programme (Figure 28). 
 
 
Figure 28.  The crystallographic pose of ZM241385 inside the binding cavity 
of  hA2A receptor reproduced using different docking  programmes  A. MOE-
Dock (rmsd  2.25) B. PLANTS (rmsd  2.48) C. Autodock (rmsd 2.94).  
 
            On the basis of the best docking performance, all ligands were docked 
into the hypothetical TM binding site of the hA3AR model and that of the 
hA2AAR crystal structure by using the docking tool of the  MOE suite.
180
 In 
the MOE-Dock, the Alpha PMI placement method, followed by force field 
reﬁnement and london dG scoring, were used for the docking runs.  MOE-
Dock performed an independent docking runs (100 for our specific case) and 
wrote the resulting conformations and their energies in a molecular database 
file. The resulting docked complexes were subjected to MMFF94x energy 
minimization until the rms of conjugate gradient was <0.1 kcal mol-1 Ǻ-1. 
Prediction of  antagonist-receptor complex stability (in terms of corresponding 
pKi value) and the quantitative analysis for non bonded intermolecular 
interactions (H-bonds, hydrophobic, electrostatic) were calculated and 
visualized using several tools implemented in MOEsuite.
180
 Electrostatic 
contributions to the binding energy of individual amino acids have been 
calculated using software  package Hooman’s  IF-E 6.0 as implemented in 
MOE suite. 
3.6.3.3  Results and Discussion 
             From the docking simulation analysis, the synthesized derivatives 
were mostly seen to share a slightly similar binding pose in the TM region of 
the hA3AR. Moreover, the  ligand-recognition occurred in the upper region of 
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the TM bundle, and the pyrazolo[3,4-d]pyrimidine scaffold was surrounded by 
TMs 2, 3, 5, 6, 7 with the benzamide ring at the C
6
 position located towards 
the intracellular environment.  
Common binding interactions at the bicyclic nucleus and C
4
-position 
             In the molecular docking studies on the pyrazolo[3,4-d]pyrimidine 
derivatives, four main interactions were involved in the binding of the ligands 
to the hA3AR, namely hydrophobic interactions, hydrogen bonding,  π-π 
stacking and dipole-dipole interactions. Among these interactions, the 
hydrogen bonding and hydrophobic interactions appeared to be vital for ligand 
affinity and stability.  
            In all ligands, π-π stacking interaction of the planar bicyclic nucleus 
with the phenyl ring of Phe168 (ECL2) was observed.  Notably, this 
interaction was also present in the binding modes of other classes of hA3AR 
antagonists, including the pyrazolo-triazolo-pyrimidines (PTP).
118  
Data from 
literature and docking studies on PTP analogues suggested the importance of 
the binding of the Phe168 for the hA3 antagonistic activity. Moreover, the 
mutagenesis analyses conducted at the A2AAR demonstrated the importance of 
Phe168 for antagonist binding.
186
  Thus, as this residue was conserved in both 
the A2AAR and A3AR, it was deduced that Phe168 could be implicated in 
antagonist affinity at the latter receptor.
187
  
            Similalry, C
4
 chloro group was found to interact with some 
hydrophobic leucine based residues such as Leu90 (TM3), Leu91 (TM3) and 
leu246 (TM6). However, these residues do not seem to be recognized for an 
antagonistic activity. Therefore, from the binding study, the contribution of  
chloro functional group present in the simplified PP structures seems to be 
negligible, as it did not make an impact on potential interaction with some 
conserved residues which are essential for the antagonist recognition. 
Considering its lower importance towards binding, it is worth to mention that 
chloro group was mainly assigned because it could be easily substituted and 
subsequently could help in improving the affinity by further functionalization 










 substituents with residues 
             All the important binding interactions between the substituents  at N
2 
positions of new 4-Chloro-PPs (81-84 & 101-124) and the corresponding 
residues in hA3 receptor were summarized in Figure 29. As seen in the Figure 
29, less bulky groups such as methyl and isopropyl, bound with some common 
hydrophobic residues such as Ala69 (TM2), Ile268 (TM7) and Val 72 (TM2). 
Similarly, lengthy bulky substituents such as neopentyl and phenylethyl, 
shared the common interaction with hydrophobic residues such as Ala69 
(TM2), Val72 (TM2), Leu90 (TM3), Tyr265 (TM7) and Ile268 (TM7).  
 
Residue: Involved in π-π interaction, Residue: Involved in hydrophobic 
interaction 
Figure  29. Common binding interactions of new series of 4-Chloro PPs (81-

























Ser73 (TM2), Ala69 (TM2)
Ile268 (TM7), Leu90 (TM3),
Val72 (TM2), Ala69 (TM2),
Tyr265 (TM7),Leu264 (ECL3)
Tyr265 (TM7), Ile268 (TM7)
Leu90 (TM3). Val72 (TM2)







Residue: Involved in H-bonding, Residue: Involved in hydrophobic 
interaction, Residue: Involved in van der Waals interaction 
 
 
Figure 30. Common binding interactions of new series of 4-Chloro PPs  (81-
84 & 101-124) at  C
6
 position with respective residues in hA3AR. 
a
Residues 
found to interact with N
2 
methyl substitution only, 
b
Residues found to interact 
with N
2 
isopropyl substitution only. 
 
Among the different residues, Tyr 265 (TM7) and Leu90 (TM3) which are not 
observed with small substituents, seem to be essential for the antagonist 
binding, as the lengthy bulky groups in turn showed high affinity (Table 3). 
Moreover, previous binding interaction of PTP analogues showed that these 
two residues were essential for the antagonistic recognition (Figure 20). 
 
             In addition, common binding interaction involved between C
6
 
substituents and crucial residues are summarized in  Figure 30. Notably, 
residues such as Ser181 (TM5), Ser247 (TM6), made van der Waals 
interactions with ligands, whereas residues such as Ile186 (TM5), Phe182 


























































Ala69 (TM2)a, Met86 (TM3)a,
Thr87 (TM3)a, Leu91 (TM3)a,






 benzamide substituents. However, few residues such as Met177 
(TM5), Trp243 (TM6) are observed in para-CF3 and para-CH3 benzamide 
substituents only.  Moreover, compounds with these two substituents 
displayed the highest binding affinity towards the hA3 receptor in the whole 
series (Table 3). Interestingly, similar type of hydrophobic interactions were 
observed for the PTP analogues, where binding interactions with Met177 
(TM5) and Trp243 (TM6) were deemed vital for the adenosine receptor 
activation and antagonistic recognition.
142 
 




             In this section, binding interactions of analogues of N
2
 alkyl series 
(especially N
2
 methyl and isopropyl) is evaluated by comparing its binding 
mode with the binding pattern of  the most potent compound, 116, inside the 
hA3AR. Figure 31 (panel A) presents the hypothetical binding pose of 
compound 116 at the hA3AR, which possesses the highest hA3 affinity among 
all the newly synthesized derivatives (Ki hA3=1.5 µM). It appeared that the 
bicyclic pyrazolo[3,4-d]pyrimidine core was anchored within the binding cleft 
through  an aromatic  π-π stacking interaction with Phe168 (EL2). Moreover, 
the carbonyl group of the exocyclic acyl chain at the bicyclic core interacted 
with polar residue Asn250 (TM6), forming a lone stabilizing H-bonding 
interaction. The N
2
 phenylethyl chain of  the ligand was directed towards  the  
TM2 and TM3. In addition, the phenyl ring of the acyl chain was located deep 
within the ligand binding cavity and formed hydrophobic interactions with the 
highly conserved Trp243 (TM6), an important residue in receptor activation 
and antagonist binding. Compound 116 also formed hydrophobic interaction 
with several residues in the binding cleft such as Leu90 (TM3), Leu91 (TM3), 
Met177 (TM5), Trp243 (TM6), Leu246 (TM6), Tyr265 (TM7), Leu264 (EL3) 
and Ile268 (TM7). 




-isopropyl derivatives, displayed slightly different 
binding pose as compared  to 116.   However,  as an exception, compound  
117 in the N
2 
methyl series and compound 118 in the isopropyl series showed 
a similar pattern as compound 116, which in turn was reflected in the high 
binding activity of these compounds. The pyrazolo ring of these compounds is 
105 
 
directed towards the extracellular environment rather than towards TM2 and 
TM3, and also the main nucleus pyrazolo[3,4-d]pyrimidine was rotated of 
about 45° compared to the binding pose of compound 116.   
 
 
Figure 31. A. Hypothetical binding mode of compound 116 obtained after 
docking simulations inside the hA3AR binding site. Poses are viewed from the 
membrane side facing TM6, TM7, and TM1. The view of TM7 is omitted. B. 
2D view of binding residue with ligand 116 inside hA3AR binding site. 
 





-isopropyl derivatives, displayed slightly different 
binding pose as compared  to 116.   However,  as an exception, compound  
117 in the N
2 
methyl series and compound 118 in the isopropyl series showed 
a similar pattern as compound 116, which in turn was reflected in the high 
binding activity of these compounds. The pyrazolo ring of these compounds is 
directed towards the extracellular environment rather than towards TM2 and 
TM3, and also the main nucleus pyrazolo[3,4-d]pyrimidine was rotated of 
about 45° compared to the binding pose of compound 116. Because of this 
different orientation of the molecule inside the binding cleft, derivatives of N
2
 
methyl and isopropyl (101-104, 105-108 & 122) might have lost the H-
bonding interaction with Asn250 (TM6). The lack of these important 
interactions resulting from different orientation seems to be responsible for the 







Binding interactions of bulky group substituted derivatives at N
2
 position 
              Interestingly, the pyrazolo[3,4-d]pyrimidine derivatives bearing 
lipophillic moieties at N
2
 position, such as phenylethyl and neopentyl 
derivatives, shared similar binding patterns, which accounted for high binding 
affinity of the compounds in these series. In fact, for all these derivatives, the 
pyrazolo[3,4-d]pyrimidine scaffold is utterly aligned inside the TM region of 
hA3 receptor with the exception of compound 109 in the neopentyl series and 
compound 114  in the phenylethyl series. In particular, the aromatic stacking 
interaction with Phe168 (EL2), a lone H-bonding interaction with Asn250 
(TM6) and the hydrophobic interaction with Try243 (TM6) are conserved 
among these derivatives. As seen in Table 3, compounds 115 & 116 of the N
2
 
phenylethyl series and compounds 110, 111 & 112 of the N
2
 neopentyl series 
showed close binding affinity value, which is reflected in the overlapping 
binding pattern with one another inside the binding cleft. Notably, due to the 
flexible nature of the neopentyl and phenylethyl substituents, which possess 
lengthy and multiple rotatable bonds (2 for neopentyl and 3 for phenylethyl), 
enabled the scaffold to obtain a different conformation to fit into the binding 
cleft. Therefore, it is deduced that the presence of sterically bulky but lengthy 
chains at N
2
 position ensures high binding affinity of the derivatives at the 
hA3AR.  
 
Binding interactions of  PP analogues at  hA2A AR  
             As shown in Figure 32 (panel B), the hypothetical binding pose of 
compound 116, obtained after docking inside the hA2A receptor crystal 
structure (Figure 32, panel B), is quite different compared to its pose inside 
the hA3 subtype. However, the same region of  the TM bundle is involved in 
the ligand recognition. Particularly, the phenylethyl ring points toward EL2 
and the pyrimidine nucleus is oriented towards the intra cellular environment. 
The ligand formed an aromatic π-π stacking interaction with Phe168 (EL2), 
however it lost the H-bonding interaction with Asn253 (TM6) and the 
hydrophobic interaction with Try243 (TM6). Most of the newly synthesized 
derivatives showed slightly different binding orientation (except N
2
 isopropyl 
analogues) inside the hA2A receptor pocket as compared to hA3 receptor 
pocket. Interestingly, it made weak interaction with Glu169 (ECL2), which is 
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essential for hA2A affinity. All the isopropyl derivatives 105-108, 118 & 120 
showed this same binding mode inside the hA2A receptor pocket. Moreover, 
comparing the docking pose of compound 116  on the hA2A receptor with the 
crystallographic pose of the antagonist ZM-241385 (Figure 32, panel A) we 
noted that the bicyclic core of the pyrazolo[3,4-d]pyrimidine derivative was 
















Figure 32. A. Crystallographic binding mode of ZM-241385 inside the hA2A 
receptor (PDB code 3EML) and hypothetical binding mode of compound 116 
obtained after docking simulations B. inside the hA2AAR binding site and 
poses are viewed from the membrane side facing TM6, TM7, and TM1. The 












Figure  33. Binding orientation  of  ZM-241385 (grey) and analogue 118 





              In contrast, N
2
 isopropyl derivatives (105-108, 118 & 122) showed 
slightly similar binding pattern as compared to ZM-241385. Among the 
isopropyl derivatives, compound 118, with diacyl substitution at C
6
 position 
and with the highest hA2A affinity (Ki =0.8 µM) among all the isopropyl 
derivatives, showed a binding pattern close to ZM-241385 (Figure 33).  
Notably, impeded free rotation of isopropyl group due to ring constraints 
directed the ligand to obtain a fixed conformation and this accounted for the 
shifting of affinity towards the hA2A receptor. The isopropyl substituents of  
the main scaffold are located towards the TM2, one of the diacyl chains 
pointing towards the EL2, whereas other acyl chains pointed towards the 
TM6. This result indicates that the receptor pocket, where the C
6 
appended 
moiety of these derivatives is accommodated, is roomy enough to hold the  
 
 
Figure 34. A. Hypothetical binding mode of analogue 118 inside the hA2AAR 
binding site. The view of TM7 is voluntarily omitted. B. 2D view of binding 
residue with ligand 118 inside hA2A AR binding site. 
 
rather bulky and broadened diacyl chain. In addition, N
1
 of the pyrazole ring 
formed a H-bonding interaction with Asn253 (TM6) and a stable interaction 
with Glu169 (EL2), which is considered to be vital for ligand binding at the 
hA2AAR (Figure 34, Panel A). Similarly, compound 108, with a para-toluoyl 
group of the C
6
-benzoyl substituent, bound to hA2A receptor in a similar 
fashion as compound 118, thus justifying an equally potent affinity at this 
receptor subtype. To analyze the possible ligand-receptor recognition 
mechanism in a quantitative way an individual electrostatic contribution 
(ΔEelint) to the interaction energy (ΔEint) of each receptor  residue was 
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calculated (Figure A3 in appendix). The calculated electrostatic contribution 
per residue to the whole interaction energy for both the complexes between 
compound 116  and two adenosine receptor subtypes were  analysed. The 
pattern showed stronger per residue contributions for hA3AR-ligand 
complexes compared to the ones  at  the hA2A AR.  From this analysis, it was 
found that one of the most critical residues   affecting the affinity at ARs 
seems to be the asparagine 6.55 (Asn 253 in hA2A and Asn 250 in hA3) due to 
the H-bonding interactions with the ligand mentioned above. It is evidenced 
that calculated  electrostatic contribution  of  Asn (6.55)   is moderate  and  
more stabilizing  for  hA3AR complex  (-5 kcal/mol, Figure A3-C in 
appendix) due to a different orientations  of  ligand 116  inside the hA3AR, as  
compared  to  Asn 253 (< -2 kcal/mol, Figure A3-B in appendix) in hA2AAR 
complex (no hydrogen bonding interactions). Similarly, the hydrophobic 
interaction score pattern showed  that one of the strong stabilizing 
contributions corresponded  to the bicyclic core interactions with Phe168 
(EL2) and the moderate stabilizing contributions of  Leu246 (6.51). Both of 
these residues are essential for the hA3AR affinity, however, one of the main 
residues, Phe168, showed  weaker  interactions  at  hA2AAR  and  resulted in 
lower affinity towards the same receptor. 
 
Comparison of  binding interactions of PP analogues with PTP analogues 
in hA3 binding site  
             Eventually, we compared the binding pose of the analogue 116 with 
the most potent PTP analogue, bearing a methyl group at N
8
 position, 
phenylacetyl moiety at C
5


























Figure  35.  Hypothetical binding mode of  PTP inside the hA3AR binding 
site. The view of  TM7  is voluntarily omitted.  
 
 
Moreover, most of the compounds in the N
2
 neopentyl and N
2
 phenylethyl 
series shared almost similar binding pattern as PTP scaffold. 
 
 Generally, the main scaffold pyrazolopyrimidine aligned exactly over the 
pyrazolopyrimidine moiety of the PTP scaffold (Figure 36). In addition, the 
triazole ring of the PTP aligned over Cl functional group of PP. Coherently, 
these compounds displayed similar interactions, such as, aromatic π-π stacking 













Figure 36. Binding orientation of  PTP (magenta) and analogue 116 (grey) 













including Met177 (TM5), Leu246 (TM6) and Leu264 (EL3), which are crucial 
for hA3 affinity. Moreover, the phenyl ring of the C
6
 phenyl acetamide chain 
of the PTP made strong aromatic π-π stacking interaction with Trp243(TM6) 
(Figure 35). 
              In contrast, PP analogue made a weak hydrophobic interaction with 
Trp243 (TM6). Additionally, the PTP scaffold formed two stabilizing H-
bonding interactions (one with the carbonyl oxygen atom and other one with N 
of triazole ring) with Asn250 (TM6) residue. On the contrary, the PP 
analogues of bulky series formed only a lone stabilizing hydrogen bonding 
interaction with Asn250 (TM6). Consequently, missing one H-bonding 
interaction of  PP scaffold along with weak  aromatic interaction with Trp243 
(TM6)  seem to explain the decrease in the binding affinity of PP analogues as 
compared to the PTP analogues. 
 
3.6.3.4 Conclusion 
              A homology model for the hA3 receptor has been constructed using a 
single-template homology modeling approach based on hA2AAR crystal 
structure. Improved stereochemistry parameters were obtained for the hA3 
‘hybrid’ model as compared to the previous study (as evidenced from 
Ramachandran Plot). These observations suggest that the ligand binding 
modes and interactions within the ‘hybrid’ model might be efficient, which 
could be further justified by the docking studies. 
               Indeed, through our molecular modeling investigation, the 
experimental findings have been rationalized by depicting the hypothetical 
binding mode between these newly synthesized derivatives and the specific 
amino acid residues within the binding site of hA3 and hA2A receptors. 
Overall, the molecular docking studies provided new useful insights about the 
steric, lipophilic, and electrostatic requirements that are important for the 
optimal anchoring of these derivatives to the hA3AR recognition site. 
Generally, the binding pattern of the PP analogues varied depending on the 
length of substituents at the N
2
- and / or C
6
-positions of the PP. As mentioned 





-isopropyl derivatives, displayed slightly different binding 
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pose as compared to lengthy bulky substituents (neopentyl and phenylethyl) at 
N
2
 position inside the hA3 model and hA2AAR. 
             Overall, the ligands and the residues have made the following 
interaction at hA3 model: (i) hydrophobic interactions of N
2
-substituents with 
non-polar residues, which are crucial for conferring hA3 affinity; (ii) 
hydrophobic interactions of phenyl ring of benzamide chain at C
6
-position, 
vital for affinity; (iii) van der Waals interactions of  steric electron donor and 
or electron acceptor groups at  para position of the benzamide chain, essential 
for affinity. (iv) aromatic planar bicyclic moiety like pyrazolopyrimidine ring 
involved in π-π interaction with the nearby aromatic residues, essential for 
antagonistic activity; (iv) van der Waals interactions (e.g. dipole-dipole) 
between the polar moiety at amidic group at C
6
 position  and polar residues.  
 For the binding interactions of ligands at hA2AAR, a restricted rotation of  




is needed along with benzamide moiety at C
6
 
position to make potential interaction with Glu169. As discussed in the above 
section, most of the compounds of PP lost the  potential H bonding interaction 
with Asn250 (TM6), and displayed weak hydrophobic interactions with 
Trp243 (TM6). However, the potent compounds of PP series still enabled the 
other essential hydrophobic binding interactions as PTP derivatives. This 
seems to explain why PP derivatives showed inferior activity to PTP scaffold. 
Moreover, a chloro group at C
4
 position is in close vicinity to polar residues 
such as Asn250 (TM6). Consequently, further structural modification such as 
replacing the chloro functional group at the C
4
 position with some hydrogen 
bond donor (CONH2) or acceptor groups (COOC2H5) could potentially 
improve the binding affinity at hA3 receptor and selectivity at other receptor 










Chapter 4   Rationale of further ligand modification  
 
             The SAR and the molecular modeling  studies of the previously 
synthesized 4-chloro-pyrazolo[3,4-d]pyrimidine derivatives provided useful 
information about the relevant structural features of PP scaffold and essential 
amino acid interaction at the receptor’s binding site required for the 
improvement of  affinity and selectivity of PPs at the hA3AR. Following that 
study, we aimed to improve the potency and selectivity of 4-chloro 
pyrazolo[3,4-d]pyrimidines, by modifying certain structural features in the 
previously synthesized PP derivatives. 
Towards that purpose, we speculated that the following features could be vital 
for the hA3 receptor antagonistic activity: 
I. C6 substituents with benzamide chain with different electronic 
properties seem crucial for good affinity at the hA3AR. Hence 
benzamide chain with different substituents at para position will be 
introduced in the new series of derivatives (Chart 4).  
II. Electron withdrawing bulky groups at para position of C4 benzamide 
are essential for the selectivity, hence more bulky groups with 
electronic properties will be introduced (e.g.  3,4-F, 3,4-Cl, 4-Br, 3,4-
Br). 
III. Considering the wide space of the A3 binding pocket, which can 
accommodate relatively bulky size substituents, more C
6 
diacylated 
compounds will be introduced in order to determine the maximum 
spatial tolerability at the receptor pocket. 
IV. Upon analyzing docking results of molecular modeling studies, it was 
noticed that PP scaffold lacks one of the two hydrogen bonding 
interactions with Asn250, which was deemed essential for hA3AR 
affinity as in the PTP series. Therefore, it was decided to replace the 
chloro group with hydrogen bond donor or hydrogen bond acceptor 
groups such as ester or amide groups in the new series (Chart 4). 
V. N2 substituents with lipophilic groups such as neopentyl and 
phenylethyl are essential for affinity. Therefore, in the new derivatives, 





 methyl and isopropyl substituted derivatives will also be 
synthesized to observe the impact of  hydrophilic ester substitutents on 
the  small alkyl chain derivatives  and also to derive a detailed 
comparative structure activity relationship analysis. 
 
 
Chart 4. Structural features of pyrazolo[3,4-d]pyrimidines and proposed 
changes (R denotes N
2
 position, R1 denotes C
6
 position).  
 
Hypothesis 1: 
             Based on the above mentioned structural limitations of  the chloro 
group and advantages of different substituents introduced in the original PP 
scaffold,  it is therefore hypothesized that the replacement of chloro group by 
ester substituents at C
4





positions, will improve the hA3AR affinity and selectivity.  
 
Hypothesis 2: 
              It is also hypothesized that pertinent molecular docking investigations 





 position of  bicyclic nucleus, towards the design of more 








H bond donor or
acceptor group (eg.CONH2 or COOCH2CH3)
Alkyl (e.g CH3,CH(CH3)2,
CH2C(CH3)3 & CH2CH2C6H5NH2, different acyl groups
eg.NHCOPh, NHCOCH2Ph,











Main objectives:      
To test these hypotheses, the following investigations were planned and 
carried out: 
a) Design, synthesis and characterization of a new series of pyrazolo[3,4-
d]pyrimidine-4-carboxylate derivatives bearing an ester functional group at the 
C
4





the bicyclic scaffold. 
 b) Pharmacological investigation of the new series of compounds to assess the 
importance of different structural parameters at each position of PP bicyclic 
nucleus towards the affinity and selectivity profile at the hA3AR. This is 
achieved through binding affinity assays at the hA1, hA2A and hA3 receptors as 
well as functional assays at the hA2BAR. 
c) Detailed analyses of the SAR for the new series of pyrazolo[3,4-d] 
pyrimidines-4-carboxylate towards hA3AR subtype. 
d) Rationalization of the experimental binding affinity data through molecular 
docking simulations for the new series of pyrazolo[3,4-d]pyrimidines-4-
















Chapter 5  Design, Synthesis, Pharmacological and Molecular 
Docking Evaluation of Pyrazolo[3,4-d]Pyrimidine-4-
carboxylate derivatives 
*Pharmacological assays were performed by our collaborator, Professor Karl-




             This section describes the design and synthesis of a new series of 
pyrazolo[3,4-d]pyrimidine-4-carboxylate  bearing ester substitutents at C
6
-
position (based on the proposed structural  modification as mentioned  in  





positions of the bicyclic nucleus. The discussion will first elaborate the 
synthetic schemes followed by details of the reaction and mechanism.  
 
5.2  Chemical considerations 
             The  new  series  of   6-amino-2-(alkyl or aralkyl)-2H-pyrazolo[3,4-
d]pyrimidine-4-carboxylates 133-136  and its derivatives  137-162  were 
synthesized as summarized in  Schemes 3 & 4, respectively. Scheme 3 shows 
the synthesis of compounds  133-136  and Scheme 4 depicts the synthesis of 
derivatives 137-162.  
 













Scheme  3. 
 
Reagents :  (a) NaCN / p-toluene sulfinate sodium / DMF, 80
°
C, 
2h;  (b) K2CO3 /  30% H2O2, rt, 1h; (c) ethanol / conc. H2SO4, reflux, 12 h.  



















































Scheme  4. Reagents :  (a)  substituted benzoyl chloride/ DIPEA/ toluene, 
120°C, reflux, 24 h ; (b) phenyacetyl chloride / DIPEA/ toluene, 120°C, 
reflux, 24 h. 
 
No R R1 R2 R3  R R1 R2 R3 
133 CH3 - - - 148 CH2CH2 
C6H5 
H H H 
134 CH (CH3)2 - - - 149 CH2CH2 
C6H5 
H F H 
135 CH2C(CH3)3 - - - 150 CH2CH2 
C6H5 
H CF3 H 
136 CH2CH2 
C6H5 
- - - 151 CH2CH2 
C6H5 
H CH3 H 
137 CH3 H H H 152 CH2CH2C6H5 H Br H 
138 CH3 H F H 153 CH2CH2C6H5 H Cl Cl 
139 CH3 H CF3 H 154 CH3 C6H5CO H H 
140 CH3 H CH3 H 155 CH3 4-Br-
C6H5CO 
Br H 
141 CH (CH3)2 H H H 156 CH3 3,4-F-
C6H5CO 
F F 
142 CH (CH3)2 H F H 157 CH (CH3)2 C6H5CO H H 
143 CH (CH3)2 H CF3 H 158 CH2CH2C6H5 C6H5CO H H 
144 CH (CH3)2 H CH3 H 159 CH3 - - - 
145 CH2C(CH3)3 H F H 160 CH (CH3)2 - - - 
146 CH2C(CH3)3 H CF3 H 161 CH2C(CH3)3 - - - 





























5.2.1 Synthesis of ethyl 6-amino-2-(alkyl or aralkyl)-2H-pyrazolo[3,4-
d]pyrimidine-4-carboxylate (133-136), ethyl 6-benzamido-(alkyl or 
aralkyl)-2H-pyrazolo[3,4-d]pyrimidine-4-carboxylate (137-153), ethyl 6-
(N-benzoylbenzamido)-2-methyl-2H-pyrazolo[3,4-d]pyrimidine-4 
carboxylate (154-158), ethyl 2-(alkyl or aralkyl)-6-(2-phenylacetamido)-
2H-pyrazolo[3,4-d]pyrimidine-4-carboxylate (159-162) 
            Nucleophilic substitution of chloro group by cyanide ion for 
heterocycles (e.g. purine, pyrimidine etc.) was reported by various research 
groups.
188-190
 Among them, cross coupling reaction involving KCN and 
palladium complex such as Pd(PPh3)2Cl2 or Pd (PPh3)4 and Zn(CN)2 in NMP 
were the most commonly used reaction conditions for the preparation of  
heteroarynitriles from chloro heteroarenes.
190-192
 The method from literature 
was followed for the cyanation; however, the reaction did not progress as 
expected. Subsequently, we also attempted to prepare heterocarbonitriles  
analogues by treatment of   halohetero compounds with tetraethyl ammonium 
cyanide (TEACN) in the presence of  base, as reported for the synthesis of  
purine-6-carbonitriles.
192
 However, the reaction was not successful. It was 
noticed that, in order to substitute the cyanide group, the less active chloro 












         Chart 5. Proposed mechanism of formation of 125-128 
 
              It is well known that if sulfonyl group attached with the heteroarenes, 
the electrophilicity of the heteroarene would be increased and subsequent 























catalytic amount of sulfinate for the cyanation of chlroheteroarenes with 
sodium or potassium cyanide through formation of sulfonylheteroarenes. 
(Chart 5) 
             Compounds  125-128  were prepared  by treating sodium cyanide in 
the presence of p-toluene sulfinate sodium as catalyst in dry DMF at 80°C for 
2 h. The nitrile groups were detected by the presence of  CN peak at 115 ppm 
at 
13
C NMR and also confirmed by presence of CN peak between 2250-2260 
cm
-1 
in IR spectroscopy.  
              Hydrolysis of   nitrile   group was reported by several groups.
189, 190, 
194
 Nitrile group can be hydrolysed by acidic or basic condition. Initially, we 
tried this hydrolysis using 98% H2SO4 in both cold and hot condition, however  
the  reaction  was  not  progressed. Then the reaction was carried out using 
literature method called “Radziszewski reaction” using  aqueous hydrogen 
peroxide and  aqueous potassium carbonate in cold or  hot condition.
195
 
However, the product was obtained with low yield in cold and hot condition. 
Hence, with the slight modification to reported procedure, the reaction was 
carried out at a room temperature to obtain carbamides (129-132) with good 
yield. Mechanism related to the hydrolysis of CN to CONH2 is depicted in the 
Chart 6.  
 
 
                  
                    
                  Chart 6. Proposed mechanism of formation of 129-132 
 
              Esterification of  heterocyclic amide was a straightforward 
reaction.
151
 Subsequently, these intermediate compounds (129-132) were 
esterified in the presence of conc.H2SO4 with absolute ethanol under reflux 
condition to obtain the corresponding carboxylates 133-136 as solid (Chart 



































            Chart 7. Proposed mechanism of formation of 133-136 
 
             Acylation of compounds 133-136 was carried out as reported in 
Scheme 4. With a slight modification to previous 4-chloro substituted 
pyrazolopyrimidines, 3 equivalents of substituted benzoyl chlorides and 
diisopropylethylamine were used to obtain monoacylated compounds 137-153. 
Disubstituted derivatives were prepared under standard conditions, using 6 
equivalents of substituted benzoyl chlorides and DIPEA (compounds 154-
158). Similarly, compounds 159-162 (with phenylacetyl substitutions) were 
synthesized under similar conditions as compounds 137-153. In addition, 
similar to C
6
 acylated 4-chloro PP derivatives, the amide formation in the ester 
series  was confirmed by observing the absence of  NH2  peak between 7.1 to 
7.5  ppm in 
1
H NMR and the presence of  amide (CONH) peak between 11.1 
to 11.7 ppm in the 
1
H NMR spectra. Further, CONH formation was confirmed  
by observing (C=O) carbonyl peak  around 163 ppm  in  
13
C NMR and HMQC 
NMR  analysis and these NMR analysis  were performed for one compound in 
each N-alkyl (ar-alkyl) substituted  and C
6
 acylated derivatives. 
 
5.2.2 Experimental section 
5.2.2.1 Chemistry 
             Reactions were routinely monitored by thin-layer chromatography 
(TLC) on silica gel plate (precoated 60 F254 Merck plate). Column 
chromatographies were performed using silica gel 60 (Merck, 70-230 mesh). 
Melting points were determined on a Gallenkamp instrument and were 
uncorrected. Compounds were dissolved in HPLC (high performance liquid 
chromatography) grade methanol for determination of mass to charge m/z on a 
LCQ Finnigan MAT mass spectrometer (source of ionization: Electron spin 




C NMR spectra were determined in the 



































ultrashield NMR (400 MHz) spectrometers, with chemical shifts given in parts 
per million (δ) downfield relative to tetramethylsilane (TMS) as internal 
standard, and J values (coupling constants) given in hertz. The  following  
abbreviations were used: s, singlet; d, doublet; t, triplet; sep, septet; m, 
multiplet; br, broad. 
HPLC Studies. The purity of the compounds were determined using 
analytical HPLC using  HITACHI, version 3.1.8b on a Phenomenex Gemini 
5U C18 (5 μM, 110 Å, 150mm × 4.60 mm i.d.) column at room temperature  
at a flow rate of 1.0 mL/min with two different mobile phase eluent systems at  
254 nm UV detection. The isocratic elution was followed and analysis was 
carried out using two different mobile phase eluent systems such as, Eluent 1; 
ACN (65%): H2O, Eluent 2; MeOH (55%): H2O. 
 
5.2.2.2 General procedure for synthesis of 6-amino-2-(alkyl or aralkyl)-
2H-pyrazolo[3,4-d]pyrimidine-4-carbonitrile (125-128). A mixture of  4-
chloro-2-(alkyl or aralkyl)-2H-pyrazolo[3,4-d]pyrimidin-6-amines  81-84 
(0.00054 mol), sodium cyanide (0.0011 mol, 2 equiv), sodium p-toluene 
sulfinate  (0.00016 mol, 0.3 equiv) in  5 mL of  anhydrous  DMF  was  heated  
on an oil bath at 80
°
C for 2 h. The resultant  mixture  was cooled, poured  into 
ice water mixture and stirred for 10 min. The solid was collected by filtration, 
washed with water and recrystallized from dimethylformamide and methanol 
mixture to obtain the desired products (125-128) as solids.  
6-amino-2-methyl-2H-pyrazolo[3,4-d]pyrimidine-4-carbonitrile (125): 
Yield: 65%;  pale yellow solid, mp 131-133 °C; 
1
H NMR (400 MHz, DMSO-
d6): δ 3.88 (s, 3H, N-CH3), 7.51 (s, 2H, NH2), 8.24 (s, 1H, pyrazole-H). 
13
C 
NMR (400 MHz, DMSO-d6): δ 33.7 (N-CH3), 108.7 (C), 115.1 (CN), 131.9 
(CH-pyrazole), 135.3 (C-CN), 155.7 (C-NH2), 162.2 (N-C-N). LC-MS (ESI) 




Yield: 77%; pale yellow solid, mp 125-127 °C; 
 1
H NMR (400 MHz, DMSO-
d6): δ 1.47 (d, J= 6.64 Hz, 6H, 2CH3), 4.91 (sep, J=6.40 Hz, 1H, CH), 7.46 (s, 
2H, NH2), 8.23 (s,1H, pyrazole-H). 
13
CNMR (400 MHz, DMSO-d6): δ21.9 
(CH3), 48.3 (CH-alkyl), 109.1 (C), 115.1 (CN), 131.8 (CH-pyrazole), 135.3    
122 
 
(C-CN), 154.8 (C-NH2), 162.0 (N-C-N-). LC-MS (ESI) analysis (m/z) calcd 




   
6-amino-2-neopentyl-2H-pyrazolo[3,4-d]pyrimidine-4-carbonitrile (127): 
Yield: 62%;  pale yellow solid, mp 148-150 °C; 
1
H NMR (400 MHz, DMSO-
d6): δ 0.98 (s, 9H, 3CH3), 4.06 (s, 2H, CH2), 7.48 (s, 2H, NH2), 8.27 (s, 1H, 
pyrazole-H).
13
C NMR (400 MHz, DMSO-d6) : δ 28.1 (CH3), 33.7 (C), 57.2 
(CH2), 108.5 (C), 115.1(CN),  131.8 (CH-pyrazole), 135.4 (C-CN),  156.6 (C-
NH2), 162.3 (N-C-N-). LC-MS (ESI) analysis (m/z) calcd for C11H14N6 




Yield: 81%; pale yellow solid, mp 135-137 °C; 
1
H NMR (400 MHz, DMSO-
d6): δ 3.14 (t, J= 7.16 Hz, 2H, CH2), 4.44 (t,  J= 7.16 Hz, 2H, CH2), 7.12-7.26 
(m, 5H, Ar-H), 7.43 (s, 2H, NH2), 8.21 (s, 1H, pyrazole-H). 
13
CNMR (400 
MHz, DMSO-d6): δ 34.9 (CH2), 47.6 (N-CH2), 108.8 (C), 115.0 (CN), 126.9 
(CH), 128.8 (CH), 129.0 (CH), 132.1 (CH), 135.3 (C-CN), 138.5 (CH-
pyrazole), 155.8 (C-NH2), 162.2 (N-C-N-). LC-MS (ESI) analysis (m/z) calcd 




5.2.2.3 General procedure for synthesis of 6-amino-2-(alkyl or aralkyl)-
2H-pyrazolo[3,4-d]pyrimidine-4-carboxamide (129-132). To a stirred 
solution of 6-amino-2-(alkyl or aralkyl)-2H-pyrazolo[3,4-d] pyrimidine-4-
carbonitriles 125-128 (0.00057 mol) in DMSO (3 mL) at cold condition, 30% 
H2O2 (0.0023 mol, 4 equiv) and anhydrous K2CO3 (0.0011 mol,  2 equiv)  
were added. The mixture was stirred at room temperature for one hour. Then 
the resultant mixture was poured into ice water mixture and stirred for 10 min. 
The solid was collected by filtration, washed with water and recrystallized 
from methanol to obtain the desired products (129-132) as solids. 
6-amino-2-methyl-2H-pyrazolo[3,4-d]pyrimidine-4-carboxamide  (129): 
Yield: 78%; White solid, mp >300 °C; 
1
H NMR (DMSO- d6): δ 3.83 (s, 3H, 
CH3), 7.03 (s, 2H, NH2), 7.84 (br s, 1H, NH), 7.96 (br s, 1H, NH), 8.16 (s, 1H, 




6-amino-2-isopropyl-2H-pyrazolo[3,4-d]pyrimidine-4-carboxamide  (130): 
Yield : 70%; White solid,  mp 177-179 °C; 
1
H NMR (DMSO- d6):  δ 1.48 (d, 
123 
 
J= 6.8 Hz,  6H, 2CH3), 4.93 (sep, J=6.52 Hz, 1H, CH), 7.03 (s, 2H, NH2), 7.90 
(br s, 1H, NH), 7.98 (br s, 1H, NH), 8.23 (s, 1H, pyrazole-H). LC-MS (ESI) 




(131): Yield: 79%; White solid,  mp 174-176 °C; 
1
H NMR (DMSO- d6): δ 
0.99 (s, 9H, 3CH3), 4.07 (s, 2H, CH2), 7.03 (s, 2H, NH2), 7.89 (br s, 1H, NH), 
8.00 (br s, 1H, NH), 8.24 (s, 1H, pyrazole-H). LC-MS (ESI) analysis (m/z) 




Yield: 84%; pale yellow solid, mp 182-184 °C; 
1
H NMR (400 MHz, DMSO-
d6): δ 3.16 (br s, 2H, CH2), 4.44 (br s, 2H, CH2), 7.00 (s, 2H, NH2), 7.16-7.25 
(m, 5H, Ar-H), 7.85 (br s, 1H, NH), 7.96 (br s, 1H, NH), 8.19 (s, 1H, pyrazole-





5.2.2.4 General procedure for synthesis of ethyl 6-amino-2-(alkyl or 
aralkyl)-2H-pyrazolo[3,4-d]pyrimidine-4-carboxylate (133-136). To a 
solution of 6-amino-2-(alkyl or aralkyl)-2H-pyrazolo[3,4-d]pyrimidine-4-
carboxamides 129-132 (0.00052 mol) in absolute ethanol (30 mL), conc. 
H2SO4 (3 mL) was added slowly and the resulting mixture was refluxed at 
80
°
C for 12h. The reaction mixture was cooled and excess ethanol was 
evaporated and the resulting oily residue was poured into ice water mixture, 
stirred for 10 min. The solid was collected by filtration, washed with water 
and recrystallized from methanol to obtain the desired products (133-136) as 
solids. 
Ethyl-6-amino-2-methyl-2H-pyrazolo[3,4-d]pyrimidine-4-carboxylate 
(133): Yield : 72%; pale brown,  mp 155-156 °C; 
1
H NMR (DMSO- d6): δ 
1.37 (t, J= 7.16 Hz, 3H, CH3), 3.83 (s, 3H, N-CH3),  4.42 (q, J1= 7.10 Hz, J2= 
14.20 Hz, 2H, COOCH2), 7.26 (s, 2H, NH2), 8.09 (s, 1H, pyrazole-H). 
13
C 
NMR (400 MHz, DMSO-d6): δ 14.5 (CH3), 33.6 (CH3), 62.3 (COO-CH2), 
106.4 (C), 133.9 (CH-pyrazole), 150.8 (C-COO), 156.9 (C-NH2), 162.4 (N-C-
N-), 163.8 (COO).  LC-MS (ESI) analysis (m/z) calcd for C9H11N5O2 (221.22) 




. HPLC purity (254 nm); eluent 1: 
99.7%, 
t
R = 2.8 min and eluent 2: 99.7%, 
t




(134): Yield: 75%; pale yellow  solid,  mp. 139-141 °C; 
1
H NMR (DMSO- 
d6): δ 1.37 (t, J= 7.16 Hz, 3H, CH3), 1.43 (d, J= 6.76 Hz, 6H, 2CH3), 4.42 (q, 
J1= 7.16Hz, J2= 14.16Hz, 2H, COOCH2), 4.89 (sep,  J=6.64 Hz, CH), 7.22 (s, 
2H, NH2), 8.11 (s,1H, pyrazole-H).
 13
CNMR (400 MHz, DMSO-d6): δ 14.5 
(CH3), 22.0 (CH3), 47.9 (CH-alkyl), 62.3 (CH2), 106.6 (C), 133.7 (CH-
pyrazole), 151.0 (C-COO), 155.9 (C-NH2), 162.4 (N-C-N-), 163.9 (COO).
 
DEPT (400 MHz, DMSO-d6): δ 14.5(CH3), 22.0 (CH3), 47.9 (CH-alkyl), 62.3 
(CH2), 133.7 (CH-pyrazole). LC-MS (ESI) analysis (m/z) calcd for 
C11H15N5O2 (249.27) : found 250.1 [M+H]
+
. HPLC purity (254 nm); eluent 1: 
100%, 
t
R = 2.7 min and eluent 2: 99.1%, 
t
R = 3.2 min. 
Ethyl-6-amino-2-neopentyl-2H-pyrazolo[3,4-d]pyrimidine-4-carboxylate 
(135): Yield: 84%; pale yellow solid,  mp. 120-122 °C; 
1
H NMR (DMSO- d6): 
δ 0.99 (s, 9H, 3CH3), 1.43 (t, J= 7.0 Hz, 3H,CH3),  4.07 (s, 2H, CH2), 4.47 (q, 
J1= 7.0Hz, J2= 14.18 Hz, 2H, COOCH2), 7.27 (s, 2H, NH2),  8.18 (s, 1H, 
pyrazole-H).
13
CNMR (400 MHz, DMSO-d6): δ 14.5 (CH3), 28.2 (CH3)3, 33.8 
(C), 57.0 (CH2), 62.3 (COOCH2), 106.0 (C), 133.7 (CH-pyrazole), 151.0 (C-
COO), 157.7 (C-NH2), 162.7 (N-C-N-), 163.9 (COO).
 
LC-MS (ESI) analysis 





HPLC purity (254 nm); eluent 1: 97.9 %, 
t
R = 3.6 min and eluent 2: 100.0 %, 
t
R = 3.5 min. 
Ethyl-6-amino-2-phenethyl-2H-pyrazolo[3,4-d]pyrimidine-4-carboxylate 
(136): Yield: 88%; yellowish brown  solid,  mp 131-132 °C; 
1
H NMR (400 
MHz, DMSO-d6): δ 1.37 (t, J= 6.96 Hz, 3H, CH3),  3.15 (t, J= 6.84 Hz, 2H, 
CH2), 4.39-4.46 (m, 4H, COOCH2, CH2), 7.14-7.24 (m, 7H, Ar-H), 8.11 (s, 
1H, pyrazole-H).  
13
C NMR (400 MHz, DMSO-d6): δ 14.5 (CH3), 35.1 (CH2), 
47.5 (N-CH2), 62.3 (COOCH2), 106.4 (C), 126.8 (CH-Ar), 128.8 (CH), 129.1 
(CH), 133.9 (CH-pyrazole), 138.7 (C), 151.0 (C-COO), 156.9 (N-C-N-), 162.6 
(C-NH2), 163.9 (COO). LC-MS (ESI) analysis (m/z) calcd for C16H17N5O2 
(311.34): found 312.0 [M+H]
+
. HPLC purity (254 nm); eluent 1: 100 %, 
t
R = 
3.1 min and eluent 2: 99.4 %, 
t





5.2.2.5 General procedure for synthesis of ethyl 6-benzamido-(alkyl or 
aralkyl)-2H-pyrazolo[3,4-d]pyrimidine-4-carboxylate (137-151). To a 
suspension of ethyl 6-amino-2-(alkyl or aralkyl)-2H-pyrazolo[3,4-
d]pyrimidine-4-carboxylates 133-136 (0.00045 mol)  in anhydrous  toluene (5 
mL), diisopropylethylamine (0.00135 mol, 3 equiv) and substituted benzoyl 
chlorides (0.00135 mol, 3 equiv) were added. The mixture was heated under   
reflux for  24 hours. The solvent was removed under reduced pressure and the 
resulting residue was purified by column chromatography (hexane: EtOAc, 
4:6) to obtain the desired products (137-151) as solids. 
Ethyl-6-benzamido-2-methyl-2H-pyrazolo[3,4-d]pyrimidine-4-carboxylate 
(137): Yield : 51%; White solid,  mp 107-109 °C;  
1
H NMR (DMSO- d6): δ 
1.42 (t, J= 7.16 Hz, 3H, CH3), 4.03 (s, 3H, N-CH3),  4.50 (q, J1= 7.20 Hz, J2= 
14.22 Hz, 2H, COOCH2), 7.51-8.03 (m, 5H, Ar-H), 8.45 (s, 1H, pyrazole-H), 
11.47 (s, 1H, NH).
 13
C NMR (400 MHz, DMSO-d6): δ 14.5 (CH3), 34.2 
(CH3), 62.8 (COO-CH2), 109.9 (C), 128.8 (CH), 128.9 (CH), 129.7 (CH-
pyrazole), 132.7 (CH), 134.0 (C), 150.8 (C-COO), 155.6 (C-NH), 156.2 (N-C-
N), 163.4 (CO), 166.3 (COO). LC-MS (ESI) analysis (m/z) calcd for 




. HPLC purity 
(254 nm); eluent 1: 100%, 
t
R = 3.0 min and eluent 2: 96.5%, 
t
R = 3.4 min. 
Ethyl-6-(4-fluorobenzamido)-2-methyl-2H-pyrazolo[3,4-d]pyrimidine-4-
carboxylate (138): Yield: 53%; White solid,  mp 103-105 °C;   
1
H NMR 
(DMSO- d6): δ 1.42 (t, J= 7.04 Hz, 3H, CH3), 4.03 (s, 3H, N-CH3), 4.50 (q, 
J1= 7.08 Hz, J2= 14.24 Hz, 2H, COOCH2), 7.34-8.11 (m, 4H, Ar-H), 8.45 (s, 
1H, pyrazole-H), 11.52 (s, 1H, NH). LC-MS (ESI) analysis (m/z) calcd for 
C16H14FN5O3 (343.31) : found 344.2 [M+H]
+
. HPLC purity (254 nm); eluent 
1: 95.6%, 
t
R = 3.0 min and eluent 2: 95.8%, 
t
R = 3.5 min. 
Ethyl-2-methyl-6-(4-(trifluoromethyl)benzamido)-2H-pyrazolo[3,4-
d]pyrimidine-4-carboxylate (139): Yield : 55%; White solid. mp. 114-116 
°C; 
 1
H NMR (DMSO- d6): δ 1.42 (t, J= 7.16 Hz, 3H, CH3), 4.02 (s, 3H, N-
CH3), 4.50 (q, J1= 7.14Hz, J2= 14.24 Hz, 2H,COOCH2),), 7.89-8.18 (m, 4H, 
Ar-H),  8.46 (s, 1H, pyrazole-H), 11.75 (s, 1H, NH). LC-MS (ESI) analysis 





HPLC purity (254 nm); eluent 1: 98.4%, 
t
R = 5.9 min and eluent 2: 99.2%, 
t
R 




carboxylate (140): Yield: 58%; White solid,  mp. 109-111 °C;  
 1
H NMR 
(DMSO- d6): δ 1.42 (t,  J= 7.16 Hz, 3H, CH3), 2.40 (s, 3H, CH3), 4.03 (s, 3H, 
N-CH3), 4.50 (q, J1= 7.08 Hz, J2= 14.24 Hz, 2H, COOCH2), 7.33-7.95 (m, 
4H, Ar-H), 8.44 (s, 1H, pyrazole-H), 11.38 (s, 1H, NH). LC-MS (ESI) analysis 





HPLC purity (254 nm); eluent 1: 100.0%, 
t
R = 3.7 min and eluent 2: 100%, 
t
R 
= 3.8 min. 
Ethyl-6-benzamido-2-isopropyl-2H-pyrazolo[3,4-d]pyrimidine-4-
carboxylate (141): Yield : 49%; White solid,  mp 115-117 °C;  
1
H NMR 
(DMSO- d6): δ 1.42 (t, J= 7.12 Hz, 3H, CH3), 1.51 (d, J= 6.64 Hz, 6H, 2CH3), 
4.50 (q, J1= 7.10 Hz, J2= 14.26 Hz, 2H, COOCH2), 5.07  (sep, J= 6.64 Hz, 
1H, CH), 7.51-8.02  (m, 5H, Ar-H), 8.45 (s, 1H, pyrazole-H), 11.44 (s, 1H, 





. HPLC purity (254 nm); eluent 1: 100%, 
t
R = 
4.0 min and eluent 2: 100%, 
t
R = 4.6 min. 
Ethyl-6-(4-fluorobenzamido)-2-isopropyl-2H-pyrazolo[3,4-d]pyrimidine-
4-carboxylate (142): Yield : 42%; White solid,  mp 107-109 °C;  
1
H NMR 
(DMSO- d6): δ 1.41 (t, J= 7.12 Hz, 3H,CH3), 1.51 (d, J= 6.64 Hz,  6H, 2CH3), 
4.50 (q, J1= 7.08 Hz, J2= 14.24 Hz,  2H, COOCH2), 5.07 (sep, J= 6.64 Hz, 
1H, CH), 7.33-8.10 (m, 4H, Ar-H), 8.45 (s, 1H, pyrazole-H),
 
11.49 (s, 1H, 
NH).
 13
CNMR (400 MHz, DMSO-d6): δ 14.5 (CH3), 22.1 (CH3), 49.3 (CH-
alkyl), 62.7 (COOCH2), 110.2 (C), 115.6 (CH), 115.8 (CH), 131.6 (C-F), 
131.7 (C), 133.9 (CH-pyrazole), 150.8 (N-C-N), 154.5 (C-COO), 155.8 (C-
NH), 163.4 (CO), 165.3 (COO). LC-MS (ESI) analysis (m/z) calcd  for  
C18H18FN5O3  (371.37):  found  372.1 [M+H]
+
,  394.1 [M+Na]
+
. HPLC purity 
(254 nm); eluent 1: 97.7%, 
t
R = 4.3 min and eluent 2: 97.8%, 
t
R = 4.7 min. 
Ethyl-2-isopropyl-6-(4-(trifluoromethyl)benzamido)-2H-pyrazolo[3,4-
d]pyrimidine-4-carboxylate (143): Yield : 53%; White solid,  mp 128-130 
°C;  
1
H NMR (DMSO- d6): δ 1.41 (t, J= 7.04 Hz, 3H, CH3), 1.49 (d, J= 6.68 
Hz, 6H, 2CH3), 4.49 (q,  J1= 7.16 Hz,  J2= 14.20 Hz, 2H,COOCH2), 5.01 
(sep, J= 6.04 Hz, 1H, CH), 7.88-8.15 (m, 4H, Ar-H), 8.46 (s, 1H, pyrazole-H),
 
11.72 (s, 1H, NH). LC-MS (ESI) analysis (m/z) calcd for C19H18F3N5O3 
127 
 




. HPLC purity (254 nm); 
eluent 1: 98.1%, 
t
R = 6.9  min and eluent 2: 98.8%, 
t
R = 7.3 min. 
Ethyl-2-isopropyl-6-(4-methylbenzamido)-2H-pyrazolo[3,4-d]pyrimidine-
4-carboxylate (144): Yield : 51%; White solid.  mp. 131-133 °C;   
1
H NMR 
(DMSO- d6): δ 1.42 (t, J= 7.16 Hz, 3H, CH3), 1.51 (d, J= 6.76 Hz, 6H, 2CH3), 
2.40 (s, 3H, CH3), 4.50 (q,  J1= 7.14Hz, J2= 14.18Hz, 2H, COOCH2), 5.08 
(sep, J= 6.76 Hz, 1H, CH), 7.32-7.94 (m, 4H, Ar-H), 8.45 (s, 1H, pyrazole-H), 
11.36 (s, 1H, NH). LC-MS (ESI) analysis (m/z) calcd for  C19H21N5O3 
(367.40): found 390.3 [M+Na]
+
. HPLC purity (254 nm); eluent 1: 98.1%,
 t
R = 
5.0 min  and eluent 2: 99.1%, 
t
R = 5.4 min. 
Ethyl-6-(4-fluorobenzamido)-2-neopentyl-2H-pyrazolo[3,4-d]pyrimidine-
4-carboxylate (145): Yield: 57%; pale yellow solid, mp 112-114 °C;  
1
H 
NMR (400 MHz, DMSO-d6): δ  0.96 (s, 9H, 3CH3), 1.43 (t, J= 7.16 Hz, 3H, 
CH3), 4.21 (s, 2H, CH2), 4.49 (q, J1= 7.14 Hz, J2= 14.18 Hz,  2H, CH2),  7.33-
8.09 (m, 4H, Ar-H), 8.48 (s, 1H, pyrazole-H), 11.49 (s, 1H, NH). LC-MS 





. HPLC purity (254 nm); eluent 1: 98.9%, 
t
R= 6.6 min and 
eluent 2: 96.3%, 
t
R = 6.7 min. 
Ethyl-2-neopentyl-6-(4-(trifluoromethyl)benzamido)-2H-pyrazolo[3,4-
d]pyrimidine-4-carboxylate (146): Yield: 61%; pale yellow solid, mp 116-
118 °C; 
1
H NMR (400 MHz, DMSO-d6): δ  0.99 (s, 9H, 3CH3), 1.47 (t, J= 7.0 
Hz, 3H, CH3), 4.20 (s, 2H, CH2), 4.55 (q, J1= 7.02 Hz, J2= 14.18 Hz,  2H, 
CH2),  7.93-8.20 (m, 4H, Ar-H), 8.53 (s, 1H, pyrazole-H), 11.76 (s, 1H, NH). 





. HPLC purity (254 nm); eluent 1: 100%, 
t
R = 8.0 min 
and eluent 2: 97.4%, 
t
R = 7.9 min. 
Ethyl-6-(4-methylbenzamido)-2-neopentyl-2H-pyrazolo[3,4-d]pyrimidine-
4-carboxylate (147): Yield: 48%; pale yellow solid, mp 97- 99 °C;  
1
H NMR 
(400 MHz, DMSO-d6): δ  1.01 (s, 9H, 3CH3), 1.48 (t, J= 7.16 Hz, 3H, CH3), 
2.45 (s, 3H, CH3),  4.25 (s, 2H, CH2), 4.55 (q, J1= 7.16 Hz, J2 = 14.16 Hz, 
2H, CH2),  7.36-7.98 (m, 4H, Ar-H), 8.51 (s,1H, pyrazole-H), 11.39 (s, 1H, 
NH).
 13
C NMR (400 MHz, DMSO-d6): δ 14.5 (CH3), 21.5 (CH3), 28.1 (CH3)3, 
33.8 (C-alkyl), 57.8 (CH2), 62.7 (COOCH2), 109.4 (C), 128.9 (CH), 129.3 
(CH), 129.9 (C), 131.7 (C), 133.9 (CH-pyrazole), 142.8 (N-C-N), 150.9 (C-
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COO), 156.3 (C-NH),  163.5 (CO), 166.3 (COO).
 
 LC-MS (ESI) analysis (m/z) 





purity (254 nm); eluent 1: 100%, 
t
R = 7.1 min and eluent 2: 98.4%, 
t
R = 7.1 
min. 
Ethyl-6-benzamido-2-phenethyl-2H-pyrazolo[3,4-d]pyrimidine-4-
carboxylate (148): Yield: 57%; pale yellow solid, mp 106-108 °C;  
1
H NMR 
(400 MHz, DMSO-d6): δ 1.48 (t, J= 7.16 Hz, 3H, CH3), 3.34 (t, J= 7.28 Hz, 
2H, CH2), 4.56 (q, J1 = 7.10 Hz, J2 = 14.26 Hz,  2H, CH2), 4.72 (t, J= 7.0 Hz, 
2H, CH2),  7.22-7.32 (m, 5H, Ar-H), 7.57-8.08 (m, 5H, acyl-H),  8.49 (s, 1H, 
pyrazole-H), 11.51 (s, 1H, NH). LC-MS (ESI) analysis (m/z) calcd for 




. HPLC purity 
(254 nm); eluent 1: 99.7%, 
t
R = 3.3 min  and eluent 2: 99.7%, 
t
R = 3.1 min. 
Ethyl-6-(4-fluorobenzamido)-2-phenethyl-2H-pyrazolo[3,4-d]pyrimidine-
4-carboxylate (149): Yield: 56%; pale yellow solid, mp 112-113 °C; 
1
H NMR 
(400 MHz, DMSO-d6): δ 1.42 (t, J= 7.12 Hz, 3H, CH3), 3.25 (t, J= 7.24 Hz, 
2H, CH2), 4.49 (q, J1= 7.08 Hz, J2= 14.24 Hz,  2H, CH2), 4.65 (t, J= 7.4 Hz, 
2H, CH2),  7.16-7.25 (m, 5H, Ar-H), 7.33-8.10 (m, 4H, acyl-H),  8.42 (s, 1H, 
pyrazole-H), 11.49 (s, 1H, NH). LC-MS (ESI) analysis (m/z) calcd for 




. HPLC purity 
(254 nm); eluent 1: 100%, 
t
R = 6.5 min and eluent 2: 97.3%, 
t
R = 6.1 min. 
Ethyl-2-phenethyl-6-(4-(trifluoromethyl)benzamido)-2H-pyrazolo[3,4-
d]pyrimidine-4-carboxylate (150): Yield: 52%; pale yellow solid, mp 105-
107 °C;
 1
H NMR (400 MHz, DMSO-d6): δ  1.48 (t, J= 7.16 Hz, 3H, CH3), 
3.31 (t, J= 7.16 Hz, 2H, CH2), 4.56 (q, J1= 7.10 Hz, J2= 14.22 Hz, 2H, CH2), 
4.72 (t, J= 7.0Hz, 2H, CH2),  7.24-7.31 (m, 5H, Ar-H), 7.39-8.16 (m, 4H, acyl-
H), 8.49 (s, 1H, pyrazole-H), 11.56 (s, 1H, NH). LC-MS (ESI) analysis (m/z) 





purity (254 nm); eluent 1: 100%, 
t
R = 6.7 min and eluent 2: 99.6%, 
t
R = 6.9 
min. 
Ethyl-6-(4-methylbenzamido)-2-phenethyl-2H-pyrazolo[3,4-d]pyrimidine-
4-carboxylate (151): Yield: 50%; pale yellow solid, mp 143-144 °C;  
1
H 
NMR (400 MHz, DMSO-d6): δ  1.47 (t, J= 7.16 Hz, 3H, CH3), 2.45 (s, 3H, 
CH3),  3.30 (t, J= 7.28 Hz, 2H, CH2), 4.54 (q, J1 = 7.10 Hz, J2 = 14.26 Hz,  
2H, CH2), 4.71 (t, J= 7.0 Hz, 2H, CH2),  7.21-7.30 (m, 5H, Ar-H), 7.37-7.99 
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(m, 4H, Acyl-H),  8.47 (s, 1H, pyrazole-H), 11.40 (s, 1H, NH). LC-MS (ESI) 





. HPLC purity (254 nm); eluent 1: 100%, 
t
R = 7.2 min and eluent 2: 
100%, 
t
R = 7.8 min. 
Ethyl-6-(4-bromobenzamido)-2-phenethyl-2H-pyrazolo[3,4-d]pyrimidine-
4-carboxylate (152): Yield: 67%; pale yellow solid, mp 139-141 °C;  
1
H 
NMR (400 MHz, DMSO-d6): δ 1.42 (t, J= 7.04 Hz, 3H, CH3), 3.25 (t, J= 7.28 
Hz, 2H, CH2), 4.49 (q, J1 = 7.08 Hz, J2 = 14.24 Hz, 2H, CH2), 4.65 (t, J= 7.16 
Hz, 2H, CH2),  7.16-7.52 (m, 5H, Ar-H), 7.81-8.19 (m, 4H, acyl-H),  8.43 (s, 
1H, pyrazole-H), 11.59 (s, 1H, NH). LC-MS (ESI) analysis (m/z) calcd for 









. HPLC purity (254 nm); eluent 1: 97.9%, 
t
R = 10.3 
min and eluent 2: 100%, 
t
R = 9.1 min. 
Ethyl-6-(3,4-dichlorobenzamido)-2-phenethyl-2H-pyrazolo[3,4-
d]pyrimidine-4-carboxylate (153): Yield: 64%; pale yellow solid, mp 147-
149 °C;  
1
H NMR (400 MHz, DMSO-d6): δ  1.42 (t, J= 7.16 Hz, 3H, CH3), 
3.25 (t, J= 7.28 Hz, 2H, CH2), 4.49 (q, J1 = 7.10 Hz, J2 = 14.26 Hz,  2H, 
CH2), 4.65 (t, J= 7.16 Hz, 2H, CH2),  7.14-7.25 (m, 5H, Ar-H), 7.77-8.26 (m, 
3H, acyl-H),  8.43 (s, 1H, pyrazole-H), 11.66 (s, 1H, NH).
 13
C NMR (400 
MHz, DMSO-d6): δ 14.5 (CH3), 34.9 (CH2), 48.3 (CH2), 62.8 (COOCH2), 
110.0 (C), 126.9 (CH-Ar), 128.8 (CH), 129.1 (CH), 130.9 (C), 131.1 (CH), 
131.4 (CH), 131.7 (C-Cl), 134. 2 (CH-pyrazole), 135.0 (C-Cl), 138.4 (C), 
150.8 (C-NH), 155.4 (C-COO), 155.7 (N-C-N-), 163.3 (CO), 164.3 (COO). 





. HPLC purity (254 nm); eluent 1: 97.7%, 
t
R = 11.1 min 
and eluent 2: 100.0%, 
t
R = 12.0 min. 
 
5.2.2.6 General procedure for synthesis of ethyl 6-(N-benzoylbenzamido)-
2-methyl-2H-pyrazolo[3,4-d]pyrimidine-4-carboxylate (154-158). To a 
suspension of ethyl 6-amino-2-(alkyl or aralkyl)-2H-pyrazolo[3,4-
d]pyrimidine-4-carboxylates 133-136 (0.00045 mol)  in anhydrous toluene (5 
mL), diisopropylethylamine (0.0027 mol, 6 equiv) and benzoyl chloride or 
substituted benzoyl chlorides (0.0027 mol, 6 equiv) were added. The mixture 
was heated under reflux   for  24 hours. The   solvent was removed under 
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reduced pressure and the resulting residue was purified by column 
chromatography (hexane: EtOAc, 4:6). 
Ethyl-6-(N-benzoylbenzamido)-2-methyl-2H-pyrazolo[3,4-d]pyrimidine-4-
carboxylate  (154):  Yield: 56%; White solid,  mp. 105-107 °C;    
1
H NMR 
(DMSO- d6): δ 1.36 (t,  J= 7.16 Hz, 3H, CH3), 3.87 (s, 3H, N-CH3), 4.43 (q,  
J1= 7.16 Hz, J2= 14.16 Hz, 2H, COOCH2), 7.47-7.83 (m, 10H, Ar-H), 8.53 (s, 
1H, pyrazole-H). LC-MS (ESI) analysis (m/z) calcd for C23H19N5O4  (429.43): 




. HPLC purity (254 nm); eluent 1:  
98.0%, 
t
R = 5.4 min and eluent 2: 97.8%, 
t
R = 5.4 min. 
Ethyl-6-(4-bromo-N-(4-bromobenzoyl)benzamido)-2-methyl-2H-
pyrazolo[3,4-d]pyrimidine-4-carboxylate (155): Yield: 53%; White solid,  
mp. 128-130 °C; 
1
H NMR (DMSO- d6): δ 1.36 (t, J= 7.0 Hz, 3H, CH3), 3.92 
(s, 3H, N-CH3), 4.43 (q, J1= 7.08 Hz, J2= 14.24 Hz, 2H, COOCH2), 7.40-8.05 
(m, 8H, Ar-H), 8.56 (s, 1H, pyrazole-H). LC-MS (ESI) analysis (m/z) calcd for 




. HPLC purity 
(254 nm); eluent 1: 95.5%, 
t
R = 13.0 min and eluent 2: 13.7%, 
t
R = 99.5 min. 
Ethyl-6-(N-(3,4-difluorobenzoyl)-3,4-difluorobenzamido)-2-methyl-2H-
pyrazolo[3,4-d]pyrimidine-4-carboxylate (156): Yield: 59%; White solid,  
mp. 169-171 °C;   
1
H NMR (DMSO- d6): δ 1.36 (t, J= 7.16 Hz, 3H, CH3), 3.92 
(s, 3H, N-CH3), 4.43 (q, J1 = 7.16 Hz, J2 = 14.20 Hz, 2H, COOCH2), 7.52-
8.00 (m, 6H, Ar-H), 8.55 (s, 1H, pyrazole-H). LC-MS (ESI) analysis (m/z) 





HPLC purity (254 nm); eluent 1: 100.0%, 
t
R = 11.6 min and eluent 2: 100.0%, 
t
R = 13.0 min. 
Ethyl-6-(N-benzoylbenzamido)-2-isopropyl-2H-pyrazolo[3,4-
d]pyrimidine-4-carboxylate (157): Yield: 53%; White solid,  mp 140-142 
°C;  
1
H NMR (DMSO- d6):  δ 1.25 (d, J= 6.64 Hz, 6H, 2CH3), 1.37 (t, J= 7.04 
Hz, 3H, CH3), 4.45 (q, J1= 7.04 Hz, J2= 14.04 Hz, 2H, COOCH2), 4.79 (sep, 
J= 6.52 Hz, 1H, CH), 7.47-7.97 (m, 10H, Ar-H), 8.51 (s, 1H, pyrazole-H). 





. HPLC purity (254 nm); eluent 1: 99.7%, 
t
R = 8.0 
min and eluent 2: 99.3%,
 t
R = 8.3 min. 
Ethyl-6-(N-benzoylbenzamido)-2-phenethyl-2H-pyrazolo[3,4-
d]pyrimidine-4-carboxylate (158): Yield: 55%; pale yellow solid, mp 157-
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159 °C;  
1
HNMR (400 MHz, DMSO-d6): δ 1.41 (t, J= 7.04 Hz, 3H, CH3), 2.87 
(t, J= 6.92 Hz, 2H, CH2), 4.48 (q, J1= 7.08 Hz, J2= 14.12 Hz,  2H, CH2), 4.57 
(t, J= 6.92 Hz, 2H, CH2),  6.92-7.25 (m, 5H, Ar-H), 7.54-8.02 (m, 10H, acyl-
H),  8.50 (s, 1H, pyrazole-H), LC-MS (ESI) analysis (m/z) calcd for 
C30H25N5O4 (519.55): found  520.1 [M+H]
+
, 542.3 [M+Na]. HPLC purity (254 
nm); eluent 1: 95.8%, 
t
R = 9.4 min and eluent 2: 97.9%, 
t
R = 9.3 min. 
 
5.2.2.7 General procedure for synthesis of ethyl 2-(alkyl or aralkyl)-6-(2-
phenylacetamido)-2H-pyrazolo[3,4-d]pyrimidine-4-carboxylate (159-162). 
To a suspension of ethyl-6-amino-2-(alkyl or aralkyl)-2H-pyrazolo[3,4-
d]pyrimidine-4-carboxylates 133-136 (0.00045 mol)  in anhydrous toluene (5 
mL), diisopropylethylamine (0.00135 mol, 3 equiv) and phenylacetyl chloride 
(0.00135 mol, 3 equiv) were added. The mixture was heated under reflux for 
24 hours. The solvent was removed under reduced pressure and the resulting 
residue was purified by column chromatography (hexane: EtOAc, 4:6) 
Ethyl-2-methyl-6-(2-phenylacetamido)-2H-pyrazolo[3,4-d]pyrimidine-4-
carboxylate (159): Yield: 49%; White solid, mp. 168-170 °C;  
1
H NMR 
(DMSO- d6): δ 1.42 (t, J= 7.16 Hz, 3H, CH3), 3.87 (s, 2H, CH2), 3.98 (s, 3H, 
N-CH3), 4.49 (q, J1=7.10 Hz, J2=14.26 Hz, 2H, COOCH2), 7.24-7.38 (m, 5H, 
Ar-H), 8.39 (s,1H, pyrazole-H), 11.29 (s, 1H, NH). LC-MS (ESI) analysis 





HPLC purity (254 nm); eluent 1: 100%, 
t





4-carboxylate (160): Yield: 45%; White solid,  mp. 120-122 °C;  
1
H NMR 
(DMSO- d6): δ 1.41 (t, J= 7.16 Hz, 3H, CH3), 1.49 (d, J= 6.64 Hz, 6H, 2CH3), 
3.87 (s, 2H, CH2), 4.49 (q, J1= 7.16 Hz, J2= 14.20 Hz, 2H, COOCH2), 5.04 
(sep, J= 6.52 Hz, 1H, CH), 7.25-7.37 (m, 5H, Ar-H), 8.39 (s, 1H, pyrazole-H), 





. HPLC purity (254 nm); eluent 1: 100%, 
t
R = 4.1 min and eluent 2: 99.7%, 
t
R = 4.2 min. 
Ethyl-2-neopentyl-6-(2-phenylacetamido)-2H-pyrazolo[3,4-d]pyrimidine-
4-carboxylate (161): Yield: 47%; pale yellow solid, mp 112-114 °C;  
1
H 
NMR (400 MHz, DMSO-d6): δ  0.97 (s, 9H, 3CH3), 1.46 (t, J= 7.16 Hz, 2H, 
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CH2), 3.92 (s, 2H, CH2),  4.21 (s, 2H, Ar-CH2), 4.53 (q, J1= 7.08 Hz, J2= 
14.24 Hz, 2H, COOCH2),  7.28 -7.41 (m, 5H, Ar-H), 8.45 (s, 1H, pyrazole-H), 
11.30 (s, 1H, NH). LC-MS (ESI) analysis (m/z) calcd for C21H25N5O3 (395.45) 




. HPLC purity (254 nm); eluent 1: 
99.9%, 
t
R = 5.7 min and eluent 2: 97.2%, 
t
R = 5.5 min. 
Ethyl-2-phenethyl-6-(2-phenylacetamido)-2H-pyrazolo[3,4-d]pyrimidine-
4-carboxylate (162): Yield: 53%; pale yellow solid, mp 141-143 °C;  
1
H 
NMR (400 MHz, DMSO-d6): δ 1.44 (t, J= 7.16 Hz, 3H, CH3), 3.26 (t, J= 7.16 
Hz, 2H, CH2), 3.92 (s, 2H, CH2), 4.51 (q, J1= 7.08 Hz, J2= 14.24 Hz,  2H, 
CH2), 4.65 (t, J= 7.0 Hz, 2H, CH2),  7.16-7.31 (m, 5H, Ar-H), 7.35-7.41 (m, 
5H, acyl-H),  8.41 (s, 1H, pyrazole-H), 11.28 (s, 1H, NH). LC-MS (ESI) 





. HPLC purity (254 nm); eluent1: 100%, 
t
R = 7.7 min and eluent 2: 
100%, 
t
R = 7.5 min. 
 
5.2.3   Conclusion 
             The synthesis of 34 new pyrazolopyrimidine-4-carboxylates 
derivatives was successfully achieved using optimized synthetic procedures as 




C NMR and mass spectrometry (ESI). Additionally, final 
compounds 135, 136 and derivatives 137, 142, 147 & 153 were confirmed by 
2D NMR (HMQC). The purity of the compounds was determined by HPLC 
analysis (HPLC data of newly synthesized compounds 129-136 were tabulated 
in Table A5 under appendix) and all of the compounds showed purity of 95% 












5.3 Pharmacological Evaluation of a Novel Series of PyrazoloPyrimidine-
4-Carboxylate Derivatives  
 
5.3.1 Introduction 
             Binding affinities of  the novel series of pyrazolo[3,4-d]pyrimidine-4-
carboxylates at the human A1, A2A and A3 adenosine receptor subtypes and the 
adenylyl cyclase activity of the derivatives at the human A2B receptor  are 
described in this chapter. In addition, the selectivities were also assessed by 
comparing the binding affinity values (Ki) against the hA3 receptor with Ki 
values against the hA1 and hA2A receptors. This section also describes the 
docking studies of pyrazolo[3,4-d]pyrimidine-4-carboxylate derivatives 
performed on hA2AAR based on hA3AR homology model and crystal structure 
of hA2AAR, to rationalize the predicted binding affinity with experimental 
binding affinities. 
 
5.3.2 Experimental Methods 
             The displacement of selective radioligands towards respective 
adenosine receptors (expressed in Chinese Hamster Ovary cells (CHO) for 
hA1, hA2A, hA3 receptors),
 
which were previously bound to cell surface 
expressed by receptors, was measured to evaluate the binding affinities of the 
new synthesized compounds. Binding experiments were carried out as 
reported in the Chapter 4. For more details on experimental methods which 
include, CHO membrane preparation, binding assay of human cloned A1, A2A, 
A3 adenosine receptor and adenylyl cyclase assay, please refer Chapter 4, 












5.3.3  Results and discussion 
5.3.3.1 Binding affinity towards human A1, A2A and A3 adenosine 
receptors: Structure-affinity relationships 
             Pharmacological evaluation was performed for the novel series of 
pyrazolo[3,4-d]pyrimidine-4-carboxylate to examine their binding affinities at 
all four adenosine receptor subtypes. The receptor binding affinities of 
compounds 129-162 were determined at the human A1, A2A, A3 receptors and 
the corresponding adenylyl cyclase activity in CHO cells which expressed the 
human A2B receptors are summarized in Table 11. 
             In this project, ligand modification of 4-chloro-PP derivatives bearing 
pyrazolopyrimidine basic nucleus,  C
4
 ester substituents (different to chloro 
group  of previous PP series), various lipophilic N
2
 alkyl and aralkyl 
substituents and  different substituents with electronic properties at C
6
 
benzamide chain, was carried out to improve the hA3AR affinity and 
selectivity profile towards other receptor subtypes. Towards that purpose, a 
new series of 2-(alkyl and aralkyl substituted)-2H-pyrazolo[3,4-d]pyrimidine-






 positions, was 
successfully synthesized and characterized. The binding assay results 
indicated that the ligand modification increased the affinity and remarkably 
improved selectivity towards other receptor subtypes as compared to the 4-
chloro-PP series. Indeed, most of the pyrazolo[3,4-d]pyrimidine-4-
carboxylates improved the affinity at hA3 receptors as indicated by the  very 
low micromolar range (Ki hA3 = 0.7-34 µM) and some of the compounds 
displayed high selectivity (>111 at hA1 / hA3 and hA2A / hA3 ) towards the 
other receptor subtypes. 
 
Effect of  C4 amide and C4 ester  with C6 free amino substitution on affinity 
of  PP scaffold 
             The binding assay results of the analogues bearing various alkyl 
substitutions (i.e. methyl, isopropyl & neopentyl) or a phenylethyl group at N
2
 
position were compared to examine the impact of the alkyl group substitutions 
at N
2 
on the pharmacological profile. Based on the bioassay results, the alkyl 
substituents (methyl, isopropyl & neopentyl) at N
2
 position of the pyrazolo 
ring seemed to modulate the affinity at hA3AR to a considerable level. In 
135 
 
addition, binding affinity of C
4
 amide substituents (129-132) with free amino 
groups was compared with C
4
 ester substituted compounds (133-136). All of 
the C
4
 amide substituted compounds exhibited a weak affinity towards the 
hA3AR (Ki hA3 = 16.9 - >100 µM) as compared to the C
4
 ester compounds (Ki 
hA3 = 0.7 - 30 µM). However, these C
4
-amide derivatives propelled the 
affinity towards hA2AAR and hA1AR and displayed 13-15 times selectivity 
over hA3AR. Conversely, among the compounds with C
6
 free amino 
substituents but with an ester group at C
4
 (133-136), compound 133, with a 
methyl group at N
2
 displayed the best affinity at the hA3AR (Ki hA3 = 0.7 µM) 
in the whole series and also exhibited moderate affinity towards other receptor 
subtypes (Ki hA2A = 2 µM and Ki hA1 = 9.3 µM). In addition, compound 134, 
with a N
2
 isopropyl group, displayed a sub micromolar affinity towards the 
hA1AR (Ki hA1= 0.9 µM), with 35 times selectivity over the hA3AR.  
 




 substitution on affinity of  PP scaffold 
N
2
-methyl: Substitution of benzamide or substituted benzamide groups at C
6
 
position and a methyl group at N
2
 gave rise to compounds with drastically 
decreased affinity towards  the  hA3AR (137-140, 154&156,  Ki hA3 = >100 
µM), with the only exception of compound 155, with a dibenzamide 
substitution along with para-Br group at C
6
: this compound, in fact, presented 
the best combined affinity and selectivity profile in N
2
 small alkyl substituted 
derivatives (155, Ki hA3 = 2.9 µM, hA1/A3  >34, hA2A/A3  >34). The reason 
behind such affinity profile is still unclear, since similar dibenzamide 
substituted compounds 154 and 156 with 3,4-F group at para position (Ki hA3 
= >100 µM) were inactive at hA3AR (Ki hA3 >100 µM). This emphasize the 
fact that steric group (Br) at para position of dibenzoyl chain might have 
played a role essential for the improvement of  affinity at hA3AR. 
Interestingly, similar trend was also observed with the  other receptor subtypes 
(137-140, 154-156;  Ki hA1 = 21.5 - >100 µM, Ki hA2A = 14 - >100 µM) 
throughout the series. However, this is in contrast with previous findings of 4-
chloro-PP and PTP derivatives,
118
 where corresponding benzamide 




                 Table 11. Binding affinity (Ki) of synthesized compounds at hA1, hA2A, and hA3 adenosine receptors
[a] 
 and selectivity  
                                  against hA1 and hA2A receptors (R denotes N
2




























 hA1/h3 hA2A/h3 
129 CH3 - - - 8.3 3.8 >100 >100 >0.08 >0.04 
130 CH(CH3)2 - - - 8.4 9.3 >100 >100 >0.08 >0.09 
131 CH2C(CH3)3 - - - ~80 ~80 >100 16.9 4.7 4.7 
132 CH2CH2C6H5 - - - 43 12.5 >100 34.4 1.2 0.4 
133 CH3 - - - 9.3 2.0 >100 0.7 13.2 2.9 
134 CH(CH3)2 - - - 0.9 2.7 ~80 30.0 0.03 0.09 
135 CH2C(CH3)3 - - - 4.0 5.3 ~80 18.6 0.2 0.3 
136 CH2CH2C6H5 - - - 3.7 4.9 ~60 17.0 0.2 0.3 
137 CH3 H H - 21.5 16.1 >100 >100 >0.2 >0.1 
138 CH3 H F - >100 14.0 >100 >100 >1 >1 

















































































140 CH3 H CH3 - >100 12 >100 ~100 >1 >1 
141 CH(CH3)2 H H - 4.8 3.3 ~100 5.3 0.9 0.6 
142 CH(CH3)2 H F - 2.9 3.1 >100 5.7 0.5 0.5 
143 CH(CH3)2 H CF3 - >100 >100 >100 >100 >1 >1 
144 CH(CH3)2 H CH3 - 0.7 3.1 ~100 28.7 0.02 0.1 
145 CH2C(CH3)3 H F - 2.7 5.9 >100 4.5 0.6 1.3 
146 CH2C(CH3)3 H CF3 - >100 >100 >100 1.3 >77 >77 
147 CH2C(CH3)3 H CH3 - >100 >100 >100 0.9 >111 >111 
148 CH2CH2C6H5 H H - 5.2 3.7 ~80 7.4 0.7 0.5 
149 CH2CH2C6H5 H F - 5.2 6.1 >100 7.0 0.7 0.8 
150 CH2CH2C6H5 H CF3 - 2.7 7.5 ~100 9.0 0.3 0.8 
151 CH2CH2C6H5 H CH3 - >100 6.0 >100 3.0 >33 2 
152 CH2CH2C6H5 H Br - 2.6 4.5 ~100 3.6 0.7 1.2 
153 CH2CH2C6H5 - Cl Cl >100 >100 >100 2.2 >46 >46 
154 CH3 C6H5CO H - >100 >100 >100 >100 >1 >1 















            
 
                  [a] Adenylyl cyclase activity of synthesized compounds at the hA2BAR. [b] Displacement of specific [
3
H]-CCPA binding  
                  at human A1 receptors expressed in Chinese hamster ovary (CHO) cells (n=3–6). [c] Displacement of specific [
3
H]-5’N- 
                  ethyl carboxamido adenosine (NECA) binding at human A2A receptors expressed in CHO cells (n=3–6). [d] Ki values  
                  for inhibition of NECA-stimulated adenylyl cyclase activity in CHO cells (n=3–6). [e] Displacement of specific [3H]-2- 
                  (1-hexynyl)-N
6
-methyl adenosine (HEMADO) binding at human A3 receptors expressed in CHO cells (n=3-6). 




























156 CH3 (3,4F)C6H5CO F F >100 >100 >100 >100 >1 >1 
157 CH(CH3)2 C6H5CO H  17.7 >100 >100 5.4 3.2 >19 
158 CH2CH2C6H5 C6H5CO H  >100 >100 >100 >100 >1 >1 
159 CH3 - - - 5.9 7.3 >100 15.2 0.3 0.5 
160 CH(CH3)2 - - - 0.7 8.8 ~80 9.5 0.07 0.9 
161 CH2C(CH3)3 - - - 6.0 8.3 >100 8.1 0.7 1.0 




-isopropyl: On the other hand, benzamide substitution of N
2
 isopropyl 
derivatives (141-144) showed much improved affinity (Ki hA3 = 5.4-28.7 
µM)as compared to its N
2
-methyl counterpart derivatives, with the exception 
of compound 143, which was inactive at all the receptor subtypes. Similarly, 
these derivatives (141-144) showed a comparable or even better affinity at 
hA2AAR and hA1AR, thus determining a weak selectivity of the compounds. 
Compound 157, with C
6
-dibenzamide substitution, displayed good affinity (Ki 
hA3=5.4 µM) and high selectivity (hA2A/A3 = >19) towards the hA2AAR 
subtype. Moreover, its selectivity towards the hA2AAR subtype is improved 
190 fold as compared to similar substitution with 4-chloro PP derivatives 
(Compound 120 in Table 3). In contrast, compound 144 (Ki hA1 = 0.7 µM) 
with para-CH3 benzamide chain at C
6
 position, was inactive at the hA3AR and 




-neopentyl: Similarly, C6-benzamide substitution of N2 neopentyl analogues 
displayed the overall best affinity (Ki hA3 = 0.9-8.1 µM) and selectivity among 
the different N2 alkyl and phenylethyl substituted derivatives. Presence of para-F  
group in the benzamide chain  led to compound 145 with improved affinity (Ki 
hA3 = 4.5 µM) as compared to its N
2 isopropyl counterpart (142). When the para-
F group of benzamide was replaced by electron withdrawing steric CF3 group, the 
activity was increased by 4 fold (146, Ki hA3 = 1.3 µM). as compared to 145. In 
addition, the selectivity was remarkably improved to large extent by 77 fold 
towards both hA2AAR and hA1AR. Interestingly, the same C
6
 substituted 
compound of the previous chloro series (Compound 111 in Table 3) displayed 
only 15 fold selectivity towards the hA2AAR and hA1AR. Similarly, when 
para-CH3 group was introduced at the benzamide chain, the affinity was 
further improved (147, Ki hA3 = 0.9 µM) to 5 fold as compared to compound 
145. Moreover, this compound (147) showed second best affinity and the best 
overall selectivity (111 fold versus hA2AAR and hA1AR) in the whole series. 
This strongly suggests that both electron withdrawing CF3 and electron 
donating CH3 groups are highly essential for the affinity at hA3AR and 
selectivity towards the other receptor subtypes. Moreover, this compound 






























Figure 37. Overview of structure-affinity relationship (SAR) profile for the 





favoured high hA3 affinity.  
 
versus hA1AR and 278 fold versus hA2AAR enhancement in the selectivity as 
compared to its N
2




 phenylethyl: Benzamide substitution in the N
2
 phenylethyl derivatives 
(148-153 &162) further improved the affinity (Ki hA3= 2.2-9.0 µM)  as 
compared to free amino compound 136, with the exception of compound 158, 
which was not active at any of the receptor subtypes. Among these derivatives, 
unsubstituted benzamide (148) showed moderate affinity (Ki hA3 = 7.4 µM). 
Essential for  affinity and 
selectivity 
Longer and bulky alkyl chain (e.g. 



















 =  NH-COPh (p-CF3, p-CH3 )            High hA3 affinity and 
                                                           high selectivity against 













Surprisingly, electron withdrawing substitution such as F (149 Ki hA3 = 7.0) 
and CF3 (150, Ki hA3 = 9.0 µM) failed to make any additional impact on the 
affinity at hA3AR. Conversely, para-CH3 benzamide (151, Ki hA3 = 3.0 µM) 
improved affinity around 2.5 fold as compared to unsubstituted benzamide 
derivative (148) and also strengthened the selectivity against hA1AR by 33 
fold. In addition, introduction of a bulky Br group at the para position of  
benzamide (152) led to a  2 fold improvement  in the affinity (Ki hA3 = 3.6 
µM)  as compared to 148. Similarly, steric dichloro substitution at 3&4
  
positions of benzamide (153) ameliorated the affinity by >3 fold as compared 
to 148. This compound (153) was 46 times more selective for hA3AR against 
the hA2AAR and hA1AR.  
             This signifies the necessity of having a steric electronwithdrawing 
chloro group at the para position of benzamide. Surprisingly, dibenzoyl 
substitution (158, Ki hA3 = >100 µM) made the compound inactive. This is in 
contrast to the dibenzoyl substitution of the  chloro series, where the 
compound (compound 120 in Table 3) displayed comparable affinity and 
selectivity to monoacylated compounds. 
             Throughout the series, a lengthy phenylacetamide substitution (159-
162) at the C
6
 position did not improve the affinity (Ki hA3 = 7.1-15.2 µM) 
and selectivity at hA3AR significantly. This could be due to the steric 
hindrance of the phenylacetamide chain at the C
6
 position. However, 
compounds 160 (Ki hA1 = 0.7 µM), and 162 (Ki hA1 = 0.6 µM), showed high 
potent affinity towards the hA1AR. This could promote further investigations 
on hA1AR.  
 
5.3.3.2   Comparison of  SAR of  PP-4-carboxylate with 4-chloro-PP 
derivatives 
             Figure 37 summarizes the structure-affinity relationship (SAR) 
profiles observed in this new series of pyrazolopyrimidine-4-carboxylate 
derivatives (129-162).  Overall, the C
6
 free amino group with N
2
 substituents 
in the 4-chloro-PP and PP-4-carboxylate derivatives displayed similar affinity 
at the hA3AR with the exception of compound 133 of PP-4-carboxylate, which 
was remarkably (143 fold) more potent than its 4-chloro counterpart 
(Compound 81 in Table 3). Similarly, the C
6




methyl compound series displayed entirely a different affinity profile as 
compared to the chloro series. In the ester series, N
2
 isopropyl derivatives 
were non selective whereas in the chloro series, N
2
 isopropyl derivatives were 
significantly selective towards the hA2AAR. Similarly, neopentyl derivatives 
in the ester series showed much superior affinity as compared to the chloro 
series derivatives. Particularly, para-F substituted compound (145) was 22 
times more potent than that of its chloro counterpart towards hA3AR. In 
contrast, compound 150, with N
2
 phenylethyl and C
6
 para-CF3 benzamide 
chain of the ester series displayed 3 fold decrease in affinity as compared to 
the chloro series analogue. Similarly, para-CH3 group (compound 151) 
showed a slight decreased affinity and an increase in selectivity against the 
hA1AR by 5 times as compared to the chloro series compounds. 
 
           PP-4-Carboxylate                4-Chloro-PP 
N
2
 neopentyl derivatives showed 5 
fold improvement in affinity and 50 
fold  improvement  in selectivity.  
N
2
 neopentyl derivatives showed 




 Phenyl ethyl derivatives affinity 
was maintained but the selectivity 
was improved by 5 fold.  
N
2





 methyl derivatives totally lost the 
affinity at all four receptor subtypes, 




 methyl derivatives  showed 




 isopropyl derivatives showed 
affinity towards the hA1AR  
N
2
 isopropyl derivatives showed 
affinity to hA2AAR.  
 
Table. 12 Comparison of affinity of 4-Chloro-PP  derivatives with PP-4-
Carboxylate derivatives. 
              In summary, ligand modification of the 4-chloro-pyrazolopyrimidine 
led to the derivatives with improved affinity at hA3AR and selectivity over 
hA1AR and hA2AAR. Based on the binding assay results, the hypothesis of 
replacing chloro group by ester substitutents at C
4
 position and introducing 
  
electron withdrawing and electron donating substituents (e.g. CF3,CH3, Br, Cl) 
at the para position of the C
6
 benzamide chain have been successfully proven. 







positions play a key role in modulating the binding affinity at 
the hA3AR. In particular, at the N
2
 position, neopentyl substitution showed 
favourable effect on the affinity at hA3 receptor (147, Ki hA3 = 0.9 µM). 
Similarly, para-CF3 and para-CH3 groups of the same series were proven to 
be important for selectivity (147; hA1/A3 = >111, hA2A/A3 = >111 and 146; 
hA1/A3 = >77, hA2A/A3 = >77. Additionally, C
6
-free amino group with N
2
 
methyl substitution was proven to be vital for affinity (133, Ki hA3 = 0.7 µM), 
whereas subsequent acylation was detrimental for the affinity for methyl 
derivatives (137, Ki hA3 = >100 µM). In contrast, dibenzamide substituents 
with steric groups at the para position in the N
2 
methyl series was essential for 
affinity (155, Ki hA3 = 2.9 µM) and selectivity (hA1/A3 = >34, hA2A/A3 = >34), 
Similarly, additional substitution at the aromatic ring such as 3,4-Cl as in 
compound 153 (155, Ki hA3 = 2.2 µM, hA1/A3 = >46, hA2A/A3 = >46)  was 
also important for affinity and selectivity.  
           From this new design, we conclude that the simplified bicyclic 
pyrazolopyrimidines have partially overcome some of the limitations of the 
PTP analogues, as described in the Table 13. 
          
Table. 13 Comparison of physicochemical properties of PP-4-Carboxylate 




Mol. Wt range  265-552 (g/mol)  183-420 (g/mol)  
ClogP  2.8-4.9  1.0-3.5  
Yield  
 
Low (15-17%), difficult 
purification (column)  
High (72-88%), mostly 
precipitation reactions  
Synthesis difficulties  
 
High temperature and  
longer reaction time 
required 
Reflux conditions  and 
straight forward 
reactions  
Polar groups  Less  More 
  
 
  Although the new PP-4 carboxylate derivatives showed better affinity and 
selectivity profile than 4-chloro PP series derivatives (Table 12), these 
compounds are still inferior in affinity as compared to the parent PTP 
derivatives. Further, to improve the affinity and selectivity, it is deduced that, 
benzamide chain could be replaced by steric and lengthy aralkyl or substituted 
phenyl groups, since lenthy steric gropus are favoured at the C
6
 position. 
Additionally, electron withdrawing and /or electron donating groups such as 
Cl, Br, CF3, CH3 etc., could be substituted at the para position of phenyl 
groups. Moreover, considering the potent affinity of neopentyl groups at N
2
 
position, various bulky alkyl chains (e.g. tert-butyl) or halide substituted alkyl 
chain could also be introduced at this position to improve the affinity further. 
In addition, the ester group might be substituted by some bioisosteres (oxazole 
or ketoxime ether) or a free amino group. 
 




         This section describes the docking studies of pyrazolo[3,4-d]pyrimidine-
4-carboxylate derivatives performed on hA2AAR based on hA3AR homology 
model and crystal structure of hA2AAR, to rationalize the predicted binding 
affinity with experimental binding affinities. 
 
5.4.2 Results and Discussion 
 
        The molecular docking studies were performed on newly synthesized 
pyrazolopyrimidine-4-carboxylate derivatives (129-162) to identify 
hypothetical binding mode and interaction at the hA3AR and also to 
rationalize the results of the binding data. Docking studies were performed 
using molecular operating environment (MOE) programme and all new 
pyrazolo[3,4-d]pyrimidine-4-carboxylate derivatives were docked into the 
orthosteric trans-membrane (TM) binding cavities of  both hA3 and hA2A  










 substituted derivatives. Similarly, 
the binding modes and interactions of the potent compound of the new PP-4-
carboxylate series was compared with the potent compounds of both 4-chloro-
PP (116) and PTP series.  
             Docking simulation demonstrated that binding pattern of the 




position  in the 
whole series. Ligand-recognition occurred in the upper region of the TM 
bundle, and the pyrazolo[3,4-d]pyrimidine scaffold was surrounded by TMs 3, 
5, 6, 7. As seen with the 4-chloro PP compounds, 4 different types of 
interactions were observed and among them hydrophobic interactions and 














Residue: Involved in π-π interaction, Residue: Involved in hydrogen bonding 
interaction, Residue: Involved in hydrophobic interaction 
 





Residues found to interact with C
6
 free amino 
substitution only.  
 
            Figures 38 & 39 summarize the binding interactions of the 
pyrazolo[3,4-d]pyrimidine-4-carboxylate derivatives. Among the C
6
 free 
amino group compounds, compound 133 was positioned at the centre of the 
















Met177 (TM5), Ile186 (TM5),
Ser181 (TM5), Leu246 (TM6),
Ser247 (TM6)
Ala69 (TM2), Val72 (TM2)














the unrotatable nature of the N
2
-methyl group, which assisted ligand to obtain 
a stable confirmation at the centre of the binding pocket.  
 
 
Residue: Involved in π-π interaction, Residue: Involved in hydrogen bonding 
interaction, Residue: Involved in hydrophobic interaction  
 










Although the binding orientation is same as the potent compound of the chloro 
series (116 in Table 3), the ligand was inverted to about 180° and preserved 
the important  hydrophobic interactions with Tyr265, Ile268, Leu264, Leu246, 
Leu90 and Thr87. Moreover, compound 133 also made the lone stabilizing 
hydrogen bonding interaction with Asn250 and pyrimidine ring of the PP 






































































































































Val72 (TM2), Ser73 (TM2)























Ser181 (TM5), Ile186 (TM5),
Thr94 (TM3),
Se247 (TM6)




compounds (134-136) with bulky chains at N
2
 position, due to steric 















Figure 40. Hypothetical binding mode of compound 133 obtained after 
docking simulations inside the hA3AR binding site. Poses are viewed from the 
membrane side facing TM6, TM7, and TM1. The view of TM7 is omitted. 
 
Figure 41. A. Hypothetical binding mode of compound 155 obtained after 
docking simulations inside the hA3AR binding site. Poses are viewed from the 
membrane side facing TM6, TM7, and TM1. The view of TM7 is omitted. B. 
2D view of binding residue with ligand 155 inside hA3AR binding site. 
 
the centre andmoved towards the TM 4. The binding mode of compound 133 
inside the hA2AAR was also analysed. Interestingly, the compound occupied 
the same position as hA3AR and it retained the vital hydrogen bonding 
interaction with Asn253 and other hydrophobic interactions with hA2AAR. 
This led to the poor selectivity of compound 133. It is to be noted that the 
same N
2
 methyl substituted compound (81 in Table 3) with a chloro group at 
C
4
 (instead of the ester group of derivative 133) was inactive at hA3AR. This 
  
could be due to the rotatable nature of the hydrophilic ester group in 133, 
which assisted the  
ligand to obtain a suitable confirmation to make a potential hydrogen bonding 
and hydrophobic interaction. 
             In contrast, acylated compounds of N
2
 methyl derivatives (137-140, 
154) displayed different binding pose as compared to compound 133. The 
extra benzamide linkage of the analogues caused the ligands to move away 
from the centre, and to orient slightly to the interior towards TM4. This caused 
the ligands to lose an essential hydrogen bonding interaction with Asn250 and 
also a π-π stacking interaction with Phe168. Whereas compound 159, with 
lengthy phenylacetamide chain at C
6
 position, was able to interact with some 
of the hydrophobic residues because of the rotatable methylene group, which 
assisted  the ligand to attain a slightly different binding pattern. 
 
            In addition, compound 155, with para-Br dibenzamide substituent at 
C
6
 position, was positioned at the centre, due to the broaden and rotatable 
nature of the dibenzamide chain (Figure 41). Moreover, this substituted 
dibenzamide chain interacted with hydrophobic residues such as Val72, Ser73, 
Leu68 and Tyr265. Interestingly, these interactions were not seen with the 
para unsubstituted dibenzamide derivatives (compound 154), due to absence 
of steric Br group. Similarly, the ethyl group of the C
4
-ester chain interacted 
with Met177, Leu246, and Leu264, while basic nucleus PP made π-π stacking 
interaction with Phe168. Most importantly, carbonyl group of the ester 
substituents made hydrogen bonding interactions with Asn250. This proven 
the speculation that hA3AR binding site possesses the maximum spatial 
tolerability, which can accommodate the broaden diacyl chain with even 
stronger steric group (Br). 
             Generally, acylated  N
2
 isopropyl ligands moved towards the centre of 
the binding pocket due to the streic hindrance produced by the isopropyl 
group, which extended towards the TM4. Ligands were bound in a vertical 
direction at the centre of the binding pocket. These binding poses are quite 
different from the ones observed for the benzamide derivatives (137-140) of 
N
2
 methyl group series. The basic scaffold was situated at the centre of the 
binding pocket and the benzamide chains are extended towards the TM6 and 
  
TM7. Due to this close contact with TM helix, the carbonyl group of the ester 
chains were able to make a hydrogen bonding interaction with Asn250, with  
 
 
Figure 42. A. Hypothetical binding mode of compound 147 obtained after 
docking simulations inside the hA3AR binding site. B. Compound 147 inside  
the hA2AAR binding site.  Poses are viewed from the membrane side facing 
TM6, TM7, and TM1. The view of TM7 is omitted.  
 
exception of compound 143 with steric CF3 group that created a steric 
hindrance and made the chain unavailable for the interaction with Asn 250 
residue. 
 
             Interestingly, N
2
 neopentyl substituted benzamide compounds 
displayed a slightly different binding pose in comparison to compound 133. 
Among them, compound 147 (Figure 42-A), which was the most potent 
analogue of the C
4
-ester series, was placed little away from the centre of the 
binding pocket towards the TM5. In addition, the ester group was oriented 
towards the TM2 and the phenyl ring of the benzamide pointed towards the 
ECL2. Due to this reason, it was able to make a potential hydrogen bonding 
interaction with Asn250. Surprisingly, three stabilizing hydrogen bonding 
interactions were observed between ligand 147 and Asn250. Among them, one 
of the hydrogen bonding was seen with NH of the amide chain, and other two 
bondings were observed with the N-1 of the pyrazole and N-2 of pyrimidine, 
respectively. Similarly, another potent and selective compound of the series, 
compound 146, also shared a close resemblance of the binding pose and was 
  
also involved in similar binding interactions. This in turn reflected the higher 
binding affinity and selectivity of these compounds. In both  compounds (146 
and 147), para-CF3 and para-CH3 made identical hydrophobic interaction 
with residues such as Val169, Ile253, Val259 and Leu264. Among them, 
Val169, Ile253, Val259 were observed only in compound 146 & 147 and one 
of the residues, Val169, was also reported in previous work on PTP analogues, 
where Val169 was deemed to be essential for antagonist recognition.
118
 In 
addition, the neopentyl chain enabled the hydrophobic interaction with 
Trp243, Leu91, Ser181 and Ser247. The central PP scaffold was involved with 
an essential π-π stacking interaction with Phe168, which is considered to be 
crucial for the hA3 antagonistic activity.
186
 Notably, this interaction was also 
present in the binding modes of 4-chloro PP and PTPs.
  
Data from literature 
suggest the importance of the binding of the Phe168 and the mutagenesis 
analyses conducted at the A2AAR demonstrated the importance of Phe168 for 
antagonist binding.
187
    
 
 
Figure 43. A. Hypothetical binding mode of compound 153 obtained after 
docking simulations inside the hA3AR binding site. Poses are viewed from the 
membrane side facing TM6, TM7, and TM1. The view of TM7 is omitted.  B. 
2D view of binding residue with ligand 153 inside hA3AR binding site. 
 
             In addition, N
2
 phenylethyl benzamide substituted derivatives 
orientated in the same fashion as N
2 
isopropyl derivatives and were involved 
in common hydrophobic interactions and lone hydrogen bonding interactions 
with Asn250. However, compound 153 of this series made 3 additional 
stabilizing hydrogen bonding interactions with Asn250 (Figure 43-A). It was 
  
noticed that, due to the highly steric Cl group, the compound made some 
additional hydrophobic interactions with Ile186, which is not observed with 
other benzamide substituted compounds (148-152). 
           Generally, dibenzamide substituted compounds (154, 156 &158) 
moved away from the binding site, oriented deeply into the intracellular loop 
and the ligands were flipped to opposite direction as of ligand 153, i.e. the 
pyrazole towards the TM6 (instead of TM3) and the pyrimidine towards the 
TM3 (instead of TM 6). Due to the irregular orientation, phenyl ring of the 
dibenzamide made stacking interactions with Phe168. 
              We also docked the newly synthesized compounds inside the hA2A 
binding pocket. We noticed that most of the compounds shared similar binding 
pose inside the binding pocket. In addition, the most potent and selective 
compound of the series, compound 147, showed quite a opposite binding 
orientation inside the hA2A binding pocket (Figure 42-B) as compared to 
hA3AR and failed to make hydrophobic interaction with essential residue such 
as Glu169 and barely made contact with Asn253 which is essential for the 
Some of the common hydrophobic residues observed around the ligands are 
Ala63, Ile80, Val84, Leu85, Trp246 and Tyr271. 
              Finally, we compared the binding pose of the most potent compounds 
of both chloro (116) and ester series (147) inside the hA3AR. It was observed 
that compound 147 was oriented in a different pattern from compound 116 of 
the chloro series. It is speculated that rotatable ester chain at C
4
position caused 
the ligand to attain different confirmation. However, compound 147 retained 
all essential hydrophobic interactions with residues such as Met177, Leu246 
and Leu264 and Trp243. As seen earlier, compound 147 gained extra 

























Figure 44. Binding orientation of  PTP (magenta) and analogue 147 (blue) 
inside the hA3AR binding site. The view of TM7 is voluntarily omitted. 
receptor affinity.  
compound 116, a lone hydrogen bonding interaction was observed (Figure 
31-A in Chapter 6). These findings substantiate the experimental results of 
increased affinity and selectivity for compound 147 over compound 116.  
              The docking pose of the compound 147 was also compared with the 
most potent PTP compound 125. As seen in the Figure 44, the binding 
orientations of both the ligands are slightly different. However, compound 147 
is oriented in same plane as PTP. Interestingly, there is a trend observed 
between the binding pose of the PTP and compound 147. Phenyl ring of the 
benzamide linkage in the PP is aligned over the phenyl ring of the PTP, 
thereby the PP has retained the essential hydrophobic interactions with 
residues such as Met177, Leu246 and Leu264 and Trp243, which are observed 
at the phenyl ring of PTP. Moreover, the ester chain of 147 was aligned over 
N
2
 methyl group of the PTP counterpart, thus retaining interaction with 
residues associated with N
2
 methyl of PTPs. Finally, the N
2
-neopentyl group 
was aligned over phenylacetamide chain of the PTP and involved in the 
hydrophobic interactions common to the phenylacetamide chain of PTP. 
These findings signify that most of the hydrophobic interactions associated 















             Generally, binding assay results exemplified that C
4
 ester substituted 
derivatives (129-162) are more potent than that of C
4
 chloro substituted 







positions play a key role in modulating the binding 
affinity at the hA3AR. 
Overall, SAR results confirmed the importance of the following features; 
i) lipophilic neopentyl group at N2 position for favouring affinity, 
ii) N2 methyl with free amino group at C6 for favouring affinity, 
iii) para-substitution at the aromatic ring of the benzamide in C6 for 
favouring selectivity, 
iv) dibenzamide substitution with steric groups (e.g.Br) at C6 for 
favouring affinity. 
              In addition, docking evaluations were carried out on both homology 
based hA3 receptors and hA2A receptors. Slightly different binding orientation 
was observed for the ligands in the both binding pockets, which differ based 




 positions. The predicted binding affinity has 
successfully rationalized the experimental SAR data of newly synthesized 
derivatives. Docking analysis gave the essential interactions involved between 
the ligand and residues. As seen with chloro compounds, the binding pattern 
of the new PP analogues varied depending on the length of substituents at the 
N
2
- and / or C
6
-positions of the PP. As mentioned earlier, the binding pattern 
of compounds bearing N
2
-neopentyl derivatives are slightly different from the 
other N
2
 substituted analogues because of the steric hindrance produced by the 
neopentyl groups inside the hA3 model and hA2AAR. 
              Overall, the following interactions were observed between the ligands 
and the residues at hA3 model, (i) hydrophobic interactions of N
2
-substituents 
with non-polar residues, which are crucial for conferring hA3 affinity; (ii) 
hydrophobic interactions of phenyl ring of benzamide chain at C
6
-position, 
vital for affinity; (iii) van der Waals  interactions of  steric electron donor and 
or electron acceptor groups  at  para position of the benzamide chain, essential 
for the selectivity. (iv) aromatic planar bicyclic moiety like pyrazolo-
pyrimidine ring involved in π-π interaction with the nearby aromatic residues, 
  
essential for antagonistic activity; (v)  hydrogen bonding interactions of the 
ester group, amide chain and ‘N’ of pyrimidine and pyrazole ring essential for 
affinity and more precisely selectivity.  
              Generally, most of the newly synthesized derivatives showed a 
common binding orientation pattern throughout the series inside the hA2AAR, 
with exception of some compounds, which were bound in the quite a different 
fashion due to the substituents effects such as electronic properties, positional 
effects and rotatable nature. This resulted in compounds to obtain a common 
interactions which include the hydrogen bonding interactions with Asn253 and 
other hydrophobic interaction essential for hA2AAR  activation. Thus some 
compounds showed the good affinity towards the hA2AAR aswell. 
Docking evaluation confirmed that newly synthesized PP-4-carboxylate 
derivatives, are better than the 4-chloro PP derivatives. Apparently, some of 
the compounds of the new PP series made a additional stabilizing hydrogen 
bonding interactions with the Asn250, which was not found with previous PP-
chloro series derivatives. In addition most potent compounds of the series 
displayed some specific hydrophobic interactions with Val169,Val259 and 
Ile253. These hydrogen bonding and hydrophobic interactions have 
contributed for the affinity and selectivity to a considerable extent. 
              Overall, the hypothesis of ligand modification which includes the 
introduction of the ester group and other bulky groups at the para position of 














Chapter 6 Pharmacological evaluation and docking studies of 
pyrazolopyrimidine derivatives as adenosine deaminase 
inhibitors 
*Pharmacological assays were performed by our collaborator La Motta et. al 
at the Dept of  Pharmacy, University of  Pisa, Italy. 
 
6.1 Introduction 
             This chapter describes the pharmacological and docking evaluation of 
pyrazolopyrimidine derivatives as adenosine deaminase (ADA) inhibitors. 
Generally, adenosine deaminase (ADA) catalyzes the deamination of 
adenosine and 2’-deoxyadenosine to form inosine and 2’-deoxyinosine, 
respectively. This enzyme is largely present in mammalian cells and plays a 
significant role in human pathological conditions, which include severe 
immunodeficiency diseases, leukaemia diseases, lymphoproliferative 
disorders, inflammatory diseases etc. Therefore, modulation of   ADA activity 
is in great demand.  
             As described in the Chapter 1, section 1.3.6, various heterocyclic 
scaffolds which include natural products such as (+)-EHNA, deoxycoformycin 
and synthetic ligands such as pyrazolo[3,4-d]pyrimidine-4-one, imidazo[4,5-d] 
pyridazine-7-one etc,  have been tested  as ADA inhibitors. However, potent 
inhibitors such as EHNA, and deoxycoformycin are clinically unsuccessful 
because of the toxicities. Therefore, several research groups have involved in 
the identification of the synthetic lead compounds as ADA antagonists without 
toxicity. Among them, pyrazolo[3,4-d]pyrimidine-4-one with different 
structural nature is one of the compound to be identified as potent ADA 
inhibitor.  
             Considering all these aspects and the role of pyrazolopyrimidine 
scaffold on ADA modulation, we have attempted to test our 
pyrazolopyrimidine derivatives as new enzyme ADA inhibitors, with the aim 
of providing new therapeutic molecules/options. For achieving that purpose, a 
total of 20 compounds from both chloro PP and ester PP series were 
investigated for their ADA inhibitory activity in an attempt to draw the SAR 
profile based on the functional properties. 
  
6.1.1 Experimental Methods 
Matherials and Methods. Adenosine deaminase (ADA) type IX from bovine 
spleen (150-200 U/mg) and adenosine were purchased from Sigma Chemical 




 The activity of the test enzyme was determined 
spectrophotometrically by monitoring for 2 min the change in absorbance at 
262 nm, which is due to the deamination of adenosine catalyzed by ADA. The 
change in adenosine concentration/min was determined using a Beckman DU-
64 kinetics software program (Solf Pack TM Module). ADA activity was 
assayed at 30 °C in a reaction mixture containing 50 mM adenosine, 50 mM 
potassium phosphate buffer pH 7.2, and 0.3 nM enzyme solution in a total 
volume of 500 µL. The inhibitory activity of the newly synthesized 
compounds was assayed by adding 100 µL of the inhibitor solution to the 
reaction mixture described above. All the inhibitors were dissolved in water, 
and the solubility was facilitated by using DMSO, whose concentration never 
exceeded 4% in the final reaction mixture. To correct for the nonenzymatic 
changing in adenosine concentration and the absorption by the test 
compounds, a reference blank containing all the above assay components 
except the substrate were prepared. The inhibitory effect of the new 
derivatives was routinely estimated at a concentration of 10
-5
M. Those 





M. Each inhibitor concentration was tested in triplicate 
and the determination of the IC50 values was performed by using linear 
regression analysis of the log-dose response curve. The Ki values were 




6.1.2 Results and Discussion  
6.1.2.1 Biological Evaluation  
             The % inhibition of bovine spleen ADA at 100 µM by 
pyrazolopyrimidine derivatives is presented in Table 14 and (+)-EHNA was 
used as the reference standard. Twenty compounds from the derivatives of 4-




Table 14. ADA inhibition data of pyrazolo[3,4-d]pyrimidine derivatives (R 
denotes N
2









Means±SEM of three determinations, performed in duplicate. 
b
Not  active, 
inhibition occurred at concentration higher than 100 µM. 
 
properties including electron withdrawing (e.g. CF3) and electron donating 
(e.g. CH3) nature of the substituents, and they were tested for their ADA 
inhibitory activity. As shown in Table 14, some of the novel compounds were 
able to inhibit the in vitro activity of ADA, exhibiting high % inhibition.  
             Generally, the PP-4-carboxylate derivatives showed better inhibitory 
activity as compared to the 4 chloro-PP derivatives. Free amino group 








81 CH3 NH2 n.a
b
 
82 CH(CH3)2 NH2 n.a 
83 CH2C(CH3)3 NH2 7±3 
84 CH2CH2C6H5 NH2 9±1 
101 CH3 NHCOPh 51±1 
103 CH3 NHCOPh (p-CF3) 53±7 
107 CH(CH3)2 NHCOPh (p-CF3) 48±7 
108 CH(CH3)2 NHCOPh (p-CH3) 39±3 
109 CH2C(CH3)3 NHCOPh 6±2 
111 CH2C(CH3)3 NHCOPh (p-CF3) 45±4 
112 CH2C(CH3)3 NHCOPh (p-CH3) 37±5 
113 CH2CH2C6H5 NHCOPh 19±6 
115 CH2CH2C6H5 NHCOPh (p-CF3) 34±4 
116 CH2CH2C6H5 NHCOPh (p-CH3) 27±1 
124 CH2CH2C6H5 NHCOCH2Ph 65±1 
133 CH3 NH2 n.a 
136 CH2CH2C6H5 NH2 n.a 
137 CH3 NHCOPh 49±1 
151 CH2CH2C6H5 NHCOPh (p-CH3) 65±5 
162 CH2CH2C6H5 NHCOCH2Ph 64±4 















ester series did not show any activity at ADA. Similarly, compound 83 & 84, 
with bulky chain at N
2
 position, displayed poor inhibition. Generally, the 
benzamide substitution increased the inhibitory effect to a certain extent, with 
the only exception of compound 109, with para unsubstituted benzamide, 
which displayed the least activity in the whole series (6%), and very close to 
that of the C
6
 unsubstituted parent compound 83. Interestingly, compounds of 
the chloro series with less steric groups (e.g. methyl) at N
2 
position (101,  with 
51 %  and 103, with 53% ) showed moderate activity at ADA. In addition, 
compound 107 & 108, with a N
2 
isopropyl group, were less active at the ADA 
as compared to N
2
 methyl derivatives. Generally, in the N
2 
methyl and 
isopropyl series, the insertion of benzamide chains at the C
6
 position improved 
the activity at ADA (101-108, 39-53 %). Among the various substituted 
benzamide chains, insertion of both electron withdrawing (para-CF3) or 
electron donating (para-CH3) groups at the para position of the distal phenyl 
ring did not affect the inhibitory potency significantly. Indeed, compounds 103 
& 107, bearing a CF3 function, were almost as potent (53 % & 48 %) as the 
para unsubstituted compound 101 (51%). On the other hand, substitution of 
benzamide chains at C
6 
position led to detrimental effects for N
2
 neopentyl 
series (109, with 6%). Interestingly, the insertion of a para-CF3 group in the 
same series, as in 111 (45 %), made a 8-fold increase in inhibitory potency 
with respect to 109. Conversely, the same substitution in the phenyl ethyl 
series led to only 5 fold improvement in the potency as compared to N
2
 
neopentyl counterpart. Similarly, electron donating para-CH3 substituted 
analogues of both N
2
 neopentyl (112, 37 % ) and phenylethyl (116, 27 %) 
displayed diminished potency than electron withdrawing substituents (para-
CF3).  
              In the chloro series, the insertion of a phenylethyl chain at N
2
 position 
led to the detrimental effect in the inhibitory potency. The only exception was 
for compound 124, which has a rotatable methylene containing lengthy 
benzamide chain; this compound showed best inhibitory activity of 65%, with 
an increase of 7 fold as compared to the parent compound 84. Similarly, its N
2
 
phenyl ethyl counterpart with C
4
-ester substituted compound (162) also 
showed similar inhibitory potency. 
  
             As mentioned above, para substituted benzamide chain of the 
compounds in the N
2
 neopentyl and phenylethyl series displayed 7-9 times 
more potency than that of free amino group or para unsubstituted benzamide 
group compounds, indicating that presence of bulky groups are needed at the 
para position of the benzamide chain. 
             As compared to the chloro series, ester series compounds with both 
para unsubstitution (137,162) and  para substitution (151) showed much 
superior activity (49-65 %). This proves that hydrophilic ester group at C
4 
is 
more essential than the steric chloro group. This fact was again supported by 
compound 151, where its chloro counterpart 116 exhibited 3 times lower 
potency than that of 151. Additionally, longer phenyl acetamide chain 
compounds in both chloro and ester series displayed similar activity and the 
highest profile among the whole series. This in turn indicates that the presence 
of lengthy chains at C
6
 and at N
2
 are suitable for the activity. 
All these above reported observations, despite the low potency of our 
compounds, are somehow in agreement with the findings of Da Settimo
119 
where 2 amino pyrazolopyrimidine derivatives  with N
2
 alkyl susbtituents up 
to n=9 showed potent activity in the  nM  range, whereas, shorter alkyl chain 
showed loss of activity, indicating that the activity is totally depend upon the 




            On the whole, from the SAR of PP derivatives, the following features 
are deduced: 
1. As lengthy chains are preferred at the N
2
 position, the activity could be 
enhanced by increasing the length of the alkyl and aryl chain at N
2
 position. 
(e.g  n = 4-9). Various substituted alkyl or aryl chains could also be helpful. 
2. C
4
 ester group is preferred than the C
4
 chloro group for maintaining ADA’s 
inhibitory activity. 
4. Since a hydrophilic group is preferred at the C
4
 position, the ester group 
could be replaced by other polar functional groups (e.g. NH2, CONH2) to 
improve the activity.  
5. Considering the poor activity of free amino group analogues at the C
6
 
position, acyl substitution at C
6




6.2 Docking Studies 
             Molecular docking studies were carried out using X-ray crystal 
structure of ADA (Figure 45) complexed with the highly potent non-
nucleoside inhibitor (PDB code 1O5R),
196 
to rationalize the hypothetical 
binding data with results of SARs and to understand the inhibitory potency of 
synthesized compounds at a molecular level.  
Various potent inhibitors with different chemical structures have been 
deposited in the PDB database (PDB IDs: 1VFL, 3IAR, 2Z7G, 3OU8,1NDV,1 
NDW, 1NDY, 1NDZ, 3KM8, 1WXY, 1KRM, 1QXL, 3PAN, 3PBM, 1FKW, 
1O5R, 1FKX, 3OCQ, 3PAO, 1 UML). La Motta et al. described that the 
active site of ADA adopts two distinct conformations: a closed and an open 
one.
197
 In the closed form, the active site consists of a hydrophobic subsite F0, 











                     
             Figure 45. Crystal structure of Adenosine deaminase. 
 
             Moreover, it was demonstrated that S0 subsite is enclosed within a 
structural gate comprising the β-strand (Leu182-Asp185) and R-helix (Thr57-
Ala73) with two leucine side chains (Leu58 and Leu62). From the overlay of 
the open and closed ADA structures it was confirmed that the shape of the 
active site in the closed form is entirely preserved in the open conformation of 
the enzyme. Considering all the above facts, open structure form of crystal 







Figure 46. A. Binding mode of reference ligand (+)-EHNA into the ADA 
binding cavity. B. 2D view of the reference compound (+)-EHNA   inside the 
ADA. 
 
             Docking investigations were focused on the most active inhibitors 
124, 151 & 162, using the MOE docking programme. The most active 
reference compound 2’S, 3’R-erythro-enantiomer of EHNA, (+)-EHNA, was 
also docked into the catalytic site of the enzyme for a proper comparison to 
delineate the SARs of synthesized compounds.  
             From the docking studies it was noticed that the ligand EHNA was 
localized in the same active site as the inhibitor in the crystal structure 
(1O5R). As illustrated in Figure 46-A, the NH2 group of adenine formed 
hydrogen bonds with the Asp295 and the Asp296. Similarly, Zn atom 
coordinating His17 residue was making π-   stacking interactions with main 
scaffold adenine moiety.The hydrophobic alkyl chain was located at the 
entrance of the binding pocket and formed numerous favorable lipophilic 
interactions with residues such as Asp19, Phe65, Tyr102, Ser103, Leu106, 
Gly184, Met155 and His 214.  
             One of the most active compounds, 151, was found to be binding in 
the known active binding site as that of (+)-EHNA, with the long lipophilic 
phenylethyl chain localized in a deep and narrow channel at the entrance of 
the enzyme. In addition, NH proton at C
6
 position was involved in a hydrogen 






Figure 47. A. Binding mode of compound 151 inside the ADA binding cavity.  












Figure 48. Superimposition of ligand 151 (blue) & 162 (magenta) inside ADA 
binding cavity. 
 
pyrazolopyrimidine system made a hydrophobic bond with Zn atom 
coordinating the histidine residues such as His15, His17and His 214.  
             As shown in Figure 47-A, the binding orientation of 151 inside ADA 
is slightly different to that observed for (+)-EHNA binding. Hence, the 
pyrimidine ring of PP nucleus displaced little away towards the upper side of 
the enzyme. This caused the ligand to lose one of the strong stabilizing 
hydrogen bonding interactions with Asp296, which was deemed essential for 
the inhibitory activity at the receptor pocket. In addition, lipophilic 
phenylethyl group was surrounded by a small hydrophobic pocket, which 
consisted of residues such as Leu56, Leu58, Thr57, Glu217 and Glu186. Due 
  
to the shorter chain of phenylethyl as compared to the (+)-EHNA, the ligand 
151 lost some of the essential lipophilic interactions including those with 
Phe65, Tyr102, and Ser103 which were observed with (+)-EHNA and other 
potent inhibitors. As shown in Table 12, inhibitory activities varied 
significantly due to change in n-alkyl substituent. 
             Moreover, another potent compound 162, also showed similar binding 
orientation as compound 151 (Figure 48). This superimposed binding 
orientation led to similar types of hydrogen bonding and hydrophobic 
interactions with residues as those of compound 151. Interestingly, compound 
124 (counter part of the compound 162) of the chloro series, which showed 
equal potency as compound 151, shared similar binding mode and interactions 
as compound 151 &162.  
              The docking was also performed for less active or inactive 
compounds, in an effort to elucidate the reasons behind the reduced biological 
activity of  PP derivatives bearing the free amino (81-84) and unsubstituted 
benzamide chain at position C
6
 position (109 &113). It was found that the 
ligands occupied a different space at the binding site. Thus lost the essential 
hydrogen bonding with Asp 295 & Asp 296 and hydrophobic interactions with 
other residues. From a visual inspection of the free amino group compounds 
and ADA complex, it seems obvious that the absence of phenylacetamide 
chain caused the pyrazolopyrimidine system to attain a reduced rotation and 
thereby changes the optimal binding mode of the ligand significantly.  
Similarly, compounds with C
4
 chloro substitution (101, 103, 107-109, 111-113 
&115-116) exhibited a slightly different binding mode as compared to 
compound 151, which in turn mirrored the moderate ADA inhibitory potency 
of these chloro derivatives. Although these compounds showed some common 
hydrophobic interactions with Ala183, Met155, Asp19, yet they lacked the 
essential hydrogen bonding interactions with Asp295 &Asp296. Additionally, 
a hydrophobic residue Phe61, which was surrounding the ester atom of the 
compound 151, was missing in the chloro series analogues. Consequently, the 
loss of binding interaction could be due to the presence of sterically hindered, 
unrotatable chloro group. This aspect has resulted in loss of essential 
hydrophobic and hydrogen bonding interactions with Phe61 and Asp295 & 
Asp296. respectively. These observations plainly explain the loss in the 
  




             The docking simulation performed on the PP derivatives into the ADA 
binding site successfully rationalized the SARs of these inhibitors. Docking 
analysis highlighted key pharmacophoric elements which are essential for 
hydrophobic, hydrogen and π-π stacking interactions. From the SAR and 
docking studies of pyrazolopyrimidine derivatives, it is deduced that 
compounds with lengthy substitutions at N
2
 substitution and electron donating 
bulky benzamide chains at C
6
 position are essential for ADA inhibitory 
potency. In addition, considering the importance of  hydrogen bonding 
properties of ester substituents at C
4
 position, other hydrogen bond donors 
including amide(CONH) or amine(NH2) or substituted amine (N(CH3)2) could 
be replaced to improve the potency. Moreover, as mentioned in the SAR 
section, lengthy alkyl chain or substituted alkyl chain at N
2
 position could 


















Chapter 7 Concluding Remarks and Future Perspective 
 
             In this thesis, we tested the hypothesis that molecular simplification of 







of the PP scaffold, could  maintain the affinity and selectivity at the hA3AR. 
To test this hypothesis, we  
1) designed simplified analogues of previously synthesized PTPs in the 
form of bicyclic pyrazolopyrimidines (PPs), with the rationale of 
improving the physico chemical properties, to reduce the synthetic 
procedures associated with the complex PTP structures and retain the 
affinity and selectivity 
2) synthesized and characterized 2 libraries of PP compounds and we 
tested them for their ability to bind the hA3AR subtype through 
relevant pharmacological assays; 
3) rationalized the experimental results from the initial pharmacological 
evaluation with theoretical studies (i.e. QSAR, homology modeling 
and molecular docking studies), by identifying the essential structural 
features and binding interactions able to guarantee the affinity at the 
hA3AR. 





 alkyl & aralkyl, and C
6 
free amino and benzamide substituents were 
designed and synthesized successfully (CHAPTER 3). The molecular 
simplification of the tricyclic PTP resulted in the identification of 4-chloro-PP 
derivatives with moderate hA3AR affinity and selectivity towards other 
receptor subtypes. Especially, some of the  N
2
 neopentyl derivatives displayed 





 para-toluamide substituents showed  affinity in low 
micromolar (µM) range and its para-CF3 analogue 111 displayed the highest 
selectivity (hA1/A3 >15, hA2A/A3 >15) in the series. On the other hand, 
analogue 116, a N
2
phenyl ethyl counterpart of compound 112, displayed the 
best hA3 affinity profile with 5 fold increase in the affinity as compared to 
112. Further, analogues 115 & 120 of the same series emerged for their high 
  
selectivity at hA1AR, (115 & 120, 21 & 35 fold, respectively, more selective) 
and displayed almost equal affinity at the hA3AR, which are anyhow 2 fold 
better than that of compound 112 (CHAPTER 4).  
              In addition, the SAR of the new series of 4-chloro-
pyrazolopyrimidine derivatives was quantitatively elucidated by 3D-QSAR 
methodology such as Topomer CoMFA (CHAPTER 5). The structural 





position of the pyrazolopyrimidine nucleus was proposed. Notably, the steric 
effect around the N
2
 position and the electrostatic effect at C
6
 position seemed 
to play an essential role on the antagonistic activity of the PP scaffold. Such a 
3D QSAR based model exposed the important sites for chemical modifications 
and further improvement of the affinity.             
              The receptor-driven computational approach, such as molecular 
docking simulations was performed using a hA2A based hA3 homology model 
(CHAPTER 6). This study was able to predict comparable binding modes and 
interactions for the 4-chloro-PP derivatives. Through a molecular modeling 
investigation, the experimental findings have been rationalized. Docking 





π-π stacking interaction with pyrazolopyrimidine nucleus and hydrogen 
bonding with C
6
amide are essential for hA3 affinity. Further, derivatives of 4-
chloro-PP’s lost one of the potential H-bonding interaction with Asn250 
(TM6), which was deemed essential for hA3AR affinity. Hence, the PP 
derivatives showed inferior activity to PTP scaffold. 
Hence, to improve the affinity and selectivity of PP ligands, further structural 
modification was carried out to obtain pyrazolopyrimidine-4-carboxylate 
derivatives (CHAPTERS 7&8). In this new work, C
4
 chloro group was 
substituted by ester group to make potential hydrogen bonding interactions 
with Asn 250 and various lipophilic groups (e.g.CF3, CH3, Cl, Br)  were also 
introduced to improve the affinity and selectivity. 
              A new series of pyrazolo[3,4-d]pyrimidine-4-carboxylates has been 
designed and synthesized successfully in the new project. A replacement of 
chloro group by ester group and additional hydrophobic substituents at the 
para position of C
6
 benzamide linkage led to the identification of a new series 
of   PP-4-carboxylate derivatives as hA3AR antagonists  with  better  hA3 
  
affinity and improved selectivity profile towards the other adenosine receptor 
subtypes in comparison to the 4-chloro-PP derivatives (CHAPTER 9). 
Particularly, compound 133,  bearing N
2
 methyl and C
6
 amino groups, showed 
>142 fold increment in affinity  as compare to its counterpart compound 81 
and 2 fold increment  as compared to the potent compound (116) of the chloro 
series. Similarly, compound 147, bearing N
2
 neopentyl and C
6
 para-toluamide 
substitution, showed 2 fold increase in the affinity and 15-17 fold increase in 
the selectivity against other adenosine receptor subtypes. In addition, another 
compound (146) as part of the N
2
 neopentyl series, displayed almost equal 
affinity and selectivity profile as 147. Subsequently, steric para-substituted 
benzamide compounds 153 and 155 displayed comparable affinity and 
selectivity as compound 147. 
             Through docking evaluations, the experimental SAR data and 
selectivity over hA2AAR were successfully rationalized (CHAPTER 9).  
Specifically, an additional hydrogen bonding interaction at N of pyrimidine & 
pyrazole and amide of C
6
 was identified, which was not found with previous 
PP-chloro series derivatives. This additional hydrogen bonding interaction led 
to a  significant improvement in the selectivity and moderate improvement in 
affinity at hA3AR. In addition, some specific hydrophobic interactions of  
para substituted C
6 
benzamide with Val169,Val259 and Ile253 are proven to 
be essential for selectivity. Moreover, a loss of hydrogen bonding interaction 
and hydrophobic interaction with Glu169, which is due to the steric hindrance 
caused by the N
2
-neopentyl group towards TM3 and TM4, are speculated to 
be reason for the decrease in affinity towards the hA2AAR.  
In addition, new PP derivatives were also tested for their ADA inhibitory 
activity (CHAPTER 10). Some of the compounds showed promising 
inhibitory potency, which could be further improved by the additional 
substitution as recommended in the section 9.4 in Chapter 4. 
             In summary, the molecular simplification of PTP ligands and further 
ligand modification of 4-chloro-PPs to pyrazolo[3,4-d]pyrimidine-4-
carboxylates have given rise to a new class of  potent and selective hA3AR 
antagonists. Molecular modeling evaluation employed in our study has 
provided new perspectives on the structural features and binding interactions 
responsible for the hA3 affinity of new PP derivatives. 
  
In addition, the most potent compounds of the series will be tested for 
functional assays and in the future the most promising compounds could be 
biologically tested for anticancer activity. 
 
             Although the new PP-4-carboxylate derivatives improved the affinity 
and selectivity significantly as compared to the 4-chloro-PP derivatives, yet 
these compounds seem to be inferior to the parent PTP analogues in terms of 
pharmacological profile. Considering the novelty of this bicyclic scaffold, it 
can be considered as a promising starting point for developing more potent 
and selective PP antagonists towards the hA3AR. It is emphasized that further 
studies on this scaffold could enhance the pharmacological profile comparable 
to parent PTP analogues. Therefore, in order to further improve the affinity 
and selectivity, following features can be considered, which are derived from 
the SAR and molecular modeling studies of the new PP-4-carboxylate 
derivatives. Those are as follows: 
(i) Neopentyl substitution at the N
2
 position for retaining the activity. 
Additionally, steric groups such as tert-butyl and lengthy halide substituted 
alkyl groups  could be substituted at N
2
 position to optimize the substituents at 
this position. 
 (ii) Various mono substituted and disubstituted electron withdrawing groups 
other than CF3 (e.g, Cl, Br, OCF3, SF5, NO2, CF3SO2) could be substituted at 
the 4 or 3,4 position of the benzamide chain for improving affinity and 
selectivity. 
(iii) Various mono substituted and disubstituted electron donating groups other 
than CH3 (e.g. N(CH3)2, NHC4H9, OCH(CH3)2   could be substituted at the 4 or 
3,4 position of the benzamide chain for improving affinity and selectivity. 
(iv) The ester substituents at the C
4
 position could be retained for the affinity. 
In addition, the length of the alkyl substituents in the ester chain could be 
enhanced (e.g Isopropyl ester). Alternatively, the ester group may be 
substituted by thioester (C=OSCH3) or bioisosteres such as oxazole, 
oxadiazole and ketoxime ether to optimize the groups at the C
4
 position. 
              In addition, further QSAR study on newly synthesized PP-4-
carboxylate derivatives could also be carried out to derive a detailed 
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                                       Appendix 
 
Table A1 Selected X-ray crystallographic data for 81 
Table A2 Selected bond angles   [°] and  lengths [Å]   for  81 
Table A3 HPLC data of  4-chloro-pyrazolopyrimidine derivatives 
Table A4 C logP values of the pyrazolopyrimidine derivatives 
Table A5 HPLC data of  pyrazolopyrimidine-4-carboxylate derivatives 
Figure A1 Sequence alignment used to build hA3 based on hA2A template 
retrieved by Modeller 9.11 
Figure A2 Ramachandran Plot for hA2AAR-based hA3 homology model 
[A,B,L (red)]:most favoured regions; [a,b,l,p (yellow)]: additional 
allowed regions; [~a,~b,~l,~p(light green)]: generously allowed 
regions. 
Figure A3 The graph displays the electrostatic interaction energy (in 
kcal/mol) between the ligand and each single amino acid involved 
in ligand recognition observed from hypothetical binding modes of  
ZM-241385 inside  the  hA2A receptor (A), and ligand 116 inside 
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       Ligand      81 
Empirical formula C6 H6 Cl N5 
Formula weight 183.61 
T [K] 100(2) 
Wavelength [Å] 0.71073 
Crystal system Monoclinic 
Space group C2/c 
a [Å] 13.885(3) 
b [Å] 8.0801(16) 
c [Å] 14.805(3) 
α [°] 90 
β [°] 111.540 








μ [mm-1] 0.439 
θ range [°] 2.96 to 27.47 
data/restraints  
/ parameters 
1745 / 0 / 118 
max., min. transmn 
0.9290  
and 0.7784 
final R indices R1 = 0.0363 
[I>2σ(I)] wR2 = 0.0987 






peak / hole [e.Å
-3
]
   
0.495 and -0.236 




























Area Area % 
81 2.550 12711793 99.677 
82 3.290 24299692 99.542 
83 6.300 10651419 99.503 
84 5.890 32279617 99.588 
101 3.080 23203335 100.00 
102 3.757 34593321 96.600 
103 5.660 38059318 99.665 
104 3.797 4493179 99.585 
105  4.680 10934814 100.00 
106 4.780 15050677 95.121 
107 7.223 10118599 99.497 
108 5.960 13652921 95.103 
109 7.983 14111129 97.415 
110 8.490 11958016 99.658 
111 11.57 95996198 98.186 
112 8.590 44458941 97.800 
113 6.420 31048959 99.517 
114 7.573 5348241 95.860 
115 9.057 2260261 96.312 
116 6.993 4631803 95.010 
117 4.853 43700086 98.424 
118 6.910 4449642 97.656 
119 10.97 19428266 99.130 
120 11.63 14304110 97.599 
121 4.960 8840746 99.447 
122 6.053 5656546 95.100 
123 10.60 11038020 99.350 







Area Area % 
81 2.227 5781967 98.210 
82 3.397 3610977 96.831 
83 6.047 4514757 100.00 
84 5.550 3374151 99.351 
101 2.917 4291782 97.889 
102 3.337 39412268 99.479 
103 5.753 39327655 99.859 
104 3.800 46905660 99.451 
105 4.233 12402016 100.00 
106 4.270 19100046 95.569 
107 7.377 5064005 99.624 
108 5.293 11313939 95.744 
109 7.217 28864861 97.897 
110 8.013 18623701 98.315 
111 10.907 21506486 95.40 
112 8.370 27826316 98.422 
113 6.743 4347049 99.715 
114 7.377 5064005 99.624 
115 9.270 4080231 98.781 
116 6.91 4449642 97.650 
117 4.513 45034555 99.918 
118 7.24 13486107 99.400 
119 11.600 10666104 100.00 
120 12.387 7360151 98.635 
121 4.233 6149524 96.276 
122 5.323 11015801 99.594 
123 10.020 17883773 98.322 
124 7.907 4055523 99.527 
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Figure A1. Sequence alignment used to build hA3 based on hA2A template 











Figure A2. Ramachandran Plot for hA2AAR-based hA3 homology model 
([A,B,L (red)]:most favoured regions; [a,b,l,p (yellow)]: additional allowed 





































Figure A3. The graph displays the electrostatic interaction energy (in 
kcal/mol) between the ligand and each single amino acid involved in ligand 
recognition observed from hypothetical binding modes of  ZM-241385 inside  

























133 2.9 95313883 99.784 
134 3.2 35262943 99.19 
135 3.5 34708914 100.00 
136 3.5 12850231 99.470 
137 3.4 12386174 96.559 
138 3.5 23447549 95.84 
139 5.8 13386289 99.293 
140 3.8 11995260 100.00 
141 4.6 10632362 100.00 
142 4.7 15036842 97.838 
143 7.3 2963693 98.873 
144 5.4 18539288 99.13 
145 6.7 2271874 96.389 
146 7.9 13812408 97.402 
147 7.1 43130534 98.406 
148 3.1 12788841 99.74 
149 6.1 15921376 97.340 
150 6.9 12495549 99.684 
151 7.8 10767741 100.00 
152 9.1 17621393 100.00 
153 120 31194331 100.00 
154 5.4 9787411 97.841 
155 137 21404761 99.522 
156 130 30654969 100.00 
157 8.3 18900479 99.319 
158 9.3 15823593 97.910 
159 3.6 3993891 99.372 
160 4.2 23150840 99.732 
161 5.5 2383136 97.28 







Area Area % 
133 2.8 17401396 99.70 
134 2.7 892191 100.00 
135 3.7 36472694 100.00 
136 3.1 36702722 100.00 
137 3.0 31751941 100.0 
138 3.0 340165 95.617 
139 5.9 3013438 98.41 
140 3.6 899335 97.90 
141 4.0 11091539 100.00 
142 4.3 15751859 97.78 
143 6.9 9693421 98.126 
144 5.0 10282097 98.11 
145 6.6 18982572 98.91 
146 8.0 42758757 100.00 
147 7.1 34446364 100.00 
148 3.3 32580406 99.76 
149 6.5 20088939 100.00 
150 6.7 38023560 100.00 
151 7.2 21010179 100.00 
152 10.3 3025011 97.931 
153 11.1 9949223 97.776 
154 5.4 6926709 98.070 
155 13.0 5441539 95.552 
156 11.6 15453929 100.00 
157 8.0 21829456 99.716 
158 9.4 35257764 95.869 
159 3.8 35623450 100.00 
160 4.1 29236433 100.00 
161 5.7 33873733 99.98 
162 7.7 40996903 100.00 
